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CIN is frequently present in advanced tumours and associated with tumorigenesis and 
poor clinical outcomes. CIN is thought to contribute to the development of resistance 
against anti-cancer drugs. CIN is specific to cancer cells, so our lab is exploiting the 
idea of targeting CIN itself in order to develop novel therapies that kill CIN cells. We 
have developed Drosophila melanogaster induced-CIN models for in vivo screening 
and characterization and used RNAi lines to knock down candidates in a CIN 
background (Chapter 2). From our screening of phosphatase and kinase knockdowns 
that kill CIN cells, we identified some interesting metabolic candidates that caused 
lethality via apoptosis in CIN background. These metabolic changes generate elevated 
ROS levels, DNA damage, mitochondrial hyperactivity in CIN background, showing 
CIN cells are sensitive to redox stress. Subsequently, we investigated the effect of these 
metabolic candidates in our Drosophila tumour model and found a gluconeogenic 
protein, PEPCK, needed for proliferation of CIN tumours. PEPCK deficiency supressed 
the tumour growth by increasing the cytoplasmic NADH and ROS levels. Our data 
demonstrated that in PEPCK deficient tumours, the glycerol-3-phosphate shuttle 
produced high levels of ROS. High NADH and ROS production stopped the tumour 
growth (Chapter 3). We also found that the purine biosynthesis pathway is needed to 
tolerate CIN. Depletion of nucleotide synthesis candidates altered the level of adenine 
nucleotides which led to DNA damage which in turn activated PARP for DNA repair, 
further depleting ATP levels. We found increased numbers of lysosomes in nucleotide 
deficient CIN cells and if their formation was blocked, CIN cells died, which suggested 
that autophagy is activated and required for CIN cell survival (Chapter 4). In 
conclusion, our findings reveal that CIN is sensitive to metabolic aberrations. Several 
metabolic pathways including glycolysis, gluconeogenesis and nucleotide biosynthesis 
pathways are activated in response to CIN. Increasing understanding of these pathways 
that make CIN cell survive or die may ultimately allow the design of cancer-specific 





































Abnormal cell proliferation results in cancer development and cancer is one of the leading 
causes of early deaths worldwide. Cancer progression is associated with multistep 
changes in the genome such as gene mutations, deletions or insertions, and epigenetic 
aberrations, initiating less apoptosis, enhanced cell proliferation, angiogenesis, invasion 
and metastasis (Hanahan and Weinberg, 2011). In Australia, more than 14,000 new cases 
are diagnosed with colorectal cancer every year, with a mortality of around 30% and an 
annual healthcare cost of over $200m (Cancer Council of Australia). The median survival 
of metastatic colorectal cancer patients is still under 2 years (Sorbye et al., 2013). More 
than 80% of such tumours and many lung cancers exhibit CIN and become resistant to 
multiple chemotherapeutics  (Lee et al., 2011, Coldren and Miller, 2011a). However, 
there are different next generation drugs such as anti-mitotic and anti-microtubule 
therapies that are available to eradicate the disease and prolong survival but they come 
with drastic side effects and may generate drug resistance (Coldren and Miller, 2011b). 
Chromosomal instability (CIN) is a common feature of advanced tumours, in which cells 
fail to maintain a stable chromosome number as they grow (Figure 1.1).  Acquisition of 
drug resistance is often seen in cells with CIN in advanced tumours like lung, breast and 
colorectal carcinomas. 80% of these cancers exhibit CIN and develop resistance against 
multiple chemotherapeutics (Gerlinger and Swanton, 2010). Thus, there is a pressing need 
for novel therapies against cancer. 
1.2- Chromosomal Instability (CIN) 
CIN is often seen in solid tumours and many haematological malignancies (Mertens et al., 
1994) and refers to the phenomena in which whole or large parts of chromosomes are added 
or lost by the tumour cells (Figure 1.1) at a higher frequency (10-100 times) than normal or 
chromosomally stable diploid tumour cells (Lengauer et al., 1997). CIN is a main cause of 
aneuploidy (Rajagopalan and Lengauer, 2004) and has major implications in carcinogenesis, 
cancer cell evolution, metastatic potential and drug resistance (Rajagopalan and Lengauer, 
2004, Gao et al., 2007). The transition to a metastatic tumour requires genomic 
rearrangements that can be produced by CIN (Rao and Yamada, 2013). CIN induction in 
mouse models results in a two-fold increase in the frequency of spontaneous tumour growth 
(Duijf and Benezra, 2013), and CIN in human cancer is associated with significantly poorer 
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prognosis (McGranahan et al., 2012). It has been suggested that CIN promotes drug 
resistance and relapses upon chemotherapy because it is responsible for the formation of 
genetic diversity in tumours (Swanton et al., 2006). 
 
Figure 1.1: Karyotype of a typical cancer cell (Janssen & Medema, 2013) 
Although several mechanisms have been identified that can generate CIN, a comprehensive 
understanding of CIN at a molecular level in most cancers is still lacking. Considering other 
phenotypic features of tumours, it is assumed that mutations in genes required for 
chromosome stability contribute to CIN (Pfau and Amon, 2012). However, few human 
cancers with gene mutations specifically known to cause CIN have been identified. CIN can 
be classified into either whole chromosome instability (W-CIN) which arises due to defective 
segregation of whole chromosomes or structural chromosome instability (S-CIN), where 
alteration in parts of chromosomes such as deletions, duplications and translocations arise 
(Kamata and Pritchard, 2011). 
1.3- Mechanisms of CIN Development: 
There are a wide range of possible mechanisms that cause CIN, including defects in the 
spindle assembly checkpoint (SAC), centrosome amplification, merotelic kinetochore 
attachment and DNA damage and chromosome bridges. (Jallepalli et al., 2001, Fukasawa and 
Woude, 1997, Pihan et al., 2001, Weaver and Cleveland, 2006, Thompson and Compton, 
2008).  
1.3.1- SAC Component Defects and CIN 
Defects in chromosome segregation contribute to CIN phenotypes and tumorigenesis 
(Thompson and Compton, 2008). The SAC plays a crucial role in accurate chromosome 
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segregation by preventing cells from progressing into anaphase if kinetochores are either 
unattached to spindle microtubules or attached in a way that fails to generate normal tension 
between sister kinetochores (Musacchio and Salmon, 2007). This ensures proper alignment of 
all pairs of duplicated chromatids in metaphase (Musacchio and Salmon, 2007). Both 
heterozygous and hypomorphic mutations in SAC genes develop missegregation of 
chromosomes, detected by aneuploidy in mutant progeny (Foijer, 2010, Ricke et al., 2011).  
These SAC defects have been reported in colon, lung and breast cancer (Michel et al., 2001). 
SAC genes, including checkpoint sensors, mitotic arrest–deficient (Mad) and budding 
uninhibited by benzimidazoles (BUB) gene products, act to control sister chromatid 
separation and also work as signal transducers. Their activation inhibits a ubiquitin-protein 
ligase, the anaphase-promoting complex/cyclosome (APC/C), and causes cell cycle arrest 
(Cahill et al., 1998, Thompson et al., 2010).  Mutation in other genes such as P53, BRCA1 
and ATM, Rb, cyclins or cyclin dependent kinases, which are involved in checkpoint control 
of the cell cycle, DNA repair and recombination and transcription (Yarden et al., 2002) can 
also induce CIN and aneuploidy.  Ubiquitylation of cyclin B, activation of separase (caspase-
related proteases) and reduction of securin (an inhibitor of the protease separase) are 
normally initiated by APC/C–associated Cdc20 at chromosome segregation (Herzog et al., 
2009). Securin binding prevents the proteolytic activity of separase, which destroys sister 
chromatid association by dissolving the chromatid cohesin factor Scc1. Securin degradation 
is essential for the segregation of sister chromatids during mitosis. It is reported that core 
components including budding uninhibited by benzimidazoles–related 1(BubR1), Mad2, and 
Bub3 form the mitotic check point complex with Cdc20 which causes conformational 
alteration in the APC/C that stops substrate binding (Herzog et al., 2009). Before anaphase 
and after condensation of chromosomes the Mad2 protein is localized at kinetochores, it 
associates with the APC/C complex and arrests cells at metaphase (Lopez-Girona et al., 
1999) and plays a vital role in mediating the spindle checkpoint (Hardwick, 2005). A 
previous study showed that deletion of one allele of Mad2 in both human cancer cells and 
murine primary embryonic fibroblasts is sufficient to cause a spindle checkpoint defect that 
results in early separation of sister chromatids and an elevated rate of unequal chromosome 
segregation (Michel et al., 2001).  Early segregation of sister chromatids is typical of spindle 
checkpoint defects that have been found in Drosophila Bub1 mutants as well as in yeast 
Mad2 mutants (Basu et al., 1999, Minshull et al., 1996). In mice, Mad2 null cells are non-
viable and quickly undergo apoptosis owing to defects in the SAC (Dobles et al., 2000). 
Therefore, heterozygous mice Mad2+/- were examined for tumour development. Mad2+/- 
4 
 
mice were prone to develop lung tumour at an elevated rate (27%) compared to wild-type 
(Michel et al., 2001). In Drosophila melanogaster, CIN can be generated by knocking down 
the Mad2 protein, which shortens metaphase giving cells less time to align their 
chromosomes before the onset of anaphase (Figure 1.2), resulting in chromosomal bridges 
and lagging chromosomes (Buffin et al., 2007). Several studies also demonstrated that the 
overexpression of Mad2 in B-cell lymphoma, lung adenocarcinoma and hepatocellular 
carcinoma causes genomic instability by delaying mitosis, increasing mitotic inaccuracy and 
the production of polyploid cells (Alizadeh et al., 2000, Chen et al., 2002, Garber et al., 2001, 











Figure1.2: Aberrant spindle-chromosome attachments and chromosomal bridges lead to 
CIN. a) Normal chromatid separation during Anaphase, b) an induced spindle checkpoint 
defect, kinetochores attached to both poles may cause lagging chromosomes, c) ends of 
separating chromatids are unresolved, resulting in the formation of a chromosomal bridge. 
 
1.3.2- Centrosome Amplification and CIN 
Centrosome abnormality both in number and function is considered to be another possible 
cause of CIN. Cells may acquire centrosome amplification by various mechanisms such as 
cell fusion, defects in cytokinesis and perturbation in centrosome biogenesis. It has been 
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demonstrated that supernumerary centrosomes result in multiple spindle poles during mitosis 
(Figure 1.3), which can lead to missegregation of chromosomes and CIN (Ganem et al., 
2009). Work from Basto et al. (2008) found that centrosome amplification has a role in 
inducing metastatic tumours in flies (Basto et al., 2008). Several mechanisms like viral based 
cell fusion, high expressions of Eg5 and cytokinesis failure that generates tetraploidy, also 
result in the occurrence of centrosome amplification (Thompson et al., 2010). Thus, it is 










Figure 1.3: Multi-polar spindle and merotelic attachments lead to CIN. a) an induced defect 
in centrosomes that causes multiple attachments of sister chromatids to two or more 
centrosomes may delay mitosis but resolve normally, b) Multiple centrosome attachments, 
chromosomes fails to segregate: may cause CIN. 
 
1.3.3- Merotelic Kinetochore Attachment and CIN 
At least in some situations, centrosome amplification significantly increases merotelic 
binding at the kinetochore (Cimini et al., 2006). Merotely defects arise when a kinetochore 
simultaneously gets attached to microtubules originating from different spindle poles 
(Cimini, 2008) as shown in (Figure 1.4) and is commonly found in CIN cells (Thompson and 
Compton, 2008). Mutations in centromere and kinetochore structural proteins may cause 





kinetochore–microtubule attachment defects (Cimini, 2008). For example, mutations in 
histone deacetylases and retinoblastoma protein causes poorly arranged centromeric 
chromatin, leading to lagging chromosomes (Cimini et al., 2003, Manning et al., 2010). 
Additionally, alteration in microtubule-depolymerizing enzymes including the Ndc complex, 
CENP-E, CENP-F, MCAK and Kif2b cause merotely and lagging chromosomes at an 
elevated rate in anaphase, showing that these proteins are important for correcting errors in 
kinetochore-microtubule binding (DeLuca et al., 2002, Thompson et al., 2010). Specifically, 
perturbation of these proteins highly stabilizes kinetochore–microtubule binding, reducing the 











Figure 1.4: Cohesion defects lead to CIN; a) normal sister chromatid separation b) a pair of 
sister chromatids wrongly moved to one spindle pole, causing aneuploidy c) two pairs of 
chromosomes erroneously moving towards one spindle pole, causing aneuploidy for the 
respective chromosomes. 
 
1.3.4- DNA Damage and Chromosome Bridges 
Structural chromosomal instability (S-CIN) refers to a situation in which the rate of sub-
chromosomal changes increase, which results in loss or alteration of, small regions of 







Mutations in the double-strand DNA damage repair machinery can result in translocation and 
S-CIN (Duker, 2002, Natarajan and Palitti, 2008). Non homologous end joining is an error-
prone DNA damage repair pathway, which leads to S-CIN by joining two non-specific 
broken ends of DNA (Natarajan and Palitti, 2008). Double strand breaks can therefore, 
generate non-specific chromosomal fusions particularly at dysfunctional telomeres (Hastie 
and Allshire, 1989). In eukaryotes, telomeres (DNA-protein complexes) contain short 
stretches of nucleotide repeats (TTAGGG) that prevent the chromosome ends from breaking 
and joining during segregation. Due to the end-replication problem, which arises because 
DNA polymerase does not completely synthesize the 3’ end of chromosomes, telomere 
length shortens at each replication. Fusion at telomeres results in formation of di-centric 
chromosomes or ring chromosomes, which cause the formation of chromatin bridges at 
anaphase due to improper binding of microtubules to these di-centric chromosomes. These 
chromosomal bridges cause breakage at cytokinesis and fusion, a process that is repeated in 
the subsequent mitosis (Gisselsson, 2011). This breakage-fusion-bridge cycle is often found 
in multiple cell generations and can cause remarkable genome reorganization. S-CIN 
aberrations can lead to an increased rate of tumorigenesis (Pino and Chung, 2010).  
1.4- The Consequences of Chromosomal Instability:  
CIN is a common feature of cancer cells that plays a critical role in tumour progression and is 
associated with worse prognosis (Bakhoum and Compton, 2012). Approximately 85% of 
solid tumours, and 90% of advanced tumours exhibit the CIN phenotype (Mertens et al., 
1994). The accepted outcome of a moderate level of CIN is tumorigenesis but its role in 
initiating tumorigenesis and cancer progression is still uncertain (Giam and Rancati, 2015).   
Several studies revealed the involvement of CIN in tumour evolution and development. The 
overexpression of spindle assembly checkpoint proteins such as Mad2 in transgenic mice 
model resulted in CIN.  A mouse model with increased or reduced expression of Mad2 has 
shown an elevated rate of tumourigenesis (Birkbak et al., 2011). In some mouse CIN models, 
CIN induced by Bub1, Bub3, BubR1 and Rad21 has developed tumourigenesis 
(Schliekelman et al., 2009, Solomon et al., 2014). Moreover, in another mouse model, over-
expression of hec1 (a kinetochore-microtubule stabilizing protein) also developed tumours in 
lung, liver, and pancreas (Diaz-Rodríguez et al., 2008). However, numerous studies revealed 
that loss of tumour suppressor genes such as p53, p21 are required for tolerance to aneuploidy 
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in CIN cells (Bakhoum and Compton, 2012). This evidence supports a role for CIN in 
tumourigenesis, however, the role of CIN in tumor evolution is still unclear.  
One possible mechanism is that chromosome missegregation can directly result in DNA 
damage and translocation which enables fractions of CIN cells to gain a selective advantage, 
for instance, losing cancer suppression genes through loss of certain chromosomes in which 
the genes reside, therefore, promoting tumourigenesis (Janssen et al., 2011). Disruption of the 
p53/p21 tumour suppressor pathways are common in CIN cells which leads to tumorigenesis 
(Janssen et al., 2011).   
Another consequence of CIN is drug resistance (Giam and Rancati, 2015). Lee et al. (2011) 
have studied the panel of colorectal cancer (CRC) cell lines, classified as CIN+ or CIN− for 
their drug resistance.  They reported that CIN+ CRC lines displayed multi-drug resistance 
compared to the CIN- CRC lines. Similarly, CIN+ CRC was associated with worse 
progression free survival relative to CIN- CRC disease (Lee et al., 2011). One mechanism of 
developing resistance in CIN cells could be due to the high expression of Nek2 in those cells. 
Nek2 over-expression induced drug resistance in cancer cells mostly via activation of the 
efflux pumps (Zhou et al., 2013). Thus, targeting CIN genes such as Nek2 and the signalling 
pathways that activates these genes could be an important target for cancer therapy.  
CIN can also promote metastasis, e.g., through the copy number gain of pro-metastatic genes, 
the copy number loss of anti-metastatic genes or a cytosolic DNA response. Bakhoum, et al. 
(2018) recently reported that CIN can promote metastasis via a cyclic GMP–AMP 
synthase (cGAS)–stimulator of interferon genes (STING) pathway-dependent response to 
cytosolic DNA. To examine causality, the authors transplanted CIN suppressed metastatic 
cancer cell lines (human breast cancer, mouse breast cancer and human lung cancer cells) 
into mice. To retain the aneuploid karyotypes during cell proliferation, the kinesin-like 
proteins KIF2B or KIF2C were overexpressed in these cancer cells (CIN-low cells). 
Intracardiac injection (CIN-low cells) showed that these cells are less able to colonize 
metastatic sites compared with cells overexpressing a (KIF2A) that did not affect CIN 
(CIN-high cells). They further examined the role of CIN in spontaneous metastasis and 
observed that suppression of CIN did not reduce the efficacy of primary tumour 




1.5-Targeting Chromosomal Instability  
Therapeutic interventions to target CIN is based on levels of CIN in the specific tumour 
(Bakhoum and Compton, 2012). It was found that depletion of kinetochore proteins such as 
APC or kinesin-13 protein MCAK, which are responsible for destabilization of attached 
microtubules could significantly decrease the level of CIN in cancer cell lines (Bakhoum et 
al., 2009). Conversely, another study reported that increased CIN levels were induced by 
suppressing mitotic checkpoint proteins such as BubR1 or Mad2, resulting in apoptosis in 
human cancer cells (Kops et al., 2005). Therefore, an elevated CIN phenotype could be used 
as a strategy to target CIN mediated tumorigenesis. However, targeting CIN mediated 
tumorigenesis by manipulating the CIN level has been constrained by the adverse effect of 
the drugs used, such as haematological and neurological dysfunction (Caley and Jones, 
2012).  
Another strategy to target cancer cells that exhibit CIN could be to target the pathways that 
are needed to maintain the CIN level or the adaptations which cancer cells acquire to tolerate 
CIN related stress. CIN results in an unbalanced genome which further evokes a proteotoxic 
stress response in aneuploid cells (Oromendia et al., 2012).  Many cancers display 
overexpression of genes that are involved in protein translation and protein folding. It has 
been reported that protein aggregation (polyglutamine aggregate formation) was increased by 
aneuploidy, and overloading of chaperones such as HSP90 was observed in human aneuploid 
cells (Oromendia et al., 2012, Donnelly et al., 2014). Aneuploidy is also linked with 
increased autophagy and recent findings of our lab demonstrated that autophagy is activated 
in CIN cells and modulation of the autophagy pathway could affect the fate of CIN cells (Liu 
et al., 2016, Santaguida et al., 2015). CIN and autophagy protects cancer cells from apoptosis 
and promotes resistance to chemotherapy treatment (Li et al., 2017). Thus, targeting 
autophagy and its related pathways could improve the efficacy of anti-cancer drugs by 
reducing the chance of developing drug resistance caused by either CIN or autophagy.  
CIN is also linked to metabolic alteration and oxidative stress; cancer cells exhibiting CIN 
adapt to tolerate these stresses (Shaukat et al., 2015).  Targeting these metabolic adaptations 
could lead to cancer specific cell death (Shaukat et al., 2015).  For instance, G6PD, a rate 
limiting enzyme of the Pentose Phosphate (PP) pathway that regulates the antioxidant and 
nucleotide levels in cells, is mostly high in cancer cells (Wang et al., 2012). G6PD 
overexpression increases tumorigenesis and its depletion makes the cells sensitive to 
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radiotherapy and chemical oxidants (Zhang et al., 2014). G6PD depletion in CIN cells result 
in an increase in oxidative stress and DNA damage which further cause cell death (Shaukat et 
al., 2015). 
 In order to kill CIN cells, Pas domain-containing serine/threonine protein kinase (PASK) and 
Phosphofructokinase (Pfrx) have also been identified as metabolic targets. PASK promotes 
glycolysis and loss of PASK led to elevated mitochondrial activity, ROS generation and 
apoptosis in CIN cells (Shaukat et al., 2012). Other specific knockdowns affecting the TCA 
cycle, fat metabolism, gluconeogenesis and oxidative stress response enzymes could all 
promote CIN-specific apoptosis. Thus, metabolic interventions are potentially a highly 
effective way of killing CIN cells without affecting normal dividing cells. Identification of 
metabolic targets that are either required for CIN-specific cell death or CIN tolerance could 
serve as potential therapeutic targets to specifically kill advanced tumours that exhibit CIN.  
1.6- Cancer Metabolism 
Otto Warburg observed the metabolic alterations that are specific for tumours nearly a 
century ago (Warburg, 1956). This discovery paved the way for understanding cancer 
metabolism and has become an emergent field of interest in the past decade. Multiple 
molecular mechanisms contribute to altering cellular metabolism in cancer, however, their 
main purpose is to provide support for the three basic requirements: rapid ATP production, 
enhanced biosynthesis of macromolecules and redox balance for the maintenance of 
tumorigenic state (Pavlova and Thompson, 2016).  
1.6.1- Altered Bioenergetics 
Warburg’s observation that tumours utilise glucose and generate ample amounts of lactate 
despite the presence of oxygen (Warburg effect) due to impaired mitochondrial function has 
led to the hypothesis that cancer cells rely on aerobic glycolysis instead of oxidative 
phosphorylation (DeBerardinis and Chandel, 2016). The emerging evidence favours that the 
Warburg effect is vital for anabolic pathways, not just for energy production, and a high rate 
of glucose consumption is associated with activation of oncogenes or loss of tumour 
suppressors and up-regulation of the PI3K pathway (Pavlova and Thompson, 2016). Several 
studies revealed the importance of mitochondrial metabolism in cancer cells to conduct 
oxidative phosphorylation for ATP production (Weinberg et al., 2010, Martínez-Reyes et al., 
2016). Moreover, depletion of mitochondrial DNA reduces the tumorigenic potential of 
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cancer cells (Tran et al., 2016). However, slowing down glycolysis in tumour cells has not 
been very useful to prevent tumorigenesis (Joshi et al., 2015).  Furthermore, fatty acids and 
amino acids provide substrates to the TCA cycle to maintain the mitochondrial ATP supply in 
cancer cells. In mitochondria, breakdown of fatty acids produces acetyl-CoA, NADH and 
FADH2, which are supplied to the ETC (electron transport chain) for mitochondrial ATP 
production. The amino acids isoleucine, valine, and leucine are elevated in some cancers and 
are converted to acetyl-CoA and other organic molecules that are used to fuel the TCA cycle 
for ATP production (Mayers et al., 2014). Under hypoxic and nutrient-deprived condition, 
tumour cells decrease the demand for ATP in order to adapt to the microenvironment. 
Subsequently, tumour cells maintain their ATP/ADP ratio to sustain viability in unfavourable 
conditions. If the ATP/ADP ratio is difficult to maintain, the increase in ADP can activate 
AMP kinase (AMPK) via a rise in AMP, which stimulates catabolic pathways in tumour cells 
to increase ATP production for survival. Certain cancer cells in nutrient deprived conditions 
employ fatty acids to fuel the TCA cycle for ATP production. Thus, in metabolic stress 
conditions cancer cells maintain their ATP/ADP ratio via multiple mechanism to sustain their 
viability (Hardie et al., 2016). Metabolic reprogramming in cancer cells makes it hard to 
target a specific metabolic dysregulation for cancer therapy. However, malignant cells use 
conventional metabolic pathways to produce more glucose, pyruvate, lactate, glutamine, fatty 
acids and nucleotide than the normal proliferating cells. Therefore, common metabolic 
features of malignant cells can potentially be targeted for cancer therapy.  
1.6.2- Enhanced Biosynthesis 
Enhanced biosynthesis is a vital characteristic of cancer metabolism because it enables cancer 
cells to produce the macromolecules needed for replicative cell division, DNA repair, 
angiogenesis, hypoxic response and tumour growth (DeBerardinis and Chandel, 2016). 
Biosynthetic pathways are involved in the acquisition of simple nutrients such as sugars and 
essential amino acids, taken from the extracellular space, that are converted into biosynthetic 
intermediates via core metabolic pathways such as glycolysis, the PPP, the TCA cycle, and 
nonessential amino acid synthesis. Glucose and glutamine are two principal nutrients that are 
needed for cell survival. It has been observed that glucose consumption is remarkably high in 
tumour cells as compared to normal non-proliferating cells (Warburg et al., 1927). An 
increase in aerobic glycolysis is used for lipogenesis, proteiogenesis and nucleogenesis to 
fulfil the demands of proliferating cells (Lunt and Vander Heiden, 2011).  
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Nucleotide biosynthesis is required for DNA replication, RNA production and a variety of 
cellular processes.  De novo biosynthesis of nucleotides is an energy intensive process 
coordinating several metabolic pathways into one fine-tuned metabolic network. Glucose is 
converted to ribose-5-phosphate during the PP pathway, which is used for both purine and 
pyrimidine synthesis and increased glycolytic flux in cancer cells can enhance the nucleotide 
synthesis by upregulating the PP pathway. Another pool of nucleotides comes from the TCA 
cycle via oxaloacetate, which is transaminated to aspartate, and converted to nucleotides 
(Stanton, 2012). Various nonessential amino acids and methyl groups from the one-
carbon/folate pool are used for the production of purine and pyrimidine bases. As well as 
these intermediates and pathways, NADH is also employed for nucleotide synthesis. For 
instance, conversion of ribonucleotides to deoxyribonucleotides via ribonucleotide reductase 
is NADPH dependent.  
Balanced levels of the intracellular deoxynucleoside triphosphate (dNTP) pool is critical in 
maintaining genomic stability and preventing cancer development. In many types of cancer 
cells, reduction or imbalance of dNTP pools enhances the tumour progression and causes 
dysregulation of cell cycle (Aird and Zhang, 2015). In eukaryotes, nucleotide levels are 
maintained by two distinct pathways: the de novo synthesis in the cytoplasm, and the salvage 
pathway that takes place both in cytoplasm and mitochondria. In de novo synthesis, purine 
ribonucleotides are synthesized from basic components including phosphoribosyl 
pyrophosphate (PRPP), glutamine, and glycine and pyrimidine biosynthesis is accomplished 
by carbamoyl phosphate, aspartate and PRPP (Figure 1.5). The enzyme ribonucleotide 
reductase (RNR) catalyses the rate-limiting step of de novo pathway that converts 
ribonucleotide diphosphates to deoxyribonucleotides (Aird and Zhang, 2015).  
Salvage pathways also supply nucleotides to organisms. In salvage reactions, the free purine 
bases, adenine, guanine, and hypoxanthine, can be reconverted to their corresponding 
nucleotides by phosphoribosylation after phosphoribosyl pyrophosphate (PRPP) has been 
made by the activation of ribose‐5‐phosphate. Two key transferase enzymes including 
adenosine phosphoribosyltransferase (APRT) and hypoxanthine-guanine 
phosphoribosyltransferase (HGPRT) are involved in the salvage of purines (Figure 1.5). 
APRT mediates AMP formation and HGPRT can act on either hypoxanthine to form IMP or 
guanine to form GMP. A critically important enzyme of purine salvage in rapidly dividing 
cells is adenosine deaminase (ADA) which catalyses the deamination of adenosine to inosine. 
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In the salvage pathway, dNTPs are synthesized by deaminases and phosphorylases, along 
with mammalian triphosphohydrolase, histidine/aspartate (HD)-domain containing protein 
1 SAMHD1 (Goldstone et al., 2011). Maintaining dNTP concentrations at optimum levels is 
achieved by cell cycle-dependent activity and allosteric regulation of RNR and SAMHD1 (Ji 
et al., 2013). Elevated RNR activity in yeast cells increases the dNTP level that can lead to an 
increased mutation rate and can also affect its function in DNA repair but does not arrest cell 
cycle progression (Kumar et al., 2010). In mammalian cells, depletion of the dNTP pool 
decreases PARP-1 activity and impairs Chk1 activation, resulting in inaccurate DNA 
replication leading to ultrafine anaphase bridge formation (Gemble et al., 2015). Both excess 
and deficiency of one dNTP may be detrimental. Therefore, balanced dNTP levels are 
required for DNA damage repair, which is necessary to prevent cancer development.  
Targeting nucleotide metabolism has long been considered a therapeutic strategy for cancer. 
Nucleotide enzyme inhibitors and nucleoside analogs aim to disrupt the synthetic pathways 
which result in imbalance of dNTPs in cancer cells; this is a common therapeutic target used 
in the treatment of many types of cancer. However, still very little is known about the effect 
of cancer metabolism on nucleotide biosynthesis (Shuvalov et al., 2017). Combination 
therapies that target both the de novo and salvage pathways of nucleotides would likely result 




Figure 1.5: Nucleotide synthesis from metabolic pathways. Enzymes known to be involved in 
nucleotide production in cells are G6PD = Glycerol Phosphate dehydrogenase and TKL= 
Transketolase from Pentose phosphate pathway (PPP), PRPS2= Phosphoribosyl 
pyrophosphate synthetase2, PPAT= Phosphoribosyl pyrophosphate amidotransferase 
ADSS= Adenylosuccinate synthase, IMPDH= Inosine monophosphate dehydrogenase, 
ADSL= Adenylosuccinate lyase, GMP SYN = Guanosine monophosphate synthetase, from de 
novo pathway, APRT= Adenine phosphoribosyltransferase from salvage pathway. 
 
 
1.6.3- Redox Balance 
In addition to genetic alterations, abnormal tumour microenvironments play a major role in 
determining the metabolic phenotype of tumour cells. The redox status of tumour cells is also 
an important metabolic issue because it not only changes the microenvironment of a cell but 
also alters the signalling pathways for re-wiring of its metabolism (Dang, 2012). Reactive 
oxygen species (ROS) are radicals, ions or molecules such as superoxide (O2−), hydroxyl 
radical (OH), and hydrogen peroxide (H2O2). These molecules are synthesized within the 
cells via oxygen metabolism and at low levels they are considered important signalling 
molecules (Gough and Cotter, 2011). ROS are the most common outcome of redox 
alterations and have been known as a lethal by-product of cellular metabolism. Altered 
metabolism is expected to generate oxidative stress, which may affect the ability of cancer 
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cells to maintain ROS levels. Under normal physiological conditions, an increased ROS level 
can induce cancer by creating greater oxidative stress, oncogenic stimulation, increased 
metabolic activity, mitochondrial malfunctioning, damage of macromolecules such as DNA, 
lipid and protein (DeBerardinis and Chandel, 2016). It is also notable that different levels of 
ROS have different effects on normal and cancer cells; therefore, the role of ROS depends 
upon their levels (Majewski et al., 2004, Cairns et al., 2011). At low levels, ROS provide a 
beneficial effect, supporting cell proliferation and survival via post-translational modification 
of kinases and phosphatases (Finkel, 2012). However, at high level, ROS cause detrimental 
oxidative stress that can lead to apoptosis (Garrido et al., 2006, Han et al., 2003). To counter 
excessive oxidative stress, a cell produces antioxidants that prevent ROS inducing cellular 
damage.  In cancer cells, the high level of ROS not only induces macromolecule damage but 
also it induces the production of anti-oxidant enzymes to escape from cell death. One of the 
important mechanisms to increase anti-oxidants in cancer cells is by activating nuclear factor 
(erythroid-derived 2)–related factor 2 (NRF2) (Jaramillo and Zhang, 2013). NRF2 activation 
induces the transcription of several antioxidant proteins as well as activating the enzymes that 
increase cytosolic NADPH (anti-oxidant) levels, which is needed for redox balance to evade 
cell death (Ye et al., 2014).  
1.7- Cancer Metabolism: A Therapeutic Opportunity for Cancer Therapy 
Cancer treatment is constrained by the high genetic diversity and adaptability of tumour cells, 
making it hard to develop treatments that discriminate between normal and cancer cells. 
Abnormal cell proliferation is a common feature in cancer cells. Anti-cancer drugs such as 
cyclophosphamide, mGluR1 inhibitors (riluzole and BAY36-7620), sorafenib or vemurafenib 
with riluzole have been used for targeting cancer. In addition to this, our current 
understanding of the role of glucose and glutamine in tumour metabolism has led to the idea 
that a novel class of anti-cancer drugs that altered metabolism could be developed. Several 
glycolytic enzymes that are required to maintain a high glucose metabolism have been 
targeted in cancer cells (DeBerardinis and Chandel, 2016). Lactate dehydrogenase (LDHA) is 
associated with pyruvate conversion to lactate and its over-expression has been linked to 
cancer metabolism. LDHA inhibitors were reported to cause regression in tumour growth 
(Xie et al., 2014). Similarly, fatty acid synthase, the enzyme which catalyses the synthesis of 
palmitate, was found to be increased in many human cancers and has been targeted in a 
clinical setting (Röhrig and Schulze, 2016). The mitochondrial metabolic inhibitor metformin 
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impedes mitochondrial complex I activity and has been observed to have an effect on 
reducing cancer incidence in clinical trials to test whether it could have an anti-cancer effect 
(Wheaton et al., 2014). Alternatively, autophagy can be targeted to inhibit mitochondrial 
metabolism in certain cancer cells. Cancer cells are more reliant on autophagy than normal 
cells or tissue. Autophagy affects cancer chemotherapy associated cell death and it is related 
to development of drug resistance by activating pro-survival pathways in cancer cells. 
Numerous studies show that autophagy has a dual role during cancer progression, it has both 
cancer-promoting and cancer suppressing functions (Galluzzi et al., 2015, Guo and White, 
2013, Yang et al., 2014). For instance, monoallelic deletion of Beclin1 (autophagy gene) or 
its regulator Ambra1 causes increased cell proliferation and spontaneous tumour progression 
(Qu et al., 2003, Cianfanelli et al., 2015). Furthermore, in mice, targeted deletion of 
autophagy genes such as Atg4c, Atg5 and Atg7 induces a high level of tumorigenesis as 
compared to the wild type controls (Takamura et al., 2011). Moreover, autophagy deficiency 
is also associated with high level of ROS, DNA damage and CIN which are responsible for 
causing tumour progression (Poillet-Perez et al., 2015). Conversely, upregulation of 
autophagy is needed to promote cancer survival, growth and metastasis. In a mouse model of 
breast cancer, deficiency of the autophagy gene ATG17/ FIP200 inhibits mammary tumour 
initiation and progression (Wei et al., 2011), suggesting the role of autophagy in promoting 
tumorigenesis. Because autophagy has a dual role in tumorigenesis, interventions to either 
stimulate or impede autophagy have been proposed as anticancer therapy. However, 
targeting autophagy as a cancer therapy is still controversial. Currently, chloroquine and 
hydroxychloroquine have been used in clinical trials to inhibit autophagy. These drugs 
deacidify the lysosome and inhibit the fusion of autophagosomes with lysosomes (Yang et 
al., 2013). Other autophagy-specific inhibitors including lysosomal inhibitors such as 
Lys05 and drugs that target earlier steps in the autophagy pathway are also in pre-clinical 
stages (McAfee et al., 2012, Egan et al., 2015).   
 
As discussed earlier, altered metabolism may change the ability of cancer cells to maintain 
ROS levels. ROS depleting strategies depend upon antioxidants to suppress ROS signalling 
and tumour growth (Chandel and Tuveson, 2014). Different anticancer agents based on this 
strategy are approved by USFDA, for example, procarbazine, motexafin and gadolinium are 
used to increase ROS content and minodronate and histamine are used to eliminate ROS. 
However, ROS resistance under continuous ROS stress is a major drawback of these ROS 




Metabolic reprogramming in cancer cells contributes to tumorigenesis but also leads to 
metabolic liabilities that can be exploited for effective cancer therapy. Recent advancements 
in understanding the differential metabolic dependencies of tumours has developed new 
therapeutic plans to exploit altered metabolism (Luengo et al., 2017). However, targeting 
general proliferative metabolism may not produce an appropriate therapeutic option since 
many normal cells, such as those in the bone marrow, intestinal crypts, and hair follicles, are 
highly proliferating. Likewise, the proliferation rates of non-malignant cells are often greater 
than those of malignant cells (Vander Heiden and DeBerardinis, 2017) so adverse effects of 
antimetabolite chemotherapy arise due to destruction of normal rapidly proliferating cells. In 
addition, metabolic reprogramming in cancer cells at different stages of cancer development 
leads to drug-resistance, metastasis and tumorigenesis. These attributes make it hard to target 
a specific metabolic pathway in malignant cells, however, it may be more effective to address 
multiple metabolic targets in cancer cells.  
Glycolysis has been targeted in several studies as a cancer therapy due to the high uptake of 
glucose in many tumour cells as compared to normal tissue (DeBerardinis and Chandel, 
2016). Hexokinase 2 (HK2) catalyses the first step of glycolysis, and is overexpressed in 
many cancers. HK2 inhibition, in cancer models like NSCLC and breast cancer tissue, delays 
tumour progression.  Additionally, systemic inhibition of HK2 in mice did not show adverse 
effects on normal tissues.  Lactate dehydrogenase (LDH), which converts pyruvate to lactate 
has been another target from glycolysis. Increased glycolysis tends to generate high lactate 
levels for either conversion to other metabolites or to be secreted out of the tumour cells 
(Vander Heiden, 2011). LHD-A inhibition in MYC driven tumours including NSCLS 
tumours, and myeloid leukaemia shows either regression of the tumour or delayed 
progression (Xie et al., 2014). Glycolysis is regulated by growth factors and the energy 
sensing mechanisms of the cell, such as the PI3K-AKT, mTOR, and HIF pathways. These 
pathways also affect other cellular processes like autophagy, translation of specific genes, 
apoptosis, and ribosomal biogenesis. The effect of targeting metabolism on these cellular 
processes in cancer is still under investigation (Vander Heiden, 2011). 
Targeting nucleotide biosynthesis pathways for cancer therapy has been used for more than 
60 years. Cancer cells are highly dependent on the de novo synthesis of nucleotides for DNA 
replication and RNA production. Inhibition of 5-phosphoribosyl-1-pyrophosphatase (PRPP) 
amidotransferase, the enzyme that catalyses the first step in de novo purine biosynthesis, by 
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purine analogs 6-mercaptopurine and 6-thioguanine has been successful in treating many 
cancers, including childhood leukemia (Elion, 1989). 5-fluorouracil (5-FU), a pyrimidine 
analog that inhibits thymidylate synthase, and other 5-FU-prodrugs such as capecitabine are 
commonly used for gastrointestinal cancer treatment (Wagner et al., 2005). Nucleotide 
biosynthesis is linked with other metabolic pathways such as the PP pathway, and aspartate 
and glutamine. Thus, targeting the PP pathway and amino acid synthesis can affect nucleotide 
production. Combinatorial treatment that targets several metabolic pathways seems to be an 
attractive strategy for cancer treatment.  
1.8- Targeting Metabolism in CIN Cells 
CIN inevitably generates aneuploidy in cancers, causing changes in chromosome copy 
number. This may generate proportional alterations in the transcript level of genes located on 
aneuploid chromosomes, which may result in protein dosage changes in the encoded protein, 
which can then lead to malfunctioning of biological processes (Potapova et al., 2013).  
Defects during mitosis can cause various abnormalities in cytokinesis, mitotic spindle 
formation and mitotic checkpoints. These aberrations can cause missegregation of 
chromosomes and tetraploidy, therefore increasing the rate of CIN. Through aneuploidy, CIN 
may enable tumours to develop resistance against stressful environments, the host immune 
system, and cytotoxic effects of chemotherapies by further generating genetic variations in 
tumour cells (Potapova et al., 2013).  Continuous genetic variations in cancers make tumours 
a ‘moving target’ for anti-cancer therapies. In cancer research, the idea of targeting CIN itself 
has received much attention because this mechanism is tumour-specific and anti-CIN therapy 
can potentially inhibit the ability of tumours to develop resistance against drugs.  
CIN is a hallmark of cancer cells and causes proteotoxic stress and metabolic aberrations 
(Oromendia et al., 2012). Recent studies to selectively kill CIN and aneuploid cancer cells 
revealed that an energy and proteotoxic stress inducer AICAR, a protein folding inhibitor 
(Hsp190 inhibitor 17-AAG) and chloroquine were found to be promising interventions to 
inhibit the growth of trisomic yeast cells and high-grade aneuploid colorectal cancer cell lines 
by increasing aneuploid-induced stress (Tang et al., 2011, García Martínez et al., 2015).  
Our lab has carried out a genome wide screen for kinases and phosphatases that when 
depleted, cause CIN-dependent apoptosis. This screen identified a class of genes that has 
effects on cell metabolism. We have found that knockdown of metabolic candidates such as 
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PASK, Pfrx (a glycolysis regulator) or WW domain containing oxidoreductase (Wwox) (a 
tumour suppressor) alone has no effect on normal cells.  However, inhibiting the function of 
these candidates or similar candidates that affect the TCA cycle, fat metabolism and oxidative 
stress response enzymes in a CIN model, generates elevated ROS levels, DNA damage and 
cell death (Shaukat et al., 2014). Autophagy also is activated in CIN cells which is necessary 
for their survival (Liu et al., 2016). This finding is crucial because both CIN and autophagy 
are linked with the development of drug resistance (Tan et al., 2017). Thus, we can target the 
autophagy pathway in order to reduce the development of drug resistance initiated by either 
CIN or autophagy.  
1.9- Existing Models for Investigating CIN 
1.9.1- Culture Model 
Cell cultures that exhibit CIN are not ideal models for screening for targets that when 
depleted can induce death in CIN specific cells but avoid affecting the normal cells. Genomic 
diversity in cell lines makes them problematic for investigating CIN in general and there is 
also an issue of reproducibility, since cells have different genomes each time they are 
cultured (Roschke et al., 2005a, Wallqvist et al., 2005). However, this approach can be 
employed for the screening of chemical libraries in CIN lines (Roschke and Kirsch, 2005). 
NCI-60 human cell lines have been used to find drugs that show significant effects on these 
karyotypically diverse cell lines (Roschke et al., 2005b, Wallqvist et al., 2005). None of the 
tested current cancer drugs were found to have any effect specifically on unstable cell lines, 
but a few novel drugs were identified that could affect the growth of these cell lines. 
However, this model was not considered a suitable tool for drug discovery and additional 
procedures are needed in order to understand the mechanisms (Wallqvist et al., 2005). 
Therefore, animal CIN tumour models would be preferable if we are to identify and 
characterize the possible mechanisms of killing CIN cells.  
1.9.2- Drosophila Melanogaster Model for CIN 
Drosophila has been used as a model system for cancer research for decades (Gonzalez, 
2013).  It is considered to be an effective model for investigating aneuploidy and CIN due to 
several reasons such as the short generation time, and it is a simple and less expensive 
compared to vertebrate models. In addition, CIN can be induced in a specific tissue or the 
entire organism by tissue specific knockdown or increased expression of genes that can 
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generate CIN, which would be difficult in vertebrate CIN models.  For the Drosophila 
system, temperatures of 18°C and 25°C can be used to control the effectiveness of the altered 
gene expression and hence the level of instability. Moreover, it is an excellent model for 
analysing the role of human genes in diseases such as neurological defects, metabolic and 
storage diseases, cardiovascular diseases and cancer (Pandey and Nichols, 2011) 
We have used Drosophila induced-CIN models for in vivo screening and characterization. 
We induced chromosomal instability by knocking down the mad2 gene or Rad21, giving CIN 
models with different CIN levels. Depletion of mad2 provides less time for the cell to align 
kinetochores properly by reducing metaphase duration (Buffin et al., 2007). Reduced 
amounts of Mad2 have been shown to generate CIN, aneuploidy and tumorigenesis in human 
and mouse models (Michel et al., 2001). It has been observed that mad2 knockdown in 
Drosophila causes lagging chromosomes and chromosome bridges during cell division in > 
25% of cells without affecting the overall viability. Therefore, we employed this as a CIN 
model, knocking down target genes in normal or CIN background cells and screening for 
lethality specifically in CIN cells (Shaukat et al., 2012).  
Drosophila Rad21 is a chromatid cohesion protein and its depletion is also known to cause 
CIN. Cohesin binds the sister chromatids together during cell division until the SAC is 
satisfied (Nasmyth, 2011). Cohesion is required for faithful segregation of replicated 
chromosome during mitosis. A cohesion defect leads to loosely attached or unattached sister 
chromatids and induces difficulty in the equal distribution of chromosomes between the two 
daughter cells. Premature chromatid separation or partial failure of segregation results in 
numerical CIN (Thompson et al., 2010). Genes including Smc1, Smc3, Rad21, STAG1, 
STAG2, STAG3 and separase are involved in the cohesion of sister chromatids and frequently 
mutated in CIN cancers. We have found that knocking down of Rad21 by RNA interference 
together with UAS-Dicer2, which enhances the processing of Rad21RNAi in Drosophila, 
results in anaphase errors in about 35% of brain mitoses, and aneuploidy in more than 50% of 
wing disc cells (Liu et al., 2016). The resulting lethality makes Rad21 knockdown flies an 
ideal model organism to screen candidate genes whose depletion could give suppression of 
lethality in CIN cells.  This CIN model is also used to validate that candidates show 
suppression or lethality as a result of the presence of CIN, not just as a result of mad2 
knockdown because CIN induced by Rad21 knockdown caused a high level of CIN and 




1.10- Key Points 
 
Key points of existing CIN research related to this study are as follows: 
 
1. CIN and aneuploidy are essential hallmarks of cancer. 
2. CIN and aneuploidy are associated with tumorigenesis, drug resistance, relapse and 
worse prognosis 
3. CIN could be induced by several mechanisms such as cohesion defects, defects in 
kinetochore-microtubule attachment, defects in spindle assembly check point, DNA 
damage etc. 
4. CIN is common in cancer cells as compared to normal cells. Therefore CIN itself can 
be employed as a therapeutic target. 
5. CIN cells are sensitive to metabolic stress. Thus, specific metabolic interventions can 
be targeted for cancer therapy.  
6. Drosophila CIN models are an ideal tool for characterization of metabolic gene 































1.11- Aims of the Study 
The main objective of this study is an investigation of the role of metabolic pathways in 
response to CIN and the identification of the potential mechanism in CIN cells that amplifies 
small metabolic interventions to the point where they affect the survival of CIN cells. 
Aim 1: Screening for metabolic candidates whose knockdown can trigger cell death in CIN 
cells.  
Aim 2: Translating the CIN specific cell metabolic targeting into CIN tumours, to evaluate 
the effects of metabolism on cancer therapy. 
Aim 3: Screening and characterization of metabolic candidates whose knockdown can give 
tolerance to CIN. 
Aim 4: To investigate the effects of metabolic stress on mitosis in normal and CIN cells. 
Aim 5: To characterize the effects of the unfolded protein response and oxidative stress in 
CIN cells. 




































A common feature of advanced tumours is Chromosomal Instability (CIN), in which cells fail 
to maintain a stable chromosome number as they proliferate (Thompson et al., 2010). CIN is 
extremely common in tumours, being associated with tumour progression and poor clinical 
outcomes in a wide range of cancer types (Carter et al., 2006). Existing cell lines with CIN 
are not ideal as a CIN model research due to their high aberrant genome content, making it 
hard to distinguish whether any effect is due to the CIN or the disrupted genome. 
Drosophila melanogaster as a model organism for cancer research is well validated, and 
several key pathways driving proliferation and metastasis were discovered and/or elucidated 
in this model organism, including signaling pathways (Brumby and Richardson, 2005). 
Drosophila CIN models are considered to be an effective model for investigating aneuploidy 
and CIN due to its short generation time and ease of maintaining large numbers of fly stocks. 
It is a simple and less expensive model; more than 70% of human disease causing genes have 
functional homology in Drosophila (Pandey and Nichols, 2011). Moreover, using this model, 
CIN can be induced in a specific tissue or the entire organism by tissue specific knockdowns 
or high expression of genes, allowing us to regulate the expression of multiple genes and 
screen for novel mutations in ways not feasible in vertebrate models. This makes it a good 
model for cancer research and targeted drug discovery studies. Several mechanisms have 
been used to induce CIN in Drosophila including aberrations in mitotic processes, such as 
disruption in spindle assembly checkpoint, cytokinesis defects, and DNA damage elevation to 
develop different CIN models in order to understand the cause of CIN (Bakhoum and 
Compton, 2012a). However, constant genome shuffling in CIN tumours make it hard to 
understand the specific changes that induced CIN, and various possible mechanisms to 
induce CIN may explain why it has been difficult to understand the individual causal 
mutations in specific tumours.  
Nonetheless, it is clear that CIN is a hall mark of cancer cell. Therefore, we can exploit the 
CIN phenotype in order to target cancer cells exhibiting CIN. We can identify the targets that 
can be disrupted to specifically kill CIN cells without affecting normal proliferating cells and 
also understand the causes and cellular responses to CIN.  
Drosophila CIN-inducible in vivo models are a powerful genetic tool for understanding and 
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Abstract: Chromosomal instability (CIN) is a common feature of tumours that leads to increased 
genetic diversity in the tumour and poor clinical outcomes. There is considerable interest in 
understanding how CIN comes about and how its contribution to drug resistance and metastasis 
might be counteracted. In the last decade a number of CIN model systems have been developed in 
Drosophila that offer unique benefits both in understanding the development of CIN in a live animal 
as well as giving the potential to do genome wide screens for therapeutic candidate genes. This 
review outlines the mechanisms used in several Drosophila CIN model systems and summarizes 
some significant outcomes and opportunities that they have produced. 
Keywords: aneuploidy; cell cycle; checkpoint; chromosomal instability; DNA damage; Drosophila; 
JNK; metabolism; ROS 
 
1. Introduction 
The acquisition of mutations is a driving force in the formation of any tumour, as these 
mutations represent the genetic diversity from which aberrantly proliferative cells can emerge. 
Genomic instability, or an increased mutation rate, can be generated by numerous cellular defects, 
such as lack of DNA repair, and these typically give a strong predisposition to tumorigenesis [1]. 
Chromosomal instability, or CIN, refers to an increased rate of DNA changes on the largest scale: 
gain or loss of whole chromosomes or chromosome sections. As a common form of genomic 
instability, CIN is linked to tumorigenesis, particularly in solid tumours, where the frequency of 
chromosomal aberrations can be as high as 90% [2]. There are several reasons why CIN might be 
found so often in tumours: some common oncogenic mutations tend to promote CIN by disrupting 
mitosis, some tumours typically only progress with the gain or loss of specific chromosome arms, 
and for a tumour to go on to metastasize seems to require the kind of dramatic rearrangements that 
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CIN generates [3]. Inducing CIN in otherwise normal mouse models is able to double the rate of 
spontaneous tumour formation [4], and in human cancers CIN is associated with significantly worse 
clinical outcomes [5]. Because CIN generates genetic diversity in tumours it is thought to promote 
drug resistance and relapses following chemotherapy. For these reasons there has been considerable 
research into the causes and possible therapies for chromosomal instability. 
One of the problems in trying to understand the onset of CIN in tumours is that by the time they 
are detected, they have divided unstably many times and become so genetically diverse that it is hard 
to identify the specific changes that induced the CIN. In theory, by examining many clinical CIN 
tumour samples we should be able to find the common changes, but the limited studies available 
have not clearly identified causal mutations [6]. An alternative approach, testing specific mitotic 
defects in culture or animal models, has shown that CIN can be caused by a range of defects in the 
attachment of chromosomes to the spindle as well as by loss of checkpoints, elevated DNA damage 
or replication stress [7]. This wide range of possible mechanisms may explain why it has been 
difficult to identify individual causal mutations in specific tumours, and also raises clinical 
challenges. It may be obvious that CIN is a dangerous cellular phenotype that we would like to 
prevent, but CIN prevention is problematic even in theory, with so many possible defects that can 
cause instability. An alternative is to accept that CIN will arise in tumours, and to look instead for 
therapies that can target such cells. From this perspective, the CIN phenotype is a therapeutic 
advantage, because CIN represents a significant difference from normal proliferating cells that may 
allow targeting of therapy to avoid damaging the patient. The question then is: can we find targets 
that can be disrupted to specifically induce death in CIN cells without affecting normal dividing 
cells? 
2. CIN models and their limitations 
An obvious approach to this problem is to get cultures of CIN cells, and screen them with 
chemical libraries to find anything that kills CIN, but not normal cells. To some extent this has been 
attempted [8], but there are several challenges with this approach. CIN lines are inherently 
varied—potentially every cell has a different genome, and each cell varies as it is cultured. This 
means that it is problematic to do reproducible experiments. However, the objective is to find 
generalizable therapies that affect any CIN cells, so in theory the approach can still work if enough 
chemicals are tested enough times. Using karyotypic heterogeneity as a proxy for CIN, the well 
characterized panel of 60 human cancer cell lines from the NCI has been used to identify drugs that 
preferentially affect karyotypically diverse cell lines [9,10]. Perhaps unsurprisingly, none of the 
current cancer therapeutics tested were particularly effective against the unstable cell lines. Some 
novel drug classes were found that could inhibit the growth of unstable lines with some specificity, 
however, as the authors comment, these correlations are a “blunt tool for drug discovery requiring 
secondary experimental confirmation” [10]. In addition, the cell lines used have inevitably arisen 
with constraints very different to those faced by tumours in vivo, and the most effective chemicals 
identified gave no clear idea of how they might be working. For these reasons it is valuable to have 
animal CIN tumour models in which specific and reproducible mechanisms for killing CIN cells can 
be identified and characterized. This review will focus on the development of CIN models in 
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3. Advantages of using Drosophila 
As an animal model for studying CIN, Drosophila has some significant advantages. It is now 
straightforward to manipulate the expression of any gene in Drosophila, at any stage of development 
in any tissue of interest. In the context of CIN, this means that animals can be grown that are 
genetically normal, with CIN induced by gene mis-expression in the proliferating tissue of choice 
when required. For example, the larval wing disc can be used to provide a testbed of cells that start 
out identical each time the experiment is done, while allowing the generation of a diverse set of CIN 
cells to study [11,12,13]. This avoids the issues of reproducibility faced when using CIN cell lines, as 
well as providing an in vivo epithelium that better reflects the environment of CIN tumours when 
they arise. This could theoretically be done in mice [14,15], but large scale screening in mice is 
impracticably time consuming and expensive. To identify and characterize novel mechanisms by 
which CIN cells can be specifically killed, it is useful to have an inducible in vivo system that allows 
genome-wide screening. Using Drosophila provides such a system as well as giving access to 
unparalleled resources for genetic analysis of any candidates identified [16]. This includes easy 
screening for genetic interactions, pathway dissection by epistasis and modelling of most of the 
hallmarks of cancer [17-21]. 
4. Drosophila CIN models 
As mentioned above, there are numerous mitotic processes that are known to give CIN when 
disrupted in cell culture or mouse models, and several of these have been exploited in Drosophila to 
create inducible CIN models. They can be broadly classified as disruption of the mitotic spindle, 
checkpoints, cytokinesis or DNA repair. 
4.1. Mitotic spindle disruption 
Defects in spindle structure or kinetochore dynamics represent straightforward mechanisms for 
generating CIN. For example, if the spindle is incorrectly formed with too many poles, then 
chromosome segregation is affected (Figure 1A). Centrosome number is frequently aberrant in 
cancers, so this form of CIN has been modelled by altering the levels of centrosome regulatory genes 
such as polo or sak, and showing that neural cells with aberrant numbers of centrosomes go on to 
form malignant and metastatic tumours in Drosophila [22,23]. It is interesting that although very 
little CIN was initially detected in the mutant brains, when they had been transplanted and grown in a 
host they became strikingly aneuploid. Exactly when and how the CIN arises in these models is not 
well characterized, but they appear to recapitulate human tumorigenesis in which CIN is generally 
not an early trigger, but arises in an already hyper-proliferative tissue. Another striking observation 
from cells with elevated centrosome numbers was that spindles are surprisingly effective at 
generating a bipolar array even with many extra centrosomes present, as long as the spindle 
checkpoint is working to allow enough time to cluster the centrosomes [23,24]. This checkpoint 
control is not completely effective in neuroblasts, though, which can lose the correct spindle 
alignment and cell polarity, leading to a failure to differentiate and consequent overproliferation. 
Interestingly, CIN tumours can also be made without altering the centrosomes simply by disrupting 
neuroblast polarity. In this case, again there is a failure to differentiate, and an expansion of 
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Figure 1. Drosophila CIN models: (A) An induced defect in centrosome number 
(wavy arrow) leads to a tripolar spindle. This is resolved into a bipolar array before 
anaphase, but one chromosome fails to segregate (arrow). (B) An induced defect in 
DNA damage repair or replication leads to still catenated chromatids (enlarged). At 
anaphase this leads to a chromosome bridge (arrow) that will break, leading to loss 
or gain of chromosome segments. (C) An induced spindle checkpoint defect means 
that a kinetochore attached to both poles (wavy arrow) may not be resolved before 
anaphase, leading to failure to segregate a lagging chromosome (arrow) that is 
attached to both poles. （D） An induced cytokinesis defect (wavy arrow) leads to no 
separation of daughter cells, and results in a binucleate cell with a tetraploid 
genome and an extra centrosome. 
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proliferative neuroblasts that can be transplanted to form malignant and metastatic tumours [25]. The 
initial neuroblasts are karyotypically normal, but become aneuploid and acquire centrosome defects 
as the tumour develops. From these studies and others [26] it seems that most tissues in Drosophila 
resist tumorigenesis from centrosome alterations by dying, but neuroblasts are an exception. In these 
cells, anything that expands the ‘stem-like’ population of transit amplifying lineage neuroblasts will 
tend to not only cause overgrowth, but also the acquisition of additional defects that cause CIN and 
allow metastatic tumour growth. It will be interesting to find out what changes arise so rapidly and 
frequently to transform overgrowing neuroblasts; recent work in this direction has implicated DNA 
damage [27]. 
4.2. Elevated DNA damage 
Mutations that either increase the rate of DNA damage or that reduce the cell’s ability to repair 
DNA damage are another type of CIN model available in Drosophila (Figure 1B). For example, high 
levels of instability can be induced by blocking tefu, the Drosophila homolog of ATM, which is 
needed for DNA damage repair and telomere maintenance [28]. Interestingly, ATM also acts as a 
redox sensor protein, so it is activated either by DNA damage itself or by oxidative stress that 
threatens the DNA [29]. Balancing the levels of cellular pro- and anti-oxidants is clearly important 
for cells, as too much of either is able to generate CIN [30]. Furthermore, the aneuploidy generated 
by CIN is known to cause oxidative stress [31], which can damage DNA to cause further aneuploidy, 
so there is potential for feedback reinforcement of initially minor oxidative insults. Sophisticated 
tools are now available in Drosophila to monitor the levels and locations of redox stress in live 
tissues [32]. DNA damage itself is harder to monitor live, but some markers are available [33,34]. It 
would be particularly useful to be able to monitor the persistence of DNA damage into mitosis, as 
there are many unresolved questions about chromosome bridges and the resolution of double strand 
breaks in mitosis. For example, replication stress can induce CIN [35], but it is not clear whether this 
mechanism is often found in CIN tumours [36]. Ultrafine anaphase bridges, which result from late 
decatenation of chromatids [37], represent another potential source of CIN that has not yet been 
explored in Drosophila. These bridges indicate an unexpected level of DNA processing during 
mitosis even after the DNA damage and spindle checkpoints have been passed. This may explain 
why mitotic stability is so dependent on DNA damage repair being completed in time. The need for 
efficient DNA repair has been highlighted by our work showing that CIN cells are particularly 
dependent on JNK signalling in G2 to prevent DNA damage accumulation and apoptosis [38]. Even 
just altering G2 duration strongly affects the survival of CIN cells; we suggest this is because CIN 
cells are particularly sensitive to entering mitosis with unrepaired DNA damage. If DNA damage or 
aneuploidy levels get too high, the JNK pathway is also used to drive apoptosis [13,26,39]. How the 
JNK pathway integrates multiple stress signals to decide between repair versus death is an area of 
active research [40,41,42]. 
4.3. Spindle assembly checkpoint mutations 
The best characterized cause of CIN is a failure in the spindle assembly checkpoint that allows 
segregation of chromosomes that are not correctly bioriented on the spindle (Figure 1C). There is 
abundant evidence that a defect in the spindle checkpoint in cell culture [43], animal models [44] or 
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humans [45], leads to CIN. Analysis of mutations found in tumours suggests that complete loss of 
spindle checkpoint proteins is rare [46], presumably because that would generate an intolerably high 
level of instability. However there are numerous examples of tumours in which the checkpoint is 
aberrant, either in protein levels or localization [44,47,48]. 
Using a defective spindle checkpoint as a CIN model has some advantages: the previously 
mentioned centrosomal and DNA damage models will tend to trigger checkpoints that promote cell 
cycle arrest and apoptosis rather than the desired unstable proliferation. In vertebrate systems, the 
level of spindle checkpoint disruption must be carefully controlled to avoid lethal levels of 
aneuploidy, but in Drosophila, the process of capturing the four chromosomes is sufficiently robust 
that even complete loss of the checkpoint can give viable animals [49]. This CIN model provides a 
perfect sensitized background for genetic screening in which even minor disruptions to genes needed 
for CIN cell survival can push these checkpoint compromised animals over the threshold of viability [11]. 
This screen tested the set of kinases and phosphatases and identified the JNK pathway and 
centrosomal signaling as key areas of CIN cell sensitivity. Although this type of viability screening 
has the benefit of being high-throughput, it has the drawback of a relatively non-specific phenotype: 
the death could be due to a range of developmental defects that would not be relevant to CIN 
tumours. However, further analysis allows confirmation that depleting the candidates by RNAi in 
proliferating CIN cells, such as the wing imaginal disc, can cause cell death [11]. This screen 
discarded mutations that were lethal in wild type as well as CIN animals, potentially missing some 
effective ways to kill CIN cells, however this approach should tend to identify more clinically useful 
approaches with fewer side effects on normal cells. Subsequent testing of good candidates in 
Drosophila tumour models [18] may allow confirmation that the genes in question are needed for the 
growth of bona fide CIN tumours. Our viability screen induced CIN by using RNAi to deplete the 
spindle checkpoint protein Mad2, but numerous alternative CIN models are available to confirm the 
generalizable effectiveness of candidates, including models depleting the checkpoint protein BubR1, 
or the cohesin Rad21 [38,50].  
Another use of spindle checkpoint CIN models in Drosophila has been to explore the fate of 
CIN cells if apoptosis is prevented [12,13]. Although the spindle checkpoint is not strictly needed for 
Drosophila survival, checkpoint mutants lose many cells to apoptosis as they grow, so preventing 
apoptosis allows analysis of the behaviour of the most aneuploid and aberrant cells, which might also 
be found in apoptosis-resistant cancers. These were found to activate the JNK pathway and drop out 
of the epithelium, a metastatic behaviour seen in other similarly “undead” cells [39,51]. 
4.4. Cytokinesis defects 
It has been noticed in human tumours that although they frequently show CIN and grossly 
aberrant karyotypes, in many cases the chromosome number seems to vary around a tetraploid rather 
than a diploid complement [52,53]. In some cases tetraploidy strongly predicts human tumour 
progression [54], and elegant studies in mice have shown that simply blocking one round of 
cytokinesis to give tetraploid cells can trigger tumorigenesis [55]. Drosophila is an excellent model 
system for studying cytokinesis—many of the genes and interactions that drive the process were 
discovered in flies [56-59]. Although there are numerous Drosophila RNAi lines that allow induction 
of cytokinesis failure and the generation of tetraploid cells, the relationship of tetraploidy to CIN 
development and tumorigenesis has not been intensively studied in flies [60]. Recent work showing 
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the involvement of the Hippo pathway in tetraploid cell survival [61] may prompt further 
investigation in this area. 
All these methods for generating CIN involve genetic disruption, but it is also possible to induce 
CIN chemically, for example by inhibiting kinesins with monastrol to cause monopolar spindle 
formation [62]. This approach has been used in vertebrate cell culture for some time, and has 
recently been developed in Drosophila by replacing the fly kinesin with the human version, which is 
sensitive to inhibition by small molecules [63]. Chemical induction of CIN has the advantage that it 
is convenient for developing high-throughput screening in culture, and by using Drosophila cells, it 
is convenient to then rapidly screen candidate hits in flies for in vivo phenotypes. 
5. Conclusion 
At the beginning of this review we posed a question of particular clinical interest: can we find 
targets that can be disrupted to specifically induce death in CIN cells without affecting normal 
dividing cells? Use of induced CIN models in Drosophila has allowed some significant progress to 
be made in this direction. It has been known for over a century that centrosomes are often aberrant in 
cancers [64], but studies in Drosophila have made it clear that just having the wrong number of 
centrosomes is not in itself enough to result in tumorigenesis [18], because either the spindle 
checkpoint can delay anaphase until a bipolar spindle has formed, or because the grossly aneuploid 
progeny will die by apoptosis. The striking exception to this generalization is also significant—in 
brains, neither the spindle checkpoint nor apoptosis are able to prevent tumorigenesis from 
neuroblasts that have lost their polarity cues. In these cells, too many or too few centrosomes or 
disruption of cortical polarity markers can all trigger failure to differentiate and hyperplasia that 
often progresses to metastatic tumours. It is not yet clear why neuroblasts are insensitive to genomic 
disruption that triggers apoptosis in other cells, but since human CIN tumours share this cell death 
resistance, either neuroblasts or disc cells with blocked apoptosis are appealing CIN models for 
looking at aneuploid cell behaviour [65]. 
The significance of centrosomes has been emphasized: in CIN cells even slight perturbation of 
the centrosomes tends to give cell death [11]. This is consistent with reports showing that the spindle 
checkpoint is needed to survive extra centrosomes [66]. The JNK pathway is also clearly implicated 
in CIN cell survival and proliferation. JNK is typically activated in response to cell stress, but it is 
important to recognize that it gives two possible outcomes: if the stress is low level it promotes repair, 
whereas if the stress is acute, JNK promotes apoptosis [40]. Consequently, blocking JNK signalling 
in CIN cells can either cause their death through failed DNA repair [11,38] or prevent their death in 
response to gross aneuploidy [13,26]. Although targeting either centrosomes or JNK signalling may 
allow effective manipulation of CIN cell fates, neither is ideal as a clinical target, due to their critical 
functions in normal cells. An alternative that may offer better clinical promise is to genetically or 
chemically target the metabolism of CIN cells. We have found that CIN cells are highly sensitive to 
RNAi knockdowns that give a range of mild metabolic perturbations that do not affect normal cells [50]. 
Some of these (e.g. Pas Kinase) may be amenable to chemical inhibition. It is known that aneuploid 
cells experience redox stress [67], so one possible hypothesis is that CIN cells, with their ongoing 
and varied aneuploidy, are close to the limits of their ability to buffer redox stress, and hence are 
vulnerable to metabolic intervention. Because tumours frequently display an aberrant metabolism as 
well as chromosomal instability, there are reasons to hope that metabolic therapy may be effective at 
8 
 
AIMS Genetics  Volume 2, Issue 1, 1-12. 
generating tumour-specific apoptosis with minimal side effects [68]. 
There are a number of remaining challenges in understanding the causes and cellular responses 
to CIN. For example we still have no clear explanation for why the many varied genotypes generated 
in CIN populations so frequently seem to give the same stereotypical cell phenotype that includes 
overactive mitochondria, reactive oxygen species production, activation of the JNK pathway etc. It 
may be simply that any gene dosage variation gives protein folding stress [69], but we suspect that 
there may be other mechanisms that contribute to the response to aneuploidy. For example, many 
organisms can partially buffer gene dosage changes by down- or up-regulating the expression of 
genes in trisomic or monosomic DNA segments [70,71]. Several dosage compensation mechanisms 
exist for ensuring equal gene expression from sex chromosomes in males and females [72], and there 
are suggestions that extra somatic chromosomes can be shut down by nuclear compartmentalization [73], 
so it will be interesting to see whether CIN cells use similar processes to allow tolerance of gross 
aneuploidy. Because CIN develops fairly rapidly in Drosophila tumour models [25], they may be 
ideal for characterizing the acquisition of the changes that result in cells not only tolerating aberrant 
karyotypes, but also going on to proliferate and metastasize. 
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Our initial broad screening identified some metabolic regulators, such as phospho-fructokinase 
(Pfrx) and PAS kinase. These glycolysis regulators were not previously known to affect mitotic 
events, but we found that their knockdown causes strong CIN-specific apoptosis (Shaukat et 
al., 2015). Pfrx and PAS kinase both function to promote glycolysis so we tested whether a 
range of other metabolic disruptions could also affect CIN cells. Consistent with this findings, 
we observed that specific knockdowns affecting the TCA cycle, fat metabolism, 
gluconeogenesis and oxidative stress response enzymes could all promote CIN-specific 
apoptosis (Shaukat et al., 2015). These processes all affect the maintenance of cellular anti-
oxidant levels, so we tested whether depletion of these candidates caused oxidative stress in 
CIN cells. We observed disruption of mitochondria and glutathione levels, with high levels of 
reactive oxygen species (ROS) and oxidative damage to DNA in these cells. The oxidative 
damage was responsible for the cell death, because overexpression of antioxidant enzymes 
could block apoptosis in these cells. Significantly, oxidative damage was not seen when the 
metabolic candidates were depleted in normal cells.  
Having found that metabolic candidates when depleted cause apoptosis in CIN cells, we wished 
to understand their mechanism in a CIN tumor model. Like many animals, Drosophila are 
prone to cancer as they age (Gonzalez, 2013), but the process can be reliably induced by 
depleting tumour suppressors. We use RNAi to knock down brat, which produces aggressive, 
metastatic brain tumours that can be explanted into normal Drosophila hosts and passaged to 
follow their development (Rossi and Gonzalez, 2015). We observed that these tumours rapidly 
acquire CIN and their ROS levels are elevated. This represents a genetically manipulable CIN 
tumour model that is ideal for testing the effect of metabolic interventions on the tumour and 
host animal. 
We tested our best RNAi candidates from earlier screening to identify those that could block 
the growth of CIN tumours. Some G6PD, and JNK knockdowns gave elevated cell death and 
smaller primary tumours, but were not able to prevent the growth of explants and their 
metastases. Of note, we found that depletion of Phosphoenol-pyruvate Carboxykinase 
(PEPCK) as well as feeding the host a PEPCK inhibitor, was able to completely block the 
growth of CIN tumours. PEPCK catalyzes the formation of phosphoenolpyruvate from 
oxaloacetate, and is an early step in gluconeogenesis in the liver. PEPCK also drives the 
formation of Glycerol-3-Phosphate (Beale et al., 2004). This glyceroneogenesis is used to 
provide the backbones for lipid synthesis, which is vital for proliferating cells, as they need to 
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double their membrane content with every cell division. Glucose can be used for this purpose, 
but glyceroneogenesis appears to be the preferred source, even in fed animals (Nye et al., 2008).  
We wished to understand why PEPCK depletion blocks the growth of tumours, while it has so 
little effect on normal cell proliferation.  We checked for ROS because induced-CIN cells and 
tumours that acquire CIN have elevated ROS levels and depend on antioxidants for survival 
(Shaukat et al., 2015). We found that feeding antioxidant to the host can restore growth to 
PEPCK depleted CIN tumours. This suggests that PEPCK does something to lower redox 
stress. In this study we proposed that the critical role of PEPCK in these tumours is to lower 
cytoplasmic NADH levels. 
We concluded that CIN tumours need glycolysis to grow, so they must generate NADH, but as 
aneuploid cells they suffer redox stress that limits their capacity to tolerate any further ROS. 
PEPCK represents a way to lower NADH without making ROS, but if we block this, we have 
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Glycolysis-driven Growth in 
Drosophila Tumors
Rashid Hussain1, Zeeshan Shaukat1, Mahwish Khan1, Robert Saint2 & Stephen L. Gregory1
Tumors frequently fail to pass on all their chromosomes correctly during cell division, and this 
chromosomal instability (CIN) causes irregular aneuploidy and oxidative stress in cancer cells. Our 
objective was to test knockdowns of metabolic enzymes in Drosophila to find interventions that 
could exploit the differences between normal and CIN cells to block CIN tumor growth without 
harming the host animal. We found that depleting by RNAi or feeding the host inhibitors against 
phosphoenolpyruvate carboxykinase (PEPCK) was able to block the growth of CIN tissue in a brat 
tumor explant model. Increasing NAD+ or oxidising cytoplasmic NADH was able to rescue the growth 
of PEPCK depleted tumors, suggesting a problem in clearing cytoplasmic NADH. Consistent with this, 
blocking the glycerol-3-phosphate shuttle blocked tumor growth, as well as lowering ROS levels. This 
work suggests that proliferating CIN cells are particularly vulnerable to inhibition of PEPCK, or its 
metabolic network, because of their compromised redox status.
Chromosomal instability (CIN) refers to cell divisions that cannot maintain chromosomal integrity or number. 
This can be caused by defects including elevated DNA damage, weakened cell cycle checkpoints or an aberrant 
mitotic spindle1. CIN is a common phenotype of human tumours and generates genetic variation that has been 
associated with tumour evolution, the development of drug resistance and the consequent poor prognosis of CIN 
cancer patients2. We and others have proposed that CIN itself could be an attractive target for chemotherapy, as 
it is a relatively cancer-specific phenotype 3–6. However, as CIN cells are necessarily genetically diverse, it is chal-
lenging to identify conserved features of CIN cells as potential targets. Our approach has been to induce CIN in 
a genetically uniform population of cells in vivo in Drosophila and to screen for genes that can be knocked down 
to kill CIN cells without affecting normal proliferating cells3, 7, 8. We hypothesize that the candidates giving wide-
spread cell death in CIN cell populations are targeting vulnerabilities common to a wide range of aneuploidies.
This approach identified plausible targets such as JNK signalling and centrosomal regulators that could be 
depleted to give CIN-specific lethality3. In addition, we found metabolic targets such as Phosphoenol pyruvate 
carboxykinase (PEPCK), and Glucose-6-phosphate dehydrogenase (G6PD)7. Knockdown of these genes gave 
increased mitochondrial output, reactive oxygen species (ROS), DNA damage and cell death in CIN cells without 
affecting normal proliferating cells. Tumours are often metabolically unlike their surroundings, with elevated 
glycolysis for anabolism rather than ATP generation9. This metabolic demand is shared to some extent by all 
proliferating cells, as they must generate cellular building blocks before they can replicate their DNA and divide. 
CIN tumours carry an additional burden, however, as it has been observed that aneuploid cells suffer redox stress 
in proportion to their aneuploidy10. Though we lack a detailed understanding of how aneuploidy causes redox 
stress, the evidence implicates a combination of elevated ROS levels and protein turnover problems11. The com-
bination of this redox stress and a Warburg metabolism makes CIN tumours potentially vulnerable to metabolic 
intervention that does not affect normal cells.
Having found metabolic targets that were able to kill proliferating cells with induced CIN, we wished to under-
stand their mechanism of action in the context of a growing CIN tumour. In this paper we describe the CIN 
status of brat explant tumours and their use as a fly CIN tumour model. Chemical as well as genetic inhibition of 
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Figure 1. Characterization of brat-RNAi as a CIN tumor model. (a) RFP-labelled 3rd instar larval brain tissue 
depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) was dissected and transplanted into the abdomen of 
wild type adult hosts. Serial passages of the tumor explant were carried out into a new host within a fortnight 
to allow the tumor growth to be continued. (b) Control 3rd instar larval brain tissue (da > Gal4; UAS-RFP) was 
transplanted and showed no growth after 2 (b) or 14 days (b’). Labelled 3rd instar larval brain tissue explants 
depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) showed considerable growth on day 13 (c) compared 
to day 2 (c) after transplantation. (d) The average growth rate of brat tumor explants (da > Gal4; UAS-RFP; 
UAS-brat-RNAi). A significant decrease in the mean growth rate was observed in Passage 2 (p < 0.01, n = 19) 
and Passage 3 (p < 0.001, n = 8) relative to the first transplantation. (e) Cell death was measured in 3rd instar 
larval brains depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) and in serial passages of this tissue. The 
rate of cell death significantly increased in the second and third passage (p < 0.001, n > 13 for each), but was 
not significantly different from the larval tissue to the first explant (p > 0.06, n > 13). (f) The level of reactive 
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metabolic candidates in this model identified targets such as PEPCK that could effectively block tumour growth. 
Elevated levels of ROS were observed in the targeted tissue, and adding antioxidants could rescue growth. 
Experiments to identify the source of the ROS suggested that pressure to clear cytoplasmic NADH generated in 
glycolysis was leading to ROS generation by the glycerol phosphate shuttle. Our results suggest that metabolic 
interventions that constrain clearance of NADH can generate toxic ROS levels in CIN tumours without harming 
the host.
Results
Characterization of bratRNAi as a CIN tumor model. Mutations in the gene brain tumour (brat) cause 
tumours in Drosophila larval brains due to a failure of neuroblast differentiation12, and this tissue can be grown 
indefinitely as explant tumors if serially transplanted into the abdomen of host adult flies13 (Fig. 1a). We initially 
tested whether depletion of Brat by RNAi gave effective tumour growth comparable to mutant alleles. Dissection 
of third instar larval brains from control animals marked with RFP and transplanted in to a wild type adult 
host showed no growth (Fig. 1b), but depletion of Brat by RNAi resulted in strong growth of the RFP-tagged 
transplanted tissue (Fig. 1c) that would typically kill the host within two weeks. Serial passaging of the tumor 
tissue after ten days’ growth allowed the development of the tumors to be followed. We observed a significant 
decrease in the rate of growth (Fig. 1d) and increased cell death (Fig. 1e) in these tumors over the first three 
passages. Levels of reactive oxygen species (ROS) were high in the explants, with a significant increase relative 
to the larval brain tumour and from the first to third passage (Fig. 1f). We also observed metastasis, which is a 
common feature of these explant tumors14. Measuring the frequency of aberrant anaphases showed that the CIN 
rate was 20.2% (±3.2%) in bratRNAi larval brains (n = 15), comparable to our previous CIN model, mad2RNAi, 
which showed defects in 24% of anaphases3. We further analysed the CIN rate in bratRNAi tumor explants up to 
three passages and found the highest CIN rate in passage 1 which decreased over time in the subsequent passages, 
similar to the explant growth rate (Fig. 1g). These initial studies confirmed that depletion of brat by RNAi was 
a viable method for generating aggressive CIN tumors that shared the high-ROS phenotype that we and others 
identified when CIN was induced in normal proliferating tissue7, 15, 16.
Effect of metabolic interventions on CIN tumors. Having previously shown that cells with induced 
CIN are sensitive to several metabolic interventions7, we now wished to test the effect of such knockdowns on 
CIN tumors. We tested a range of genes affecting glucose usage (G6PD, PEPCK, Wwox), lipid metabolism (Mfe2) 
and antioxidant responses (JNK). We initially measured their effect on the size of overgrowth observed in bratRNAi 
larval brains (Fig. 2a). All of the candidate knockdowns tested gave significantly reduced overgrowth at this stage, 
with some no larger than non-tumorous controls (e.g. bratRNAiJNKRNAi). Reduced overgrowth could have been 
caused by less proliferation or more cell death; our data from wing discs suggested that cell death was likely to be 
occurring7. Surprisingly, we did not observe a significant increase in cell death relative to brat alone for any of the 
candidate knockdowns except Glucose-6-phosphate dehydrogenase (G6PD; Fig. 2b). Elevated CIN rates can also 
impact proliferation, so we tested whether the knockdown of the candidates was affecting the incidence of CIN in 
brat larval brains. Depletion of Jun N-terminal kinase (JNK) gave a significant increase in the CIN rate, while the 
others had little (Mfe2) or no effect (Fig. 2c). These data indicated that all of the candidates were able to impact the 
growth of brat larval brains, and suggested that varied mechanisms were responsible, with G6PD depletion giving 
cell death and JNK depletion causing more CIN. When these candidates were tested for their effect on ongoing 
tumor proliferation in explants, we were surprised to find that neither G6PD nor JNK depletion were able to 
effectively inhibit brat tumor growth (Fig. 2d). However, depletion of either Phosphoenolpyruvate Carboxykinase 
(PEPCK) or Multifunctional enzyme type 2 (Mfe2) did block the growth of explanted brat tumors (Figs 2d and 3).
The role of NADH in brat tumour growth inhibition by PEPCK depletion. As an enzyme with a 
relatively well characterized function in glucose metabolism, PEPCK became the focus of further investigation 
aimed at explaining how CIN tumor growth can be blocked. We found that feeding the hosts an inhibitor to 
PEPCK (hydrazine; Hyd) was able to block brat explant growth, consistent with our depletion of PEPCK in the 
tumor by RNAi (Fig. 3). PEPCK catalyses the inter-conversion of oxaloacetate and phosphoenolpyruvate (Fig. 4a) 
and is rate limiting for gluco- and glyceroneogenesis17, 18. Proliferating cells must generate lipids and nucleotides, 
and to do so typically drive glycolysis at a high rate. This leads to a build-up of NADH in the cytoplasm which 
must be cleared for glycolysis to continue. The glycerol-3-phosphate shuttle is an important sink for NADH that 
could be significant for the growth of brat tumors19. PEPCK is required for glyceroneogenesis (Fig. 4a), which is 
oxygen species (ROS), was measured in labelled 3rd instar larval brains depleted for Brat (da > Gal4; UAS-RFP; 
UAS-brat-RNAi), and compared with subsequent serial passages of the explanted tissue (P1 to P3) or with 
tissue treated with an antioxidant (EGCG) or pro-oxidant (Mnd; Menadione) as controls. A strong increase in 
ROS was observed in the first passage (p < 0.001, n = 10), with a modest increase from passage 1 to passage 3 
(p < 0.05, n = 16). (g) The rate of chromosomal instability was measured in larval brains (da > Gal4; UAS-RFP; 
UAS-brat-RNAi) and subsequent passages of this explanted tissue. The proportion of visibly aberrant anaphase 
figures was significantly higher in the first passage (78 ± 3%, n = 141 compared to 20 ± 3%, n = 622, p < 0.001), 
but then decreased over the next two passages (p < 0.001, n > 100 for each). (h,i) Representative images of 
normal and defective anaphases from Brat depleted brain tissue (da > Gal4; UAS-RFP; UAS-brat-RNAi), 
quantitated in (g). The arrow indicates an anaphase bridge. In all graphs, error bars show the 95% confidence 
intervals. Variation in means were tested for significance using Dunnett’s multiple comparisons test. Variation 
in proportions were tested for significance using Fisher’s exact tests.
www.nature.com/scientificreports/
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a significant contributor to the generation of glycerol-3-phosphate, even in the presence of glucose20. We tested 
the requirement for this shuttle by either depleting cytoplasmic Glycerol-3-Phosphate Dehydrogenase (Gpdh) 
in the tumour or by feeding the host a specific inhibitor (iGP1) of GPO1, the mitochondrial Glycerophosphate 
Figure 2. Identifying gene knockdowns that affect CIN tumor growth. (a). Comparison of the size of 3rd instar 
larval brains depleted for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) or brat and one of five genes known to 
increase apoptosis in CIN cells. Control brains were da > Gal4; UAS-RFP. Error bars indicate 95% confidence 
intervals, n > 10 in all cases. All candidate gene knockdowns gave a significant reduction in larval brain size 
relative to brat-RNAi alone (p < 0.001 for all except Wwox-RNAi, p < 0.05). (b) Apoptosis in brat-RNAi larval 
brains was compared with brat plus candidate knockdowns. Depletion of G6PD showed significantly elevated 
apoptosis compared to the brat alone control (p < 0.001, n ≥10). All other comparisons with the control showed 
no significant variation (p > 0.05). (c) The rate of chromosomal instability was measured in larval brains depleted 
for Brat (da > Gal4; UAS-RFP; UAS-brat-RNAi) and compared with brains lacking Brat and a candidate. The 
proportion of aberrant anaphases was elevated relative to the brat control (20%, n = 622 anaphases) when JNK 
(56%, p < 0.001, n = 495) or Mfe2 (32%, p < 0.05, n = 257) were also depleted. All other comparisons with the brat 
control showed no significant variation (p > 0.05 using Fisher’s exact test, n > 200 for each). (d) Growth rate of 
tumor explants. RFP labelled brain tissue from 3rd instar larvae was transplanted into a wild type adult host and 
growth was measured over two weeks. No growth was observed in control tissue (da > Gal4; UAS-RFP). Depletion 
of Brat led to rapid explant growth, which was not significantly affected by co-depleting G6PD, JNK or Wwox 
(p > 0.05, n ≥ 10). Co-depletion of PEPCK gave a strongly reduced growth rate relative to brat alone (p < 0.05, 
n = 10), as did co-depleting Mfe2 (p < 0.05, n = 10). All error bars show the 95% confidence interval, p values are 
from Dunnett’s multiple comparisons test except for proportions, for which Fisher’s exact test was used.
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Figure 3. Effect of metabolic intervention on the growth of CIN tumors. (a) Labelled 3rd instar brain tissue 
depleted for Brat (actin > Gal4; UAS-RFP; UAS-brat-RNAi) was grown in wild type hosts for up to two 
weeks. Feeding the host with the PEPCK inhibitor Hydrazine (Hyd.) blocked tumor growth, as did depleting 
PEPCK by RNAi. Co-depletion of the cytoplasmic Glycerol-3-Phosphate Dehydrogenase (Gpdh), Malate 
dehydrogenase (Mdh1) or Malic Enzyme (Men) with Brat was able to block growth, as did feeding the host 
iGP1 to inhibit the mitochondrial Glycerophosphate Oxidase. All treatments gave a statistically significant 
decrease in growth relative to the brat control (p < 0.001 for each, n ≥ 5) (b) The effect of supplementing food 
with nicotinamide (Nam) was tested on host adults carrying explanted tumors with the indicated genotypes. 
All genotypes showed significantly increased explant growth when given nicotinamide (multiple t-tests using 
the Holm-Sidak method, *p < 0.05, **p < 0.01, ***p < 0.001). (c) Explants depleted for Brat and PEPCK 
(actin > Gal4; UAS-RFP; UAS-brat-RNAi; UAS-PEPCK-RNAi) did not grow, but could be induced to grow by 
feeding their adult hosts the antioxidant propyl gallate (PG). Increasing the NAD+/NADH ratio by feeding the 
hosts ferricyanide (FeCN) or nicotinamide (Nam) could also rescue the explant growth. Significant increases 
over the brat PEPCK control (n = 18) were seen for PG and Nam (p < 0.001, n = 8 and 28), with a modest 
increase seen for FeCN (p < 0.05 by one-tailed t-test, n = 13). (d) The effect of NADH on cell death seen in 
non-tumorous CIN cells depleted for PEPCK. Cells in the posterior half of 3rd instar larval wing discs depleted 
for mad2 and PEPCK (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-PEPCK-RNAi) show a high rate of 
cell death, as measured by Acridine Orange incorporation7, relative to the wild type cells in the anterior half 
of each disc. The mad2 alone control (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-LacZ-RNAi) shows 
little signal. Increasing the NAD+/NADH ratio by feeding with either ferricyanide (FeCN) or nicotinamide 
(Nam) significantly decreased the level of cell death (p < 0.001 for both, n ≥ 10). (e) The effect of inhibiting the 
www.nature.com/scientificreports/
6ScientiFic REPORTS | 7: 11531  | DOI:10.1038/s41598-017-11613-2
Oxidase19. In either case, the growth of brat explants was blocked (Fig. 3a). We were not able to block growth by 
inhibiting hexokinase or uncoupling mitochondrial respiration (data not shown). The inhibition of tumor growth 
by blocking the glycerol phosphate shuttle suggested that these tumors may be sensitive to cytoplasmic NADH 
build-up.
Replacing NAD + can rescue PEPCK brat explant growth. This model for the role of NADH in medi-
ating the effect of PEPCK on brat tumor explants would predict that providing the tumor with NAD+ should 
bypass the need for PEPCK, allowing glycolysis to proceed and PEPCK brat explants to grow. We tested this 
model by feeding the host adult nicotinamide (Nam), a precursor in the synthesis of NAD+ 21. While brat tum-
ors depleted for PEPCK did not grow, we found that the same tumors in hosts fed nicotinamide were able to 
grow, albeit slowly (Fig. 3b). This strongly suggested that lack of NAD+ was a limiting factor when PEPCK was 
depleted. We also found that nicotinamide rescued the growth of brat tumors lacking Gpdh (Fig. 3b), confirming 
the importance of the glycerol-3-phosphate shuttle in oxidising NADH in these tumors. Ideally we would have 
confirmed this by measuring cytoplasmic NAD+/NADH ratios in the explants, but the low NADH concentration 
combined with tiny tissue size made this technically problematic. As an alternative approach, we confirmed that 
cytoplasmic NADH was growth limiting in PEPCK depleted tumors by feeding the hosts ferricyanide (FeCN)22 
which externally drives NADH oxidation, and this was also able to increase growth (Fig. 3c). To test whether this 
rescue of PEPCK phenotypes by NADH oxidation was a feature only of brat tumors, we tested non-tumorous 
proliferating cells in which CIN had been induced by Mad2 depletion. The level of cell death and ROS induced 
by PEPCK depletion in this CIN tissue was significantly rescued by feeding the larvae either ferricyanide or nic-
otinamide (Figs 3d and 5). Proliferating wing disc tissue in which CIN was induced by BubR1 depletion showed 
similar sensitivity to PEPCK depletion (Supplementary Figure 2).
An important side-effect of using the glycerol-3-phosphate shuttle is the production of ROS by mitochon-
drial Glycerophosphate Oxidase (GPO1)23, 24. Given that we observed high levels of ROS in brat tumor explants 
(Fig. 1f), we wished to test whether ROS levels were limiting the usefulness of the glycerol-3-phosphate shuttle 
when PEPCK was depleted. When adult hosts were fed with an antioxidant (propyl gallate; PG), we observed a 
significant rescue of the growth of PEPCK depleted brat tumor explants (Fig. 3c). We tested whether the antiox-
idant rescue seen with propyl gallate was affecting ROS generated by the glycerol phosphate shuttle, by feeding 
Brat depleted larvae metformin, which inhibits mitochondrial Glycerol-3-phosphate Dehydrogenase/GPO125 
(Fig. 3e). Increasing levels of metformin gave decreasing levels of ROS, consistent with the ROS in brat-RNAi 
brain tissue being generated by the glycerol-3-phosphate shuttle. Similarly, adding a specific inhibitor to the glyc-
erol phosphate shuttle in cells depleted for PEPCK and Mad2 also lowered ROS levels (Fig. 5f).
CIN tissues can have an elevated metabolic rate, consuming energy stores faster and producing more mito-
chondrial output than normal proliferating cells7. This was reflected in an increased rate of uptake of labelled 
glucose in proliferating CIN tissue (Rad21-RNAi) relative to controls (Fig. 3f). Feeding the animals a Gpo1 inhib-
itor to block the glycerol-3-phosphate shuttle significantly decreased the uptake of glucose (Fig. 3f), consistent 
with this shuttle being an important sink for NADH that allows glycolysis to continue at a high rate. Depletion 
of PEPCK did not strongly block glucose uptake (Supplementary Figure 3), however in brat tumors, depletion of 
PEPCK had a stronger effect (Fig. 4b), and could be rescued by feeding ferricyanide, confirming the importance 
of NADH oxidation for continued glycolysis in these tumors.
Discussion
CIN induced in Drosophila wing discs has reproducible phenotypic effects3–5, 15, 26, even though the genetic insta-
bility is effectively random. CIN cells typically generate reactive oxygen species, activate the p38 and JNK/Upd 
pathways, drop out of the epithelial layer and trigger an innate immune response. Because of this stereotypical 
response to induced aneuploidy, we reasoned that there should be ways to effectively target the response that 
should be specific to CIN cells. By screening for such CIN-killing interventions, we found several, such as tar-
geting JNK or centrosomes, that were effective but not ideal due to their important roles in normal proliferating 
cells3. Metabolic intervention, on the other hand, has better potential as a therapeutic tool because normal cells 
can tolerate large changes in metabolite concentrations, which they experience during feeding and fasting. On 
that basis we wished to further investigate the effect of metabolic intervention not just on epithelial cells with 
induced CIN, but on a CIN tumour growing in vivo.
Explanted Drosophila brain tumours have been used for over a decade13 and allow the development of a 
tumour to be followed for months by regular passaging. These tumours have been shown to accumulate additional 
glycerol-3-phosphate shuttle on reactive oxygen species produced in Brat depleted 3rd instar larval brain tissue 
(actin > Gal4; UAS-RFP; UAS-brat-RNAi). Adding Metformin at 10 mM or 25 mM significantly decreased 
the level of ROS observed in brat tissue (***p < 0.001, n ≥ 10; ns: p > 0.05). Menadione (Mnd.) and vitamin E 
(VitE) were used as control pro- and anti-oxidant treatments respectively. (f) The uptake of labelled glucose in 
CIN cells was decreased by blocking both PEPCK and the glycerol-3-phosphate shuttle. The posterior halves 
of 3rd instar larval wing discs were depleted for Rad21 (en > Gal4; UAS-CD8-GFP; UAS-Rad21-RNAi; UAS-
Dicer2) to induce CIN. This strongly increased the uptake of fluorescently labelled 2-NBD-Glucose. Depletion 
of PEPCK in CIN cells did not significantly decrease the rate of glucose uptake (p > 0.05, n = 25) relative to CIN 
alone (n = 18). Blocking the glycerol-3-phosphate shuttle by inhibiting GPO1 with iGP1 caused some decrease 
(p < 0.05, n = 12), while adding iGP to wings depleted for PEPCK strongly decreased the rate of glucose uptake 
(p < 0.001, n = 36). In all graphs, error bars show the 95% confidence interval. P values given are from Dunnett’s 
multiple comparisons tests unless otherwise noted.
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centrosomes and become aneuploid, so we were not surprised to find that the CIN rate in transplanted brat tissue 
was relatively high. We also observed an elevated level of reactive oxygen species, consistent with previous find-
ings from Drosophila cells with induced CIN7, 15 and from stable aneuploidy in a range of organisms27. Of course, 
brat tumours have other changes in addition to CIN28, but the phenotype of the brat tumours was sufficiently 
similar to our induced-CIN model to encourage us to examine the best metabolic candidates we had identified in 
the wing disc CIN model. Surprisingly, depleting proteins like G6PD or JNK had little effect on tumour explant 
growth (Fig. 2d), though they both strongly induced cell death in our wing disc model3. We considered whether 
the number of unstable divisions during the extended proliferation period available to the explants might have 
generated sufficient variation to allow the appearance of mutant clones resistant to the effect of our knockdowns. 
We think this unlikely, as other similar interventions, such as PEPCK-RNAi never acquired resistance and for 
G6PD or JNK we did not see a period of limited growth followed by rapid expansion, which would be expected 
if tumours were acquiring resistance. Instead we saw immediate growth upon transplantation, suggesting that in 
this environment, those knockdowns were not able to effectively block cell proliferation. Prior to transplantation, 
knockdown of G6PD did give reduced brain size and increased ROS and cell death in brat larval brains, suggest-
ing that some feature of the transplantation environment was able to rescue their growth. Further investigation 
will be needed to account for this growth difference.
Following our initial tests, we focused our attention on PEPCK, which consistently blocked the growth of 
explanted tumours. PEPCK is best known for its role in the liver, where it mediates gluconeogenesis during fast-
ing29. However, PEPCK is expressed widely in non-gluconeogenic tissue in most organisms, notably in muscle 
and gut as well as cancer cells, where its role is more complex, facilitating the catabolism of either glucose or 
glutamine30. PEPCK is regulated transcriptionally by p38 via ATF-231 and post-translationally by acetylation32. 
PEPCK is rate limiting for glyceroneogenesis, the synthesis of glycerol-3-phosphate from TCA cycle interme-
diates33. This is particularly important for the re-esterification of free fatty acids, which is needed to prevent 
the depletion of fats that we and others have noted when PEPCK is removed7, 34. Cell proliferation requires the 
doubling of membrane lipids at each division, so this demand for lipid synthesis could be an important role for 
PEPCK in non-gluconeogenic tissues. However, PEPCK null mutants and RNAi knockdowns remain viable3, 34, so 
this is insufficient to explain why PEPCK depleted brat explants cannot grow and why PEPCK depleted CIN wing 
disc cells apoptose. A possible explanation is suggested by our observation that providing antioxidants or increas-
ing NAD+ could rescue the growth of PEPCK depleted brat explants. Our data suggest that these interventions 
Figure 4. Model for the effect of PEPCK and NADH on glucose metabolism. (a) Proliferating cells require 
glucose for processes including the synthesis of nucleotides (via the pentose-phosphate pathway), membrane 
lipids (via pyruvate and citrate) and energy (via pyruvate or the glycerol-3-phosphate shuttle). Cytoplasmic 
NADH is produced in making phosphoenolpyruvate, which must be oxidised for glycolysis to continue. 
NADH can be oxidised by making lactate, but this prevents the use of pyruvate for lipid synthesis or energy. 
The glycerol-3-phosphate shuttle can oxidise NADH, but does so at the cost of generating elevated ROS levels. 
PEPCK mediates glyceroneogenesis (broad arrow), which uses citrate exported from mitochondria to generate 
glycerol-3-phosphate while oxidising NADH. Our model is that depletion of PEPCK decreases the levels of 
cytoplasmic NAD+ , which inhibits glycolysis unless the NAD+ can be regenerated by the glycerol-3-phosphate 
shuttle. This shuttle generates reactive oxygen species, so its use is limited in CIN cells which are already 
redox stressed. The inhibitors used to test this model are shown with their targets. Abbreviations: DHAP: 
dihydroxyacetone phosphate, Gpdh: Glycerol-3-phosphate Dehydrogenase, Gpo1: mitochondrial Glycerol-3-
Phosphate Dehydrogenase/Glycero-phosphate oxidase, iGP1: inhibitor of Glycerophosphate oxidase 1, Met: 
Metformin, Nam: nicotinamide, FeCN: ferricyanide, PEPCK: Phosphoenolpyruvate Carboxykinase. (b) The 
effect of PEPCK depletion on glucose uptake in brat depleted brain tissue. The uptake of fluorescently labelled 
2-NBD-glucose in 3rd instar larval brains was increased by the depletion of Brat (actin > Gal4; UAS-RFP; UAS-
brat-RNAi; p < 0.001, n ≥ 25). Depleting PEPCK in these brat tumors (actin > Gal4; UAS-RFP; UAS-brat-RNAi; 
UAS-PEPCK-RNAi) led to significantly lower uptake of labelled glucose (p < 0.001, n ≥ 25), which was rescued 
by feeding the larvae with ferricyanide (FeCN, p < 0.05, n ≥ 23). Error bars show 95% confidence intervals. 
Comparisons were done by multiple t-tests using Tukey’s method.
www.nature.com/scientificreports/
8ScientiFic REPORTS | 7: 11531  | DOI:10.1038/s41598-017-11613-2
affected the glycerol phosphate shuttle, which may be an important sink for the NADH generated during glycol-
ysis, but which also generates ROS23.
NADH is made from NAD+ in the cytoplasm during glycolysis, and must be oxidised for glycolysis to con-
tinue. Pyruvate can be converted to lactate to regenerate NAD+ , however this option is limited in proliferative 
cells as pyruvate is in demand for energy and lipid synthesis (Fig. 4a). In some organisms the Malate/Aspartate 
shuttle is used to lower levels of cytoplasmic NADH, however in Drosophila, the Mdh1 and Got1 enzymes that 
would catalyse the cytoplasmic half of the shuttle are found in peroxisomes35. Nonetheless, our data suggest Mdh1 
Figure 5. The effect of cytoplasmic NADH levels on the survival and metabolism of CIN cells depleted 
for PEPCK. (a–d) Cell death caused by depletion of Mad2 and PEPCK could be rescued by feeding larvae 
chemicals to alter cytoplasmic NADH levels. (a) Cells in the posterior half of 3rd instar larval wing discs (left 
of the dotted lines) were depleted for Mad2 and PEPCK (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-
PEPCK-RNAi) and showed an elevated level of cell death, as visualized by Acridine Orange7, relative to the 
wild type cells in the anterior half of each disc. Increasing the cytoplasmic NAD+/NADH ratio by feeding with 
either ferricyanide (d, FeCN) or nicotinamide (c, Nam) significantly decreased the level of Acridine staining, as 
did blocking the glycerol phosphate shuttle by feeding iGP1 (b). Quantitation of the rescue is shown in Fig. 3d. 
(e–h) ROS caused by depletion of Mad2 and PEPCK could also be rescued by changing NADH availability. 
(e) Cells in the posterior half of 3rd instar larval wing discs (left of the dotted lines) were depleted for Mad2 
and PEPCK (en > Gal4; UAS-CD8-GFP; UAS-mad2-RNAi; UAS-PEPCK-RNAi) and showed an elevated level 
of ROS, as visualized by CellRox, relative to the wild type cells in the anterior half of each disc. Increasing the 
cytoplasmic NAD+/NADH ratio by feeding with either 5 mM ferricyanide (h, FeCN) or 5 mM nicotinamide 
(g, Nam) decreased the level of CellRox staining, as did blocking the glycerol phosphate shuttle by feeding with 
2 μM iGP1 (f).
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is still needed to regulate NADH in CIN tumors (Fig. 3a,b). An effective alternative for oxidising cytoplasmic 
NADH is via the glycerol-phosphate shuttle. This shuttle uses Glycerol Phosphate Dehydrogenase to divert from 
glycolysis as much glyceraldehyde phosphate as required to oxidise NADH. This makes glycerol-3-phosphate, 
which can be removed by dephosphorylation to glycerol, or by acylation to make fats, however the shuttle uses 
mitochondrial Glycerophosphate Oxidase to generate energy in the mitochondria while recovering the glyc-
eraldehyde phosphate for glycolysis. This pathway is heavily used in muscle, but it can also generate signifi-
cant levels of ROS23. We found that the shuttle is important in proliferating CIN cells, as inhibiting or depleting 
Glycerophosphate Oxidase caused a significant decrease in glucose uptake, and blocked the growth of brat 
explants.
We found that increasing the availability of NAD+ by feeding the host nicotinamide rescued the growth of 
PEPCK depleted brat explants, suggesting that in these tumours, the glycerol phosphate shuttle has not been 
able to sufficiently oxidise NADH, despite the availability of glucose to fuel this pathway. One possible contrib-
utor to this limitation was the ROS generated by mitochondrial Glycerophosphate Oxidase (GPO1)23, because 
we know that cells with CIN are already redox stressed7. Consistent with this model (Fig. 4a), we found that 
inhibiting Glycerophosphate Oxidase lowered ROS levels but did not allow growth of brat explants (as the shuttle 
was then unavailable for NADH oxidation). However, lowering ROS by feeding the host antioxidants was able to 
rescue growth: in this case the shuttle is available without the toxic consequences of high ROS. Lowering endog-
enous antioxidants by depleting Malic enzyme (hence NADPH)36 was able to block the growth of brat explants. 
This effect of ROS levels on PEPCK depleted explants suggests that the glycerol-3-phophate formed in glycero-
neogenesis is not just used for lipids, but is also used to clear cytoplasmic NADH via the mitochondria. It is still 
poorly understood how PEPCK mediates retrograde carbon flow in the presence of glucose, but high rates of 
PEPCK-mediated glyceroneogenesis are observed in numerous cell types and diets, including cancer cells18, 20, 37, 38.
Our model, then, for effectively blocking the growth of brat tumours is that treatments that decrease the use 
of the glycerol-3-phosphate shuttle (PEPCK-RNAi, hydrazine, GPDH-RNAi, iGP1) are inhibiting growth by pre-
venting the oxidation of cytoplasmic NADH. If the shuttle is available, its activity is significantly limited by the 
production of ROS in redox stressed CIN cells, so treatments that lower ROS levels or that provide an alternative 
source of NAD+ , will tend to rescue tumour growth. By using the appropriate level of PEPCK and GPO1 inhib-
itors we could completely block the growth of these aggressive CIN tumours.
These results emphasize the benefit of starting with an unbiased genetic approach to identifying the key sen-
sitivities of CIN cells. We would not have predicted that PEPCK had a significant role in managing NADH, nor 
that this would be enough to block tumour growth in vivo. It is not surprising that ROS levels can limit tumour 
growth, as they provide a mutagenic advantage to tumours only at the cost of widespread cellular damage. We had 
not previously considered mitochondrial Glycerophosphate Oxidase as a significant source of ROS, however we 
find that in PEPCK brat tumors, the glycerol-3-phosphate shuttle generates growth limiting ROS levels. Blocking 
this pathway lowers ROS levels, but it also prevents PEPCK-inhibited tumours from oxidising NADH, which 
then becomes growth limiting. This trade-off between NADH and ROS suggests that the relationship between 
the glycerol-phosphate shuttle and NADH sources may be a fruitful area of research for combination therapy 
directed at CIN tumors.
Experimental procedures. Oxidative stress analysis. Oxidative damage was analysed in tumor tissue 
using CellRox Green (Invitrogen) according to the manufacturers’ recommendations. Menadione (10 mM), and 
Vitamin E (5 mM) in D22 media were used as a pro-oxidant positive control and anti-oxidant control. Another 
anti-oxidant epigallocatechin gallate-EGCG (10 µM) was used in some experiments. Tissue was dissected in D22 
media then stained in the ROS dye for 20 minutes. Photographs were taken on a Zeiss Axioplan 2 using a fixed 
exposure time for each experiment determined by the positive control (Menadione) treated tissue.
Passaged brat RNAi tissue was dissected and incubated for ROS staining in fly extract media. Fly extract was 
prepared using Schneider’s Drosophila media (0.93 ml), whole fly extract of 200 fly (50 µl), insulin 0.5 mg/1 ml 
(5 µl), penicillin/streptomycin 10,000U/ml (5 µl)39.
Glucose assay. A labelled fluorescent glucose, 2-NBDG (Sigma) was used to detect the uptake of glucose as 
recommended by the supplier. Wing discs were taken from 3rd instar larvae that were still feeding to ensure 
glycolytic metabolism and immediately incubated in 2 μM 2-NBDG for 1.5 h in wing disc culture media39 before 
imaging. Images were taken at 20X with a fixed exposure time for all genotypes and fluorescent intensity was 
measured by using ImageJ software.
Explant and measurement techniques. An injection system was developed using 1.0mm O.D × 0.78mm I.D. 
borosilicate glass capillaries, a capillary holder, a suction tube and a suction apparatus. All the explants were 
done under a dissection microscope, into the ventral side of the fly abdomen13, 40. RFP was used to detect the 
explant presence and its growth. All explants were photographed at 3X under a fluorescence dissecting micro-
scope (Nikon SMZ1500). The number of hosts that survived the transplant and hence contributed to the results 
for each experiment is shown by the number of points on its respective graph.
CIN analysis. CIN was analysed by measuring the rate of anaphase errors. Whole larval brains were fixed using 
3.7% formaldehyde in PBS for 20 minutes, put in 45% and 60% acetic acid in ddH2O for 2 minutes and 45 seconds 
respectively, then squashed onto a cover slip and frozen in liquid nitrogen. Hoechst 33342 (Sigma) at 2 μg/ml 
in PBS was used to stain chromosomes. 50 anaphases were identified per brain and anaphase aberrations were 
scored. CIN analysis for passaged tissue was treated similarly, except all the available anaphases of each explant 
were scored, due to the smaller amount of tissue.
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Cell death analysis. Brain: whole brains were incubated in CellEvent Caspase 3/7 Green (Thermo Fisher) 
according to the recommended protocol. After the treatment, brains were mounted and photographed at 10X on 
a Zeiss Axioplan 2. GFP signals were counted using the Analyse Particle plugin in ImageJ. Passaged tissues were 
treated in a similar way, except the signal was manually counted using the Cell Counter plugin.
Wing discs: wing discs were treated with 1 mM Acridine Orange/PBS stain for three minutes, then briefly 
washed. The discs were mounted in PBS and photographed at 10X on a Zeiss Axoplan 2. The intensity of RFP sig-
nal was measured in ImageJ and normalized relative to the control half of the disc as described3. For ROS analysis 
of wing discs we used CellRox Deep Red (Invitrogen) as described [7].
Drug treatments. Drugs were obtained from Sigma except where noted. For adult fly feeding, drugs were mixed in 
20% sucrose solution. For larvae, drugs were mixed in standard fly food (water, molasses, yeast, glucose, acid-mix, 
agar, semolina, Tegosept) and were given to the host fly when solidified. Drugs used were as follows unless other-
wise noted in figure legends: iGP1 (Vitas-M lab, 1 mM), hydrazine sulphate-HS (10 mM), Metformin-Met (25 mM), 
Ferricyanide-FeCN (0.05 mM), Nicotinamide-Nam (5 mM), Propyl gallate-PG (1 mM). Because hydrazine and met-
formin are relatively non-specific in their targets, they were only used in cases where we could verify the relevance of 
the phenotype by comparison with the RNAi phenotype of the relevant enzyme (PEPCK or GPO1).
Drosophila stocks. Fly stocks were from either the Vienna Drosophila Resource Centre or Bloomington Stock 
Centre, raised at 25 °C, and all treatments were done at room temperature. Gal4 drivers included daughterless-gal4 
and actin-gal4 for brain expression and engrailed-gal4 for wing expression of UAS transgenes. UAS-RFP was 
used as a reporter gene in actin-Gal4 and da-Gal4 driven UAS-bratRNAi tumours. Canton S female flies were 
used as hosts for the CIN tumor explants. Stocks used were as follows; UAS-bratRNAi (34646), UAS-RFP (27391), 
UAS-Mfe2RNAi (v108880), UAS-PEPCKRNAi (v20529), UAS-G6PDRNAi (v101507), UAS-JNKRNAi (v34138), 
UAS-WwoxRNAi (v108307), UAS-MenRNAi (41652), UAS-GpdhRNAi (v29013/GD), UAS-Mdh1RNAi (v41437/GD), 
UAS-mad2RNAi (v47918), UAS-rad21RNAi (v13669), UAS-dicer2. Standard crosses were used to generate the 
genotypes tested, using segregation away from Bl/CyO;TM2/TM6b to combine markers on 2nd and 3rd chro-
mosomes. Where recombination was necessary (en > Gal4 UAS-mad2), the stock was tested for each locus and 
taken through single pair matings to ensure a consistent genotype. The level of depletion by RNAi shown in 
Supplementary Table 1 was measured by qPCR as described (7) using the following primers:
Pepck: (f) CCGTGTGCTGGAATGGATC (r) TTGGGCAGCGAGAAGATCT;
brat: (f) AACCACAACAACTTCAACCTGAC (r) GCGATATATGTAGAGCCGATAGTC;
Gpdh: (f) TCACGACGTGTTACGGTGG (r) CCTCAATGGTTTTTCCAGAAGT;
rp49 control (f) GACGCTTCAAGGGACAGTATCTG (r) AAACGCGGTTCTGCATGAG.
Statistical analysis. In most cases, Dunnett’s multiple comparisons test was used to assess the significance 
of variation in the means of each genotype of test tumour from that observed in the control. A single-tailed t-test 
with Welch’s correction was also used for testing growth relative to a non-growing control. This was only used in 
one case of doubtful significance (the effect of FeCN on brat PEPCK tumor growth), which was also confirmed 
by other tests (e.g. cell death rescue and the effect of nicotinamide). Fisher’s exact tests were used to compare 
proportions (CIN rates). In all graphs, error bars show 95% confidence intervals.
Data availability. All data generated or analysed during this study are included in this published article (and 
its Supplementary Information files).
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A plausible contributor to the effect of CIN on cells under oxidative stress is aneuploidy. 
Trisomy is known to give inappropriate gene expression levels and stress responses, in diverse 
organisms, consistent with perturbation in the endoplasmic reticulum (ER) resulting in protein 
folding problems (Sheltzer et al., 2012, Oromendia et al., 2012a). The ER is the main site for 
protein folding, translocation and post-translation modification. Perturbation in the ER 
environment by nutrient deprivation, altered glycosylation, calcium depletion, ROS, DNA 
damage and energy disturbance/fluctuation lead to ER stress with subsequently causing 
unfolded protein response (UPR) activation (Malhotra and Kaufman, 2007). During 
tumorigenesis, cancer cells require increased activities of ER protein folding, assembly and 
transport, which induce ER stress (Lee, 2007). Robust ER stress responses have been 
documented in variety of human cancer, including breast, pancreatic, lung, skin, prostate, brain, 
and even liquid malignancies (Wang and Kaufman, 2014). The ER stress response is 
considered cytoprotective and is involved in advanced-stage disease and drug resistance (Healy 
et al., 2009, Ma and Hendershot, 2004). The UPR represents to primarily a pro-survival 
process, sustained and/or prolonged stress may result in cell death induction. UPR activation 
shows a vital process in tumour development, stage progression, and resistance to therapies.  
In yeast, cells with an extra chromosome suffer proteotoxic stress and protein aggregation 
(Oromendia et al., 2012a) and vertebrate CIN lines are particularly sensitive to Hsp inhibition 
(Santagata et al., 2013), suggesting protein folding stress. In this study we assessed whether 
CIN cells, with their abnormal gene dosage, struggle to maintain chaperone function by testing 
the toxicity of aggregation-prone Poly-Q proteins with and without CIN or the protein folding 
response proteins such as hsp90. Increased protein-folding load in the ER may result in the 
accumulation of ROS (Wang and Kaufman, 2014).  
Aneuploid cells also show elevated ROS levels (Shaukat et al., 2015, Sheltzer et al., 2012). In 
ER-stressed cells, Ca2+released from the ER is taken up by mitochondria and release 
cytochrome c that inhibits complex III of the ETC and boosts ROS production. Moreover, 
increased Ca2+ in the mitochondria stimulates Krebs cycle dehydrogenases, thus increased 
oxygen consumption and ROS production. Mitochondrial Ca2+ also activates nitric oxide 
synthase, whose product disturbs the ETC and enhances ROS generation (Brand, 2010, St-
Pierre et al., 2002). However it is not clear what is the primary cause as the accumulation of a 
misfolded protein within the ER leads to prolonged UPR activation, which in turn causes 
accumulation of ROS via the UPR-regulated oxidative protein folding machinery in the ER 
and the mitochondria (Haynes et al., 2004). In addition, aneuploid cells typically have an 
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aberrant metabolism that generates ROS and redox stress. 
We wished to understand whether the stressed ER generates the ROS (by Ca++ release) or 
whether the ROS generates the stressed ER (by damaging proteins), or both. In this study we 
addressed this question by adding antioxidants (Catalase, propyl gallate) to CIN cells and 
measuring the level of ROS (by CellRox staining) and ER stress (by XBP1-GFP) expression 
(Sone et al., 2013). We tested the effect of protein folding stress by expressing hard-to-fold 
poly-glutamine (van Eyk et al., 2011) or chaperones such as Hsp90 (Vos et al., 2016) and 
measured ROS and Ca++ release (GCaMP3) in CIN versus normal tissue (Tian et al., 2009).  
Nucleotide metabolism has a crucial role in senescence and autophagy in cancer cell (Kohnken 
et al., 2015). Thus, nucleotide metabolism has implications in genomic instability as part of 
tumour initiation and resistance to apoptosis during tumorigenesis. To determine how 
nucleotide metabolism affects CIN cells, we have examined the effect of the nucleotide 
inhibition in CIN cells by depleting the nucleotide synthesis enzymes and see their effect on 
DNA damage, ROS, cell death, cell-cycle progression and autophagy. In addition, alteration in 
adenine nucleotide level activates Poly (ADP-ribose) Polymerase (PARP), causing depletion 
of its substrate, NAD. Depletion of NAD lead to loss of ATP. Thus, in order to understand why 
ATP might be limited in CIN cells we test for PARP upregulation in CIN cells and examined 
whether adding ATP and Nicotinamide (a precursor in the synthesis of NAD+) rescue the CIN 
phenotype. 
We know that tumours adapt to therapy, so it is important to identify ways to block the available 
stress response pathways that potentially mitigate metabolic therapy we wished to understand 
the association between aneuploidy, oxidative stress, nucleotide stress and protein folding 
because CIN and aneuploidy are common, tumour-specific phenotypes that offer the prospect 
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Summary statement: Cells that gain or lose chromosomes during cell division are shown to be sensitive 
to ATP levels and protein folding stress.




Aneuploidy, having an unbalanced genome, is poorly tolerated at the cellular and organismal level. It 2 
gives rise to proteotoxic stress as well as a stereotypical oxidative shift which makes these cells 3 
sensitive to internal and environmental stresses. Using Drosophila as a model, we found that protein 4 
folding stress is exacerbated by redox stress that occurs in response to ongoing changes to ploidy 5 
(chromosomal instability, CIN). We also found that if de novo nucleotide synthesis is blocked, CIN 6 
cells are dependent on a high level of lysosome function to survive. Depletion of AMP synthesis 7 
enzymes led to DNA damage in CIN cells, which showed elevated activity of the DNA repair 8 
enzyme PARP. PARP activation causes depletion of its substrate, NAD+ and subsequent loss of 9 
ATP, and we found that adding ATP or nicotinamide (a precursor in the synthesis of NAD+) could 10 
rescue the observed phenotypes. These findings provide ways to interpret, target and exploit 11 
aneuploidy, which has the potential to offer tumour-specific therapies. 12 
INTRODUCTION  13 
Aneuploidy is known to have detrimental effects on most cells, including reduced proliferation and 14 
elevated redox stress (Sheltzer et al., 2017; Siegel and Amon, 2012). The concept of “unbalanced” 15 
mutations giving a phenotype when single chromosomes are gained or lost is now almost a century 16 
old (Blakeslee et al., 1920). In yeast, changes in gene dosage brought about by aneuploidy have been 17 
shown to generate an excess of some proteins, and increase the burden on the protein degradation 18 
apparatus (Dephoure et al., 2014). The additional demand for ATP to synthesize, fold, and turn over 19 
these excess proteins has been proposed to cause increased mitochondrial activity and the production 20 
of reactive oxygen species (ROS). ROS could also be produced from a stressed endoplasmic 21 
reticulum if there were protein folding problems (Malhotra and Kaufman, 2007), but at least in 22 
disomal yeast, activation of the unfolded protein response was not detected (Oromendia et al., 2012). 23 
Nonetheless, protein aggregation was increased by aneuploidy, and in vertebrate cells, aneuploidy 24 
has been linked with increased autophagy and overloading of chaperones such as HSP90 (Donnelly 25 
et al., 2014; Santaguida et al., 2015). Consequently, it seems likely that aneuploidy imposes a 26 
chronic strain on protein homeostasis, with the exact phenotype depending partly on the particular 27 
gene dosage changes in each aneuploid cell, but also on the type of cell. With the whole protein 28 
production and turnover system under strain, cell types are likely to differ in what breaks first – 29 
limiting levels of antioxidants, chaperones, ATP, or lysosome function have all been implicated in 30 
different cell types.  31 
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The unfolded protein response is typically activated in situations where the endoplasmic reticulum 32 
(ER) is unable to manage the load of protein folding that is required, and there is some evidence, at 33 
least in vertebrate cells, that it can be induced by aneuploidy. Studies differ as to whether simple 34 
tetraploidy is (Senovilla et al., 2012) or is not (Ohashi et al., 2015) enough to trigger robust 35 
activation of the unfolded protein response. Furthermore, it is not clear whether aberrant protein 36 
levels are the primary cause, because aneuploid cells typically also have an aberrant metabolism that 37 
generates ROS and redox stress. Protein folding is a highly redox sensitive process, so aneuploidy 38 
may both increase the load of proteins to be folded and impair the ability to process them. 39 
Nucleotide depletion is another homeostatic imbalance that affects aneuploid cells (Bester et al., 40 
2011). Insufficient nucleotides during S-phase lead to replication stress, which has been strongly 41 
linked to the induction of chromosomal instability (CIN) that produces highly aneuploid cells. 42 
Several mechanisms linking replication stress and CIN have been demonstrated, including increased 43 
double stranded DNA breaks, increased anaphase bridges, segregation errors and production of ROS 44 
(Burrell et al., 2013; Chan et al., 2009; Marchetti et al., 2006; Minocherhomji et al., 2015). 45 
Consequently, we expect that aneuploid cells will be sensitive to perturbation of nucleotide levels, 46 
which may increase aneuploidy beyond the cell’s threshold of tolerance. 47 
We wished to understand the causal relationships between aneuploidy and these failures of 48 
homeostasis because chromosomal instability and its consequent aneuploidy is a common, tumour-49 
specific phenotype that offers the prospect of similarly tumour-specific therapies. This will require 50 
the identification of features of aneuploid cells that are invariant, regardless of which DNA has been 51 
gained or lost. In this paper we describe a common phenotype of protein folding stress in genetically 52 
diverse aneuploid cells using a Drosophila model for chromosomal instability. We find that the 53 
protein folding defects are caused by redox stress and contribute to that stress. We have tested 54 
nucleotide depletion and find that it can be tolerated by aneuploid cells without causing redox stress, 55 
but this tolerance requires high levels of lysosome function. Finally, we find that CIN cells are 56 
sensitive to decreased ATP synthesis and have activated poly(ADP ribose) polymerase (PARP), 57 
which leaves these cells deficient in NAD+ and ATP. 58 
RESULTS 59 
CIN causes ER stress and oxidative stress in Drosophila 60 
Up-regulation of protein chaperones has been observed in aneuploid cells from budding yeast, mouse 61 
and humans (Pfau and Amon, 2012; Sheltzer et al., 2012). To determine whether cells in which 62 
aneuploidy was induced by chromosomal instability (CIN) were under protein folding stress, we 63 
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tested levels of the HSP70 family. We observed an increased in chaperone levels (HSP 83) in cells in 64 
which CIN had been induced by Rad21 depletion, relative to wildtype controls (Fig 1a). In this paper 65 
we use two models for induced CIN: depletion of the cohesin Rad21, which makes 46% of 66 
metaphases aneuploid, typically with gain or loss of a whole chromosome, and causes ROS and cell 67 
death (Liu et al., 2015). Alternatively we use depletion of the spindle checkpoint protein Mad2, 68 
which causes bridges or lagging chromosomes in approximately 25% of anaphases and gives very 69 
little cell death (Shaukat et al., 2012). We typically use high CIN (Rad21 depletion) where we are 70 
measuring strong CIN phenotypes and low CIN (Mad2 depletion) where we are testing for genetic 71 
enhancement of mild CIN effects. The transcription factor X-box-binding protein 1 (XBP1) is 72 
required for the activation of several unfolded protein response genes that control ER protein folding, 73 
intracellular trafficking, and ER membrane expansion in response to ER stress (Bravo et al., 2013). 74 
To observe ER stress in CIN cells, we used recombinant UAS-XBP1-GFP which only produces GFP 75 
when its mRNA is appropriately spliced in response to ER stress (Ryoo, 2015; Samali et al., 2010). 76 
We found that GFP was increased, indicating the presence of ER stress in CIN cells (Fig 1b’). We 77 
have previously observed that CIN cells have elevated levels of reactive oxygen species (ROS) and 78 
mitochondrial dysfunction (Shaukat et al., 2015), so we wished to test whether that might be caused 79 
by release of Ca++ ions from the stressed ER. The ER is a principal cytoplasmic store for Ca++, which 80 
can be released in response to protein folding stress, potentially causing loss of  mitochondrial  81 
integrity and ROS generation (Pinton et al., 2008). We observed an increase in GCaMP3 signal (Tian 82 
et al., 2009), which indicates increased Ca++ release in CIN cells relative to controls (Fig 1c).  83 
CIN affects protein aggregation in Drosophila 84 
Having observed activation of the unfolded protein response in CIN cells, we wished to test whether 85 
adding proteins that were difficult to fold would lead to aggregate formation and cell damage under 86 
these conditions (Eenjes et al., 2016). To observe protein aggregation in CIN cells, we expressed 87 
proteins containing poly-Glutamine (polyQ) repeats of different lengths (CAG55 and CAG91) that 88 
can form aggregates (van Eyk et al., 2012; Landrum and Wetzel, 2014). We observed greatly 89 
increased aggregation of myc-tagged CAG91 in CIN cells compared to the wild-type control (Fig 90 
2b), consistent with CIN cells having difficulty managing this additional protein folding burden. To 91 
test the effect of this burden on CIN cell survival, we measured Acridine Orange staining (Shaukat et 92 
al., 2012). Increased Acridine staining was observed in CIN cells expressing either CAG55 or 93 
CAG91 compared to their controls (Fig 2c, d). Our data suggests that CIN cells suffer protein folding 94 
stress so that chaperones are incapable of resolving additional stress from aggregation-prone poly-95 
Glutamine proteins. 96 
 Overexpression of antioxidants rescues the effect of protein aggregation in CIN cells. 97 
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Reactive oxygen species (ROS) production has been associated with ER stress and the unfolded 98 
protein response (Cao and Kaufman, 2014). Oxidative stress causes the formation of oxidatively 99 
modified proteins that tend to aggregate in cytosol and trigger tumour progression (Kim et al., 2010). 100 
In order to test our hypothesis that the protein aggregation in CIN cells is ROS-dependent, we 101 
measured the effect of overexpression or depletion of the antioxidant enzyme Catalase together with 102 
polyQ repeats. Catalase only directly removes hydrogen peroxide, not other reactive oxygen species, 103 
but we have previously noted that this can significantly affect CIN cell fates (Shaukat et al., 2015). 104 
We observed a significant decrease in polyQ protein aggregation in CIN wing discs of larvae co-105 
expressing UAS-catalase and polyQ repeats compared to CIN discs expressing polyQ repeats only 106 
(Fig 2e). We also observed an increase in aggregation when Catalase was depleted by RNAi in CIN 107 
cells expressing poly-Glutamine protein.  These results suggest that ROS contributes to protein 108 
folding stress in CIN cells which makes them vulnerable to the addition of hard-to-fold proteins. 109 
Effect of nucleotide interventions on CIN cells 110 
Like protein folding stress, nucleotide stress has been linked to CIN and cancer development (Bester 111 
et al., 2011). Nucleotide pool disequilibrium can result in genetic abnormalities and oncogenic 112 
transformation (Aird and Zhang, 2015). To identify the genes from nucleotide synthesis pathways 113 
that could be involved in regulating the fate of CIN cells, we tested a range of genes affecting 114 
purine biosynthesis (ADSS, PRPS2, GMP Synthetase, IMP dehydrogenase, PRAT), pyrimidine 115 
biosynthesis (CTP Synthetase, Carbamoyl Phosphate Synthetase) and the Pentose Phosphate (PP) 116 
pathway (TKL, Transaldolase, PP Epimerase). We initially measured their effect on CIN cells 117 
using RNAi to deplete the nucleotide pathway candidates in third instar larval wing discs with 118 
CIN induced by Mad2 depletion (Fig 3a). We selected the candidates based on their Acridine 119 
Orange (AO) phenotype, a cell viability assay that we have previously used to identify genes such 120 
as the positive control G6PD, that are required for CIN cell survival (Shaukat et al., 2012). The 121 
knockdown of ADSS, PRPS2 and TKL gave significantly elevated AO staining in the CIN region, 122 
while candidate depletion in non-CIN cells gave little or no AO, similar to the negative control, in 123 
this case RNAi to a gene not expressed in Drosophila (mCherry) (Fig 3c-g). Quantification of AO 124 
signals from nucleotide pathway candidates with or without CIN showed elevated AO staining in 125 
CIN cells compared to non-CIN cells (Fig. 3b). These results suggest that CIN cells are sensitive 126 
to defects in nucleotide synthesis.  127 
Effect of depletion of nucleotide synthesis enzymes on oxidative stress.  128 
We have previously found that disruptions to glucose metabolism in CIN cells not only increase 129 
Acridine staining, but also generate ROS and cause apoptosis (Shaukat et al., 2015). We carried 130 
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out ROS assays to examine whether depletion of nucleotide synthesis enzymes may also elevate 131 
oxidative stress in CIN cells. We found that that knockdown of ADSS, PRPS2 and TKL gave no 132 
detectable increase ROS in CIN cells, in contrast to the positive control G6PD (Fig 4a-d). These 133 
results suggest that depletion of nucleotide synthesis enzymes does not affect CIN cells by 134 
increasing ROS production.   135 
DNA damage in response to nucleotide synthesis enzyme depletion in CIN cells. 136 
Low nucleotide pools are known to cause replication stress and DNA damage in dividing cells 137 
(Kohnken et al., 2015). We next examined DNA damage by using anti-P-H2avD (γH2aX) 138 
antibody staining of larval wing discs with CIN in which nucleotide candidates had been knocked 139 
down (Fig 4e-i). Quantification showed that depletion of ADSS, PRPS2 and TKL in CIN cells 140 
gave an elevated level of DNA damage, compared to the mad2-RNAi, mCherry-RNAi negative 141 
control (Fig 4j). As expected, these data confirm that depletion of nucleotide synthesis enzymes 142 
caused DNA damage in CIN cells, consistent with decreased nucleotide availability.    143 
 144 
Depletion of nucleotide synthesis enzymes does not result in cell death in CIN cells.  145 
Having observed elevated Acridine staining and DNA damage, we expected that apoptosis might 146 
be elevated in CIN cells depleted for nucleotide synthesis enzymes (Abrams et al., 1993). To 147 
visualize apoptosis, we used anti-cleaved-Caspase 3 and anti-Dcp-1 antibody staining of wing 148 
discs. The levels of these antibody stainings were not elevated in double knockdowns of 149 
nucleotide candidates with Mad2 (Fig S1, Fig 5b-e) unlike the positive control (mad2-RNAi, 150 
PASK-RNAi) which generates ROS, DNA damage and apoptosis in CIN cells (Shaukat et al., 151 
2015). Quantification of Dcp-1 signals from nucleotide candidates with CIN showed no 152 
significant increase in cell death compared to the mad2-RNAi, mCherry-RNAi negative control 153 
(Fig 5f). However, cell death could have been caused by a caspase independent mechanism such 154 
as necrosis. We used Propidium Iodide (PI) staining to test for necrosis when our candidates were 155 
depleted in CIN cells. Consistent with the apoptosis data, these knockdowns in CIN cells were 156 
found to be negative for PI staining compared to the positive control (JNKRNAi, Fig S2). Together, 157 
these results suggest that that depletion of nucleotide synthesis enzymes does not cause cell death 158 
either by apoptosis or necrosis in CIN cells. This surprising finding contrasts with the high levels 159 
of apoptosis induced by disrupting glucose metabolism in CIN cells (Shaukat et al., 2015). 160 
 161 
Effect of depletion of nucleotide synthesis enzymes on the cell cycle. 162 
We observed a significant increase in DNA damage when our nucleotide candidates were 163 
depleted in CIN cells, however we did not see cell death. Based on this finding, we hypothesized 164 
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that this DNA damage could have led to cell cycle arrest in CIN cells. To test this hypothesis, we 165 
used Phospho-Histone 3 (PH3) antibody staining as a marker for scoring mitotic cells. We tested 166 
whether loss of our nucleotide candidates in CIN cells could prevent cell cycle progression by 167 
scoring the mitotic cells from larval wing discs of nucleotide candidates knocked down in cells 168 
with and without CIN. We did not observe any significant increase or decrease in PH3 staining in 169 
knockdowns of ADSS, PRPS2 and TKL in CIN or non-CIN cells (Fig S3), suggesting that 170 
depletion of nucleotide synthesis enzymes does not arrest the cell cycle even in CIN cells showing 171 
DNA damage. Consistent with this, we did not see any change in S phase duration as measured by 172 
EdU incorporation (Figure S3). 173 
 174 
Effect of depletion of nucleotide synthesis on activation of autophagy in CIN cells 175 
It is known that autophagy is activated in CIN cells, and is needed for their survival (Liu et al., 176 
2016). We wished to examine the effect of depleting nucleotide candidates on the activation of 177 
autophagy in CIN cells, to see if this could explain the Acridine staining, which normally stains 178 
the lysosomes in apoptotic cells (Abrams et al., 1993). We used lysotracker staining and found 179 
that, like Acridine, it was elevated when any of the nucleotide candidates were depleted in CIN 180 
cells, relative to non-CIN controls (Fig S4, 6A). We used a tagged form of Atg8a to confirm 181 
whether the high lysotracker staining observed was due to activation of autophagy in knockdowns 182 
of ADSS, PRPS2 and TKL in CIN cells. Unlike the lysotracker staining, only knockdown of TKL 183 
gave robust Atg8a puncta formation in CIN cells (Fig S4, 6B).  However, we did not observe 184 
Atg8a puncta in knockdown of ADSS or PRPS2 in CIN cells (Fig S4, 6B). We expect that 185 
knockdowns of ADSS and PRPS2 decrease the rate of AMP synthesis and AMP is used to maintain 186 
phosphorylated AMPK to activate autophagy (Choi and Lee, 2011). However, increased lysotracker 187 
staining in these candidates suggest that in absence of autophagy, lysosomes work hard to 188 
compensate. 189 
 190 
Feeding rATP and dATP rescue some AO phenotypes in CIN cells: 191 
Depletion of ADSS and PRPS2 should decrease the level of AMP synthesis, which will further lead 192 
to depletion of ATP. So, we examined whether feeding rATP or dATP to larvae would have an effect 193 
on the AO phenotype. First, we fed rATP to larvae knocked down for ADSS, PRPS2 and TKL in 194 
cells with CIN induced by Mad2 depletion. We observed that feeding rATP significantly rescued the 195 
AO phenotype when ADSS or PRPS2 were depleted in CIN cells. (Fig 7A, S5). The same rescue of 196 
ADSS and PRPS2 was seen when larvae were fed dATP (Fig 7B, S5). However, no rescue was seen 197 
when TKL depleted larvae were fed either nucleotide (Fig 7, S5). This was consistent with the 198 
   ATP sensitivity in CIN cells 
8 
 
autophagy seen in the TKL knockdowns: these cells do not seem to be short of adenosine. We also 199 
tested a high CIN model (Rad21 depletion) to see if CIN might generate sensitivity to ATP levels in 200 
otherwise normal cells. Depletion of Rad21 leads to high levels of aneuploidy, Acridine Orange, 201 
ROS and cell death (Liu et al., 2016). Surprisingly, we found that feeding Rad21 depleted larvae 202 
rATP strongly rescued the Acridine phenotype, but only in males (Fig 7A, S5). dATP had no effect 203 
and females were unaffected by either nucleotide (Fig 7B, S5). We conclude that elevated CIN can 204 
cause a loss of rATP, but do not know why females are less sensitive to this (c.f. Clemente-Ruiz et 205 
al., 2016). When AMP synthesis is compromised, our data suggest that CIN cells increase lysosome 206 
formation to compensate for the lack of autophagy.  207 
 208 
Lysosomal ATP levels in CIN cells. 209 
Effective lysosomal function is known to play a vital role in cancer progression and metastasis 210 
(Appelqvist et al., 2013). To examine the induction of lysosomes as a result of depletion of 211 
nucleotide synthesis enzymes in CIN cells, we used Quinacrine (QA), a marker for lysosomal ATP 212 
(Cao et al., 2014). Robust QA staining was observed in knock downs of ADSS, PRPS2 and TKL in 213 
CIN cells relative to the inert mCherry-RNAi control (Fig 8A, S6). This suggests that there is no lack 214 
of ATP inside lysosomes, although our feeding experiments argue that these cells lack ATP overall. 215 
In fact, we observed more QA staining in CIN cells than non-CIN controls (Fig S6). A multi-subunit 216 
lysosomal membrane protein, v-ATPase, maintains lysosomal acidification by importing protons 217 
from the cytoplasm to the lysosomal lumen (Collaco et al., 2013), and is required for ATP transport 218 
into the lysosome (Mauvezin et al., 2015). Blocking v-ATPase with bafilomycin significantly 219 
reduced the QA signal (Fig 8A) as expected. By blocking lysosome acidification, this inhibition of v-220 
ATPase also strongly rescued the Acridine Orange phenotype seen in CIN cells depleted for 221 
nucleotide synthesis enzymes (Fig 8B, S6). 222 
 223 
Lysosomes are needed for CIN cell survival 224 
It has been reported that advanced cancers exploit autophagy-lysosomal pathways to avoid cell 225 
death. Recent studies indicate that compromised lysosomal function in mammalian cell lines resulted 226 
in cell death (Cao et al., 2014). Moreover, having previously found that autophagy is needed for 227 
CIN cell survival (Liu et al., 2016), we wished to investigate the role of lysosomes in determining 228 
the fate of CIN cells, particularly in absence of autophagy. We treated CIN wings discs knocked 229 
down for our candidates with bafilomycin to block v-ATPase, and then stained the wings discs 230 
with Dcp-1 to measure the level of cell death. The positive control was depletion of PEPCK, 231 
which gives elevated apoptosis in CIN cells and tumours (Hussain et al., 2017). We found that 232 
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bafilomycin treatment caused some cell death in CIN cells knocked down for ADSS or PRPS2 233 
and perhaps even TKL, but not in CIN cells alone (Fig 8C, S7). These results suggest that in CIN 234 
cells in the absence of autophagy, lysosomes were able to compensate, but if we also blocked 235 
lysosomes, the CIN cells died.  236 
 237 
Replacing NAD+ rescues the AO phenotype 238 
We have shown that that depletion of ADSS and PRPS2 caused DNA damage in CIN cells and 239 
both rATP and dATP significantly rescued the AO phenotype. This led us to hypothesize that 240 
knockdowns of ADSS and PRPS2 depleted the level of adenosine, causing DNA damage during 241 
replication, which we would expect to then activate poly(ADP ribose) polymerase (PARP) as part of 242 
the repair process (Weaver and Yang, 2013). In normal cells, the depletion of nucleotide synthesis 243 
had no effect, so we wondered whether CIN cells were particularly vulnerable to PARP activation, 244 
which can further decrease ATP levels (Weaver and Yang, 2013). We found that cells with high CIN 245 
levels activated PARP to some degree even without nucleotide depletion (Fig S8). In these high CIN 246 
cells, we know that AO marks cell death (Liu et al, 2015), and we found that blocking PARP 247 
activation rescued a significant amount of that cell death (Fig 8D). Because PARP consumes NAD+ 248 
and leads to ATP depletion (Zong et al., 2004), we predicted that providing extra NAD+ to high CIN 249 
cells, might rescue the AO phenotype in these cells. To test our model, we fed larvae with 250 
nicotinamide (NAM), a precursor in the synthesis of NAD+ (Kirkland, 2012). We observed a 251 
significant reduction in the AO phenotype in wing discs when NAM was fed to larvae with 252 
decreased nucleotide synthesis (ADSS, PRPS2 or TKL) or with high CIN levels (Rad21) relative to 253 
controls (Fig 8E, S8). We conclude that CIN cells tend to activate PARP, which decreases their 254 
levels of NAD+ and ATP, making them particularly vulnerable to interventions that further limit 255 
ATP availability. At moderate CIN levels, depleted adenosine does not kill the cell, but does limit 256 
autophagy, leading to an increased dependence on lysosomes, which then become critical for CIN 257 
cell survival.  258 
 259 
DISCUSSION: 260 
Aneuploidy is a state in which cells carry unbalanced genome. Errors in chromosomal segregation 261 
lead to whole chromosome aneuploidy while segmental aneuploidy mainly originates due to defects 262 
and delays in the DNA replication and repair mechanism (Gordon et al., 2012; Janssen and Medema, 263 
2013). Aneuploidy is a hallmark of cancer and has been shown to be poorly tolerated at the cellular 264 
and organismal level (Weaver and Cleveland, 2006). Aneuploidy can have a range of effects 265 
including aberrant cell growth, proliferation, proteotoxic and oxidative stress (Pfau and Amon, 266 
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2012). We have found that the induction of aneuploidy makes cells highly glycolytic and vulnerable 267 
to oxidative stress and they show DNA damage and apoptosis in response to metabolic interventions 268 
that do not damage normal cells (Shaukat et al., 2015). The mechanism that regulates the change in 269 
metabolism in response to aneuploidy is unclear, therefore, we wished to identify the stereotypical 270 
metabolic signature of aneuploidy. Aneuploidy is known to cause ER stress and oxidative stress in 271 
most organisms such as yeast, plants, mouse and humans (Pfau and Amon, 2012; Sheltzer et al., 272 
2012). Aneuploidy related impaired proliferation, altered protein folding and ER stress is thought to 273 
be due to the changes in protein stoichiometry from the aberrant chromosomes. In this study, 274 
increases in chaperone levels (Hsc70, Hsp83) and ER stress markers (XBP1) were observed in 275 
aneuploid cells, we also observed that ER stress can cause ROS by Calcium release in aneuploid 276 
cells. Our data confirms that aneuploid cells suffer protein folding stress so that chaperones are 277 
incapable of resolving additional stress (i.e. aggregation prone Poly-Glutamine (polyQ) proteins). 278 
Successful aneuploidy tolerant cells must be able to enhance repair and reduce oxidative stress and 279 
cell death, so we wished to identify the regulation of pathways required for aneuploidy tolerance. 280 
Autophagy is known to be induced by ER stress and ROS, and is a plausible mechanism for 281 
aneuploidy tolerance (Sheltzer, 2013). Aneuploid cells have three related defects that autophagy 282 
could help to moderate: proteotoxic stress, defective mitochondria and oxidative damage (Li et al., 283 
2017; Shaukat et al., 2015). We have shown that aneuploid cells are dependent on autophagy of 284 
defective mitochondria to tolerate their aneuploidy (Liu et al., 2016). We further analysed the 285 
production of ROS and ER stress in aneuploid cells. Previous studies revealed that in ER-stressed 286 
cells, Ca2+ released from the ER is taken up by mitochondria and releases cytochrome c that inhibits 287 
complex III of the electron transport chain and increases ROS production. Moreover, increased 288 
Ca2+ in the mitochondria stimulates Krebs cycle dehydrogenases, thus increasing the oxygen 289 
consumption and ROS production. Mitochondrial Ca2+ also activates nitric oxide synthase, whose 290 
product disturbs the ETC and enhances ROS generation (Brand, 2010; St-Pierre et al., 2002). 291 
However it is not clear whether the ER stress generates the ROS or ROS generates the stressed ER or 292 
both. In this study, we addressed this question and showed that ROS contributes to protein folding 293 
defects in aneuploid cells, which could be significantly rescued by adding antioxidants.  294 
We have previously observed that aneuploid cells have overactive mitochondria, which produce 295 
ROS and hence oxidative damage to proteins, lipids and DNA and damage to macromolecules 296 
(Shaukat et al., 2015), which we now find causing protein folding defects and ER stress. Moreover, 297 
effective repair mechanisms, autophagy and antioxidant levels are required to tolerate the deleterious 298 
effects of aneuploidy.   299 
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Further we tested the effect of nucleotide stress on CIN cells. We carried out preliminary screening 300 
based on AO staining and tested that range of genes affecting purine biosynthesis, pyrimidine 301 
biosynthesis and the PP pathway. We found that the knockdown of ADSS, PRPS2 and TKL gave 302 
significantly higher AO staining in a CIN background. These nucleotide candidates play a central 303 
metabolic role in the synthesis of nucleotides. The PRPS enzyme adds a pyrophosphate group from 304 
ATP to ribose-5-phosphate generated from the PP pathway to produce a nucleotide precursor called 305 
5-phosphoribosyl-1-pyrophosphate (PRPP). PRPP is a substrate for all nucleotide salvage pathway 306 
enzymes, as well as for the rate-limiting enzymes of purine and pyridine biosynthesis. Modulation of 307 
PRPS levels by either knockdown or overexpression respectively inhibit or potentiate nucleotide 308 
production, suggesting that levels of PRPP may be sufficient to govern the overall rate of purine 309 
metabolism (Cunningham et al., 2014).  ADSS is downstream of the de novo pathway and it is a vital 310 
component of the de novo pathway as well as the salvage pathway. Similarly, ADSS is a highly 311 
conserved enzyme among all living organisms, it converts inosine monophosphate (IMP) to 312 
adenosine monophosphate (AMP) as part of ATP biosynthesis. 313 
The high AO phenotypes in nucleotide candidate knockdowns in CIN cells suggest that CIN cells 314 
are sensitive to changes in nucleotide levels. In addition, increased lysotracker and DNA damage 315 
phenotypes were observed when nucleotide synthesis enzymes ADSS, PRPS2 and TKL were 316 
depleted in a CIN background. However, we did not see any involvement of ROS or cell cycle arrest 317 
in this case. Cell death either by apoptosis or necrosis was also not observed when these candidates 318 
were depleted in CIN cells. Therefore, we expected that the autophagy pathway was being activated. 319 
Autophagy is known to be activated in response to various stresses including nutrient starvation 320 
(Jiang and Mizushima, 2014; White, 2015). We have shown that CIN cells are dependent on the 321 
autophagy of mitochondria to tolerate their aneuploidy and avoid triggering innate immune 322 
signalling (Liu et al., 2016). For example, blocking the autophagy pathway in CIN cells led to an 323 
increased number of dysfunctional mitochondria, increased levels of oxidative stress, DNA damage 324 
and apoptosis, while enhancing autophagy could reduce the level of ROS and apoptosis. So we 325 
hypothesized that autophagy might be triggered in response to nucleotide depletion. Surprisingly, 326 
autophagy was not detected in ADSS and PRPS2 deficient CIN cells. However, elevated puncta of 327 
tagged Atg8a were observed in TKL deficient CIN cells, suggesting that autophagy is activated in 328 
TKL deficient CIN cells.  TKL is a pivotal enzyme of the non-oxidative arm of the PP pathway.  It 329 
catalyses the common two-substrate reactions in order to generate glyceraldehyde-3-phosphate and 330 
fructose-6-phosphate, which re-enter glycolysis. When cells are in need of nucleotides, the PPP 331 
produces ribose via the oxidative as well as the nonoxidative arm from fructose-6-phosphate and 332 
glyceraldehyde-3-phosphate. TKL1 also enhances the PPP flux for biosynthetic reactions, as the PPP 333 
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generates ribose-5-phosphate for nucleic acid synthesis and NADPH for fatty acid synthesis and 334 
maintaining redox homeostasis to protect cells against oxidative stress and apoptosis (Diaz-Moralli et 335 
al., 2016; Vaughn and Deshmukh, 2008). Moreover, inhibition of TKL will suppress the PP pathway 336 
and interrupt the synthesis of important coenzymes such as ATP, CoA, NAD(P)+, FAD, and genetic 337 
material, RNA and DNA. We found that depletion of TKL in CIN cells triggered autophagy, which 338 
we interpret as a CIN cell survival response, based on previous work by ourselves and others 339 
(Santaguida et al, 2015, Liu et al, 2016).  340 
Increased lysosome staining in ADSS and PRPS2 deficient CIN cells suggests lysosomal 341 
involvement in CIN cells. Lysosomes play a crucial role in cancer progression by regulating complex 342 
processes involving protein secretion, endocytic receptor recycling, energy metabolism, and cell 343 
signalling (Appelqvist et al., 2013, Stingele and Storchova, 2013). Moreover, the autophagy–344 
lysosome pathway is closely linked with the hallmarks of cancer including escaping cell death 345 
pathways, evading immune surveillance, and deregulating metabolism (Hanahan and Weinberg, 346 
2011). Advanced cancer cells are extremely reliant on effective lysosomal function. As a 347 
consequence, cancer progression and metastasis are related with unusual changes in lysosomal 348 
compartments, such as lysosome volume, composition, cellular distribution, and lysosomal enzyme 349 
activity, as compared with normal cells (Gocheva et al., 2006; Nishimura et al., 1998). Furthermore, 350 
when we blocked lysosomes, ADSS or PRPS2 depleted CIN cells showed increased cell death. 351 
These results suggest that in the absence of autophagy, lysosomes worked hard in these cells to 352 
compensate for the lack of autophagy and when we blocked lysosomes the CIN cells died. So, our 353 
model is that CIN cells use lysosomes to compensate for loss of autophagy when AMP is depleted. 354 
Depletion of ADSS and PRPS2 decrease the synthesis of AMP which further leads to depletion of 355 
ATP, and we observed that in larvae knocked down for ADSS or PRPS2, feeding rATP and dATP 356 
significantly rescued the AO phenotype in CIN cells relative to their controls. These results suggest 357 
that CIN cells are sensitive to ATP changes. To further understand why ATP might be limited in CIN 358 
cells we tested for the Poly (ADP-ribose) Polymerase (PARP) and found that it is upregulated in CIN 359 
cells. We also observed rescue of oxidative stress and cell death when we knocked down PARP in 360 
CIN cells. The PARP enzyme PARylates a variety of protein substrates and alters their interaction 361 
with DNA and other proteins. PARP is currently in clinical trials for DNA damage sensitive cancers 362 
because of its role in the DNA damage response (Weaver and Yang, 2013). PARP activation causes 363 
depletion of its substrate NAD+, which further leads to loss of ATP (Zong et al., 2004) . We found 364 
that adding ATP or nicotinamide (a precursor in the synthesis of NAD+) rescued the AO phenotype 365 
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in CIN cells. These results suggest that ATP and NAD+ are consumed for PARP activation and CIN 366 
cell survival. 367 
Our model is that knockdowns of ADSS and PRPS2 in CIN cells deplete the nucleotide level which 368 
result in DNA damage. DNA damage activates PARP that causes a reduction in both the NAD+ and 369 
the ATP pool. CIN cells already lack ATP due to activation of PARP, and less ATP in CIN cells is 370 
paralleled by increasing AMP levels.  High AMP levels, sensed by AMPK, should lead to activation 371 
of autophagy, which is required for CIN cell adaptation in a nutrient starved condition. However, 372 
loss of AMP by ADSS knockdown in CIN cells seems to prevent activation of autophagy. An 373 
elevated lysosomal phenotype in ADSS deficient CIN cells shows that in the absence of autophagy, 374 
lysosomes work hard to compensate for the autophagy defect, and this is required for the cells to 375 
survive. Overall, our results suggest that cellular homeostasis is significantly disrupted by 376 
aneuploidy, with defects originating from elevated ROS levels that exacerbate protein folding stress 377 
and damage DNA. Because DNA damage activates PARP, aneuploid cells are sensitive to levels of 378 
NAD+ and ATP, making this metabolic pathway a promising therapeutic option for the treatment of 379 
aneuploid tumours. 380 
 381 
Material and Methods 382 
Drosophila Stocks 383 
The fly stocks used in this paper are as follows:  384 
mad2-RNAi (VDRC 47918) , Rad21-RNAi (Bloomington #36786), ADSS-RNAi (Bloomington 385 
#33993), PRPS2-RNAi (Bloomington #35619), TKL-RNAi (Bloomington #32884), Ribulose-386 
Phosphate3-Epimerase-RNAi (Bloomington #42816), Carbamoyl Phosphate Synthetase-RNAi 387 
(Bloomington #38332), PRAT-RNAi (Bloomington #51492), Transaldolase-RNAi (Bloomington 388 
#51709), GMP Synthetase-RNAi (Bloomington #31055), CTP Synthetase-RNAi (Bloomington 389 
#31752), UAS-IMP dehydrogenase (Bloomington #11284), JNK-RNAi (VDRC 34138), mCherry-390 
Atg8a (Bloomington #37750), PEPCK-RNAi (Bloomington #17725), PASK-RNAi (Bloomington 391 
#3105), G6PD-RNAi (Bloomington #12529), UAS-XBP1-GFP (Bloomington #39719), Hsp83-GFP 392 
(DGRC #109-697), UAS-CAG55 and UAS-CAG91 (a gift from Prof. R. Richards), UAS-Catalase 393 
(Bloomington #24621), PARP-RNAi (Bloomington #35792), Parg-RNAi (Bloomington #61333), 394 
UAS-GCaMP (Bloomington #32236). The driver stock engrailed (en-Gal4) for gene expression in 395 
the posterior region of wing discs is Bloomington #30564.  396 
Acridine Orange (AO) Staining: 397 
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Third instar larvae were dissected in PBS then discs were incubated in 1mM AO for 2 mins then 398 
transferred to a slide after a brief wash. The treated imaginal discs were immediately mounted under 399 
a bridged cover slip and imaged in PBS. For quantification, the AO stain was normalized by 400 
subtracting the wild type region value from the test region value (engrailed-driven region). The 401 
background noise of all images was subtracted in ImageJ using a rolling ball radius of 10 pixels. 402 
Propidium Iodide (PI) Staining: 403 
Propidium Iodide staining was used to measure caspase-independent cell death. Third instar larvae 404 
were dissected in PBS for imaginal discs, the collected imaginal discs were incubated in 3uM PI for 405 
5 mins then transferred to a slide after a brief wash. Mounting, imaging and quantification was done 406 
similar to AO staining as described above.  407 
Lysotracker and Hoechst staining 408 
Lysotracker staining was used to detect lysosomes in larval wing imaginal discs. The dissected 409 
imaginal discs were transferred from PBS and incubated in 1uM lysotracker (Lysotracker red DND-410 
99, Invitrogen) and 6ug/ml Hoechst (Hoechst 33342, Sigma) for 5 mins and then mounted to a slide 411 
with PBS for microscopy after a quick wash in PBS.  412 
Quinacrine (QA) Staining: 413 
To identify lysosomal ATP level, we used QA staining on the wings disc of third instar larvae. 414 
Candidates were knocked down using en-gal4 driver, approximately equal aged larvae were selected 415 
and wing discs were dissected out in PBS. Then dissected discs were incubated in 50uM Quinacrine 416 
for 2 min. Mounting and imaging was done as for the Acridine Orange staining described above.  417 
Oxidative stress assay 418 
The level of reactive oxygen species (ROS) in CIN cells was measured by using the fluorogenic 419 
probe CellROX Deep Red from Life Technologies according to manufacturer’s recommendations. 420 
The third instar larvae were dissected in D22 media with pH 6.8. Then the dissected imaginal wing 421 
discs were transferred into 5μM CellRox (in D22 media) for 20 mins. The wing discs were quickly 422 
washed in PBS and fixed in 3.7% formaldehyde for 5 min then mounted in 80% glycerol for 423 
imaging.  424 
Calcium imaging 425 
Intracellular calcium was detected by imaging of GCaMP3. Third instar wing discs were dissected in 426 
PBS, briefly fixed in 4% formaldehyde and mounted in 80% glycerol, then imaged as for GFP.  427 
Immunostaining: 428 
Immunostaining was used on dissected wing imaginal discs for different purposes. Third instar 429 
larvae were dissected in PBS for imaginal discs then the collected imaginal discs were fixed in 3.7% 430 
formaldehyde for 20 mins and then wash for 30 mins in 0.2% PBST (1xPBS+0.2% Tween). The 431 
   ATP sensitivity in CIN cells 
15 
 
fixed imaginal wing discs were then blocked in PBSTF (1xPBS+0.2% Tween+5% fetal calf serum) 432 
for 30 mins and stained with the primary antibody for overnight at 4℃. After staining with the 433 
primary antibody, the wing discs were washed in 0.2% PBST for 30 mins then transferred to a 434 
secondary antibody solution for 2.5 hrs at room temperature in the dark.  After 30 mins washing in 435 
PBST, the wing discs were mounted in 80% glycerol for imaging. For detecting Parylation, discs 436 
mutant for the deParylating enzyme Parg were used to improve the sensitivity of PAR detection (Fig. 437 
S8). 438 
The source and concentration of antibodies used are as follows:  439 
Rabbit anti-cleaved caspase 3 (D175, 1: 100) from (Cell Signalling #9661S), Rabbit anti-cleaved 440 
Drosophila Dcp1 (Asp216, 1:100) from (Cell Signalling #9578), Mouse anti-P-Histone3 (Ser10, 441 
1:500) from (Cell Signalling #9706S), Rabbit anti-P-H2avD (1:500) from (Rockland, Lot # 30352), 442 
Mouse anti-pADPr (PAR, Clone 10H; 1:100) from Tulip Biolabs, #1020/N). 443 
The secondary antibodies used were goat anti-rabbit CY3 (1: 100, Life Technologies), rhodamine 444 
anti-mouse (1: 200) and rhodamine anti-rabbit (1:200).  445 
Drug Treatments: 446 
For wing disc culture experiments, drugs were mixed with fly extract media, fly extract media was 447 
prepared by using Schneider’s media (Invitrogen) 94%, whole fly extract 5% (Currie et al., 1988), 448 
Bovine Insulin (Sigma) (1mg/ml) 0.5%, penicillin/streptomycin 1000U/ml 0.5%. 449 
For drug feeding experiments, drugs were mixed in standard fly food (semolina, yeast, molasses, 450 
agar, glucose, water, Tegosept and acid-mix) and were given to larvae when solidified. Drugs used in 451 
this paper are as follows: 452 
6-Aminonicotinamide (6-ANA) 500 uM, Bafilomycin 150 nM, Adenosine 5′-triphosphate disodium 453 
salt hydrate (rATP) 1mM,  dATP PCR Grade, sodium salt 1mM, Nicotinamide (NAM) 1mM. All 454 
drugs were obtained from SIGMA. 455 
Data analysis 456 
Statistical analysis was done in Prism (Graph Pad) using Dunnett’s multiple comparisons and two-457 
tailed t-test with Welch’s correction. In all graphs, error bars show 95% confidence intervals. All 458 
microscopy was done on a Zeiss Axioplan2 microscope. Axiovision software (Carl Zeiss), Adobe 459 
Photoshop, Adobe Illustrator and ImageJ (https://fiji.sc/) were used for image processing and 460 
quantification.  461 
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Figure 1: CIN cells are under ER stress.  
ER stress was detected by the levels of chaperones (HSP83-GFP expression, A, A’), the activation of 
XBP1 by alternative splicing (XBP1-GFP expression, B, B’) and measuring intracellular Ca++ 
release (GCaMP3 signal, C, C’) in CIN (A’, B’, C’) versus normal (A, B, C) wing imaginal tissue. 
The dotted lines show the posterior compartment of a representative wing disc pouch region from 
each genotype. (A, B, C) control wing discs show background expression of HSP-83-GFP, XBP1-
GFP and GCaMP3 in non-CIN cells.  (A’, B’) Increased GFP levels which indicate elevated levels of 
chaperone (Hsp83-GFP) and XBP1-GFP were observed when CIN was induced by depletion of 
Rad21 (UAS-Rad21RNAi, UAS-Dicer2). (C’) increased GCaMP signal was observed in CIN cells 
relative to wild type controls (C). 
Figure 2: CIN increases protein folding stress via reactive oxygen species.  
Increased aggregation of hard-to-fold poly-glutamine protein (myc-tagged CAG91 or CAG55) was 
observed in CIN cells. (A, B) Images show the anterior/posterior boundary of a representative wing 
disc from each genotype. Right of the dotted line is the engrailed-Gal4 expressing region in which 
myc-tagged poly-CAG peptides were expressed. (A) In cells expressing a shorter polyglutamine 
peptide (CAG55), aggregation was not observed, and mild CIN induction by Mad2 depletion had 
little, if any, effect on this (A’). (B) Some aggregation was observed of the hard-to-fold longer 
polyglutamine peptide CAG91 in otherwise wild type cells, which was greatly increased by the 
induction of CIN (mad2RNAi, B’). (C, C’) Third instar imaginal discs were stained for Acridine 
Orange (AO) to indicate vesicle acidification, a common precursor to cell death. The dashed line 
indicates the posterior compartment expressing CAG55 or CAG91 peptides, while the unmarked 
anterior compartment was wild type in every disc.  (D, D’) Imaginal discs in which CAG55 and 
CAG91 peptides were expressed in CIN cells (mad2RNAi), gave rise to high levels of AO staining 
compared to the non-CIN controls. (E) Quantification of polyglutamine peptide aggregation shows 
that ROS significantly contribute to the proteotoxic stress generated in CIN cells. Aggregation of 
myc-tagged CAG55 increased when co-expressed with Catalase-RNAi, while aggregation decreased 
when catalase was overexpressed (UAS-Catalase). Overexpression of Catalase was able to strongly 
rescue the aggregation seen in CIN cells. The signal was normalized by subtracting the signal from 
the wild type anterior compartment of each disc. Error bars indicate the 95% CI. n≥11 in all cases. P-
values were calculated by two-tailed t-tests with Welch’s correction: **** p<0.0001, *** p<0.001. 
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Figure 3: Nucleotide synthesis gene knockdowns affect CIN cells.  
(A) A quantitative analysis of Acridine Orange (AO) staining in third instar larvae wing discs 
knocked down for nucleotide synthesis enzymes. The y axis shows the normalized AO signals 
obtained by the subtracting the mean value of the control region from the affected region for each 
wing disc. Error bars represent 95% Confidence Intervals (CIs), n≥8 in all cases. P-values were 
calculated by two-tailed t-tests with Welch’s correction: *** p<0.001. All tests compare 
candidateRNAi mad2RNAi with the negative control mCherryRNAi mad2RNAi. (B) Quantification of AO 
staining in candidateRNAi imaginal wing discs with and without CIN (see C. below). The y axis shows 
the normalized AO signals obtained by the subtracting the mean value of the control region for each 
wing disc. Knockdown of the candidate in non-CIN cells is represented by grey bars. Candidate 
knockdowns in CIN cells are represented by black bars. Error bars represent 95% CIs, n≥8 in all 
cases. P-values were calculated by two-tailed t-tests with Welch’s correction: p<0.0001= ****, 
p<0.01=**. (C - G) Acridine Orange staining (AO) of the third instar larvae wing discs. The dotted 
regions (engrailed>Gal4, UAS-CD8-GFP, with or without UAS-mad2RNAi) show the posterior 
compartment of wing disc in which the candidates were knocked down while the remainder of each 
wing disc is a wild type internal control (C) Negative control mCherry mad2RNAi (D) Positive Control 
G6PD mad2RNAi showing high levels of AO staining (E) ADSSRNAi (E’) ADSSRNAi mad2RNAi (F) 
PRPS2RNAi (F’) PRPS2RNAi mad2RNAi (G) TKLRNAi (G’) TKLRNAi mad2RNAi. Knock down of ADSS, 
PRPS2 and TKL in CIN cells show high AO staining as compared to their knockdown in wild-type 
cells.  
Figure 4: The effect of depletion of nucleotide synthesis enzymes on oxidative stress and DNA 
damage in CIN cells.  
Reactive oxygen species (ROS) levels were visualized by CellRox staining in third instar larval wing 
discs. Images show the anterior/posterior boundary of a representative wing disc pouch region from 
each genotype. The dotted line shows the engrailed-Gal4 expressing knockdown area in each image 
and left of the dotted line is wild type (A) G6PD RNAi mad2RNAi positive control showing elevated 
ROS levels (B, C, D) We did not detect elevated ROS when nucleotide synthesis candidates were 
depleted in CIN cells. The experiment was repeated twice. (E-I) Third instar larvae wing discs were 
stained with anti-phosphorylated H2AvD (γH2AX) antibody staining to measure the level of DNA 
damage. The dashed line indicates the posterior compartment expressing (G) ADSSRNAi, (H) 
PRPS2RNAi, (I) TKLRNAi in CIN cells, (E) negative control mCherryRNAi and (F) positive control 
PASKRNAi.  The unmarked anterior compartment is wild type in each disc. (J) A quantitative analysis 
of P-H2AvD staining in third instar larval wing disc knockdowns of nucleotide synthesis enzymes in 
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CIN cells. The y axis shows the number of P-H2AvD positive puncta cells in the engrailed-driven 
knockdown region, normalized by subtracting the number of stained cells in the control region for 
each disc. Elevated rates of P-H2AvD staining were seen when nucleotide synthesis enzymes were 
depleted in CIN cells. Error bars represent 95% CIs, n≥8 in all cases. P-values were calculated by 
two-tailed t-tests with Welch’s correction: **** p<0.0001. All tests compare candidateRNAi mad2RNAi 
with mCherryRNAi mad2RNAi.  
Figure 5: Depletion of nucleotide synthesis enzymes did not cause apoptosis in CIN cells.   
Death caspase-1 antibody was used to test for apoptosis in wing discs in which candidates were 
knocked down in CIN cells (dashed region). (A) Positive Control PASK mad2RNAi showed elevated 
apoptosis; (B) negative control mCherry mad2RNAi , (C) ADSSRNAi mad2RNAi, (D) PRPS2RNAi 
mad2RNAi, (E) TKLRNAi mad2RNAi did not. (F) Quantification of Dcp-1 staining of positive control 
and candidate-RNAi imaginal wing discs. The y-axis shows the Dcp-1 stained cells in the engrailed 
driven region normalized by subtracting the number of stained cells in control region of each wing 
disc. The error bar indicates the 95% CIs, n≥10 in all cases. The p values were calculated by two-
tailed t-tests with Welch’s correction. ns=non-significant. No significant elevation in apoptosis was 
seen when nucleotide synthesis enzymes were depleted in CIN cells. The experiment was repeated 
twice and confirmed by using Caspase3 antibody staining (Fig. S1). 
Figure 6:  Nucleotide candidate knockdowns caused the accumulation of lysosomes, but not 
always autophagy, in CIN cells.  
Lysotracker staining was used to detect lysosomes. Quantification of lysotracker staining is shown in 
(A). The y axis shows the number of lysotracker puncta in the en-driven knockdown region, 
normalized by the subtracting the number of puncta in the control region for each wing disc. The 
black bars represent the candidate knockdowns in CIN cells (en>mad2RNAi) and grey bars represent 
the candidate knockdowns in wild type cells. Error bars indicate 95% CIs, n≥8 in all cases. The P 
values were calculated by two-tailed t-test with Welch’s correction: p<0.0001 ****, p<0.001 ***. 
Representative images are shown in Figure S4. (B) Quantification of the level of mCherry-Atg8a 
puncta, measured as for lysotracker. In all cases n≥10 and error bars show 95% CIs. The p values 
were calculated using two-tailed t-tests with Welch’s correction: p<0.001 ***, p<0.05 *, n.s.=non-
significant. Representative images for this data are shown in Figure S4. 
Figure 7: Feeding ATP to larvae depleted for some nucleotide synthesis enzymes rescued their 
AO phenotype.  
(A) Graph showing that depletion of ADSS, PRPS2 or JNK in CIN cells (induced by mad2 RNAi) 
showed high AO staining, which was rescued by feeding the larvae with rATP (1mM). No rescue 
was observed in ATP fed larvae of genotype TKLRNAi mad2RNAi. Male larvae with high CIN induced 
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by Rad21 depletion (UAS-rad21RNAi, UAS-Dicer2) also showed high AO staining that could be 
rescued by rATP feeding, while feeding ATP to female larvae of the same genotype did not show 
reduction in their AO phenotype. Candidate knockdowns in CIN cells are represented by black bars 
and rATP fed candidate knockdowns in CIN cells are represented by grey bars. The error bars 
represent the 95% CIs, n ≥10 in all cases. The experiment was repeated three times. Representative 
images are shown in Figure S6. (B) Feeding the larvae with dATP (1mM) rescued the AO phenotype 
in ADSS and PRPS2 knockdowns in CIN cells (grey bars) as compared to their controls (black bars). 
No rescue was observed in dATP fed larvae of genotypes TKLRNAimad2RNAi and in high-CIN larvae 
(UAS-rad21RNAi, UAS-Dicer2). The error bars represent the 95% CIs, n ≥10 in all cases. The p 
values were calculated by two-tailed t-tests with Welch’s correction: p<0.0001 ****, p<0.01 **, 
p<0.05 *, ns=non-significant. This experiment was repeated twice. Representative images are shown 
in Figure S7. (C) Graph showing Quinacrine (QA, a marker for lysosomal ATP) staining on larval 
wing discs. High QA staining was observed, when nucleotide synthesis candidates were depleted in 
CIN cells (dark grey bar) as compared to candidates knocked down in non-CIN cells (light grey bar). 
Wing discs were incubated with bafilomycin (150nM) for 30 min and then stained with QA (15uM). 
Candidates’ knockdown in CIN cells (black bar) show significantly lower QA staining after 
bafilomycin treatment. Quantifications show the normalized grey value of staining, which is obtained 
by subtracting the mean grey value of wild type from the affected region of each disc. Error bar 
indicate 95% CIs, n ≥10 in all cases. The p values were calculated by two-tailed t-test with Welch’s 
correction: p<0.0001 ****, p<0.001 ***, p<0.01 **, ns=non-significant. Representative images are 
shown in Figure S8. (D) Graph showing that blocking v-ATPase by bafilomycin (75nM) inhibits the 
AO phenotype in nucleotide candidate knockdowns in CIN cells.  When wing discs of candidate 
knockdowns in CIN cells were incubated with bafilomycin for 30 min it significantly reduced the 
AO staining in these discs compared to controls. Quantifications show the normalized grey value of 
staining, obtained by subtracting the mean grey value of wild type from the mean of the affected 
region of each disc. The error bars represent 95% CIs, n ≥12 in all cases. The p values were 
calculated by two-tailed t-tests with Welch’s correction. This experiment was repeated twice. 
Representative images are shown in Figure S9. 
 
Figure 8: Blocking v-ATPase causes cell death in nucleotide depleted CIN cells  
(A) A model for the effect of depletion of nucleotide synthesis enzymes on CIN cells. Loss of ADSS, 470 
PRPS2 or TKL decrease ATP synthesis and contribute to DNA damage in CIN cells, which are 471 
already ATP depleted by PARP activation. (B) Dcp-1 antibody staining was used to detect the level 472 
of apoptosis in bafilomycin treated wing discs of candidate knockdowns in CIN cells. The graph 473 
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shows that depletion of ADSS and PRPS2 significantly increased the level of apoptosis in CIN cells 474 
after treatment with bafilomycin. Depletion of TKL caused a non-significant increase in apoptosis in 475 
bafilomycin treated CIN cells. In all cases n≥10 and error bars show 95% CIs around the mean. The 476 
p values were calculated by two-tailed t-tests with Welch’s correction. Representative images are 477 
shown in Figure S10. (C) Graph showing that PARP knockdown in CIN cells (induced by Rad21 478 
depletion) significantly rescued the AO phenotype in these cells, which in this case we know 479 
represents apoptosis (Liu et al., 2015). Quantifications show the normalized grey value of staining 480 
obtained by subtracting the mean grey value of wild type from the affected half of each disc.  In all 481 
cases n≥23 and error bars show 95% CIs around the mean. The p values were calculated by two-482 
tailed t-tests with Welch’s correction. Representative images are shown in Figure S11. (D) 483 
Nicotinamide feeding rescued the AO phenotype caused by nucleotide synthesis enzyme depletion in 484 
CIN cells. Quantification showing that the AO phenotype of ADSS, PRPS2 and TKL depletion in 485 
CIN cells was significantly rescued by feeding the larvae with Nicotinamide (1mM). A similar 486 
reduction was observed in high CIN cells (induced by Rad21 depletion). In all cases n≥12 the error 487 
bar show 95% CIs around the mean. The p values were calculated by two-tailed t-tests with Welch’s 488 
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Figure S1 :  ( A ) Quantification of XBP1 - GFP expression.  Increased GFP levels which indicate XBP1 - GFP were  
observed when CIN was induced by depletion of  en > Rad21 (UAS - Rad21 RNAi , UAS - Dicer2) compared to the  
control  en > UAS - XBP1 - GFP.  The y axis shows the normalized anti - GFP staining obtained by the subtracting the  
mean value of the control region from the mean of the affected region for each wing disc. The error bars indicate  
the 95% confidence interval, n≥9 in all cases. The p values  were calculated by two - tailed t - tests with Welch’s  
correction. ( B ) Quantification of GCaMP3 signals.  Increased GCaMP signal was observed in  en > Rad21 (UAS - 
Rad21 RNAi , UAS - Dicer2 relative to wild type controls.  The y axis shows the normalized GCaMP3 signals o btained  
by the subtracting the mean value of the control region from the mean of the affected region for each wing disc.  
The error bars indicate the  95% confidence interval, n= 8 in all cases.  ( C)  Quantification of ROS staining. The y  
axis shows the normali zed CellROX staining obtained by the subtracting the mean value of the control region  
from the mean of the affected region for each wing disc. The error bars indicate the 95% confidence interval, n≥8  
in all cases.  Genotypes tested were  ( engrailed  driven)  positive control  G6PD  mad2 RNAi ,  negative control  mCherry  
mad2 RNAi,  ADSS RNAi   mad2 RNAi ,  PRPS2 RNAi   mad2 RNAi ,  TKL RNAi  mad2 RNAi   ( d, e, f, g, h )  Caspase3 - driven apoptosis  
was not detected when candidates were depleted in CIN cells. Anti - cleaved caspase 3 antibod y was used to  
measure the apoptosis in third instar larval wing discs. In every disc, the unmarked region does not express RNAi  
constructs, while the dashed line shows the area affected by CIN ( mad2 - RNAi ) and depletion of cand idates.  
Genotypes tested were  (d ) positive control  PASK mad2 RNAi   (e ) negative control  mCherry  mad2 RNAi  (f )  ADSS RNAi   
mad2 RNAi   ( g )  PRPS2 RNAi   mad2 RNAi   (h )  TKL RNAi  mad2 RNAi .  
Figure S2 : Propidium Iodide (PI) staining was used to measure the level  of necrosis in nucleotide depleted CIN  
cells. The candidate knockdowns in the posterior half of each wing disc are indicated by the dotted line; the  
remainder of each disc was wild type. PI staining was high in positive control (a)  JNK RNAi mad2 RNAi , while  (b)  
negative control  mCherry  mad2 RNAi , and the other genotypes (c)  ADSS RNAi mad2 RNAi , (d)  PRPS2 RNAi m ad2 RNAi , (e)  
TKL RNAi mad2 RNAi   were negative for PI staining. (f) Quantification of PI staining. The y axis shows the normalized  
PI staining obtained by the su btracting the mean value of the control region from the mean of the affected region  
for each wing disc. The error bars indicate the 95% confidence interval, n≥10 in all cases. The p values were  
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Figure S3 : The effect of nucleotide depletion on the cell cycle in CIN cells. Phospho - Histone 3 antibody staining  
was used to detect the mitotic cells in CIN larval wing discs with nucleotide candidate knockdowns. ( A ) no  
significant difference was observed in the frequency of mitotic cells in wing discs of control and genotype  
ADSS RNAi , PRPS2 RNAi   and TKL RNAi   when thes e candidates depleted with or without CIN as shown in graph ( B ).   
The error bar represents the 95% CIs, n≥8 in all cases. The p values were calculated by two - tailed t - tests with  
Welch’s correction.  ( C )  Quantification of EdU labelling on nucleotide  synthesis deficient CIN cells.  EdU labelling  
was used to detect the  S - Phase cells  in CIN larval wing discs with nucleotide candidate knockdowns . N o  
significant difference was observed in the frequency of  S - Phase  cells in wing discs of control and genotype  






























Figure S4 : Third instar larvae wing discs were stained with lysotracker  and  mCherry - Atg8a puncta  level detection  
to test for effects on lysosomes. In every disc, the unmarked region does not express RNAi constructs, while the  
dashed line shows the area  affected by CIN ( mad2 - RNAi ) and depletion of nucleotide synthesis enzymes. Control  
wings (a, a’) show no lysotracker staining when CIN is induced. (b, c, d) Imaginal discs in which candidates have  
been depleted giving rise to no lysotracker staining. (b’,  c’, d’) Imaginal discs showing that when candidates were  
depleted in CIN cells high lysotracker was observed compared to controls.  ( e ) negative control  UAS - mCherry - 
Atg8 UAS - mad2 RNAi   ( f, g ) Wing discs of  ADSS RNAi   and  PRPS2 RNAi   with CIN induced by mad2 deple tion ( engrailed  
>  Gal4 ,  UAS - CD8 - GFP, UAS - mCherry - Atg8 UAS - mad2 RNAi ) show no induction of autophagy (mCherry - Atg8a  
puncta). ( h ) Depletion of TKL in CIN background shows a high level of mCherry - Atg8a puncta, indicating the  
activation of autophagy  
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Figure S 5 : Depletion of nucleotide synthesis enzymes in CIN cells showed high AO staining which was rescued  
by feeding the larvae with rATP  and dATP  (1mM). (a, b, c, d) controls wing disc of candidates  ADSS RNAi ,  
PRPS2 RNAi ,  TKL RNAi   and  JNK RNAi   depleted in CIN cells  induced by  mad2 RNAi . (a’, b’, d’) wing discs of rATP fed  
larvae of  ADSS RNAi mad2 RNAi ,  PRPS2 RNAi mad2 RNAi   and  JNK RNAi mad2 RNAi   which show reduction in the AO  
phenotype. (c’) no rescue was observed in ATP fed larvae of genotype  TKL RNAi mad2 RNAi . (e, f) control  wing discs  
of male and female larvae with high CIN induced by Rad21 depletion (UAS - Rad21 RNAi , UAS - Dicer2 ) show a  
high AO phenotype but (e’) feeding rATP to male larvae of genotype (UAS - Rad21 RNAi , UAS - Dicer2 ) rescues the  
AO phenotype in wing discs while (f’ ) female larvae of same genotype  did not show a  reduction in the AO  
phenotype.  Feeding larvae with dATP (1mM) rescued the AO phenotype in ADSS and PRPS2 knockdowns in  
CIN cells ( g ’,  h ’) as compared to their controls ( g ,  h ). No rescue was observed in dATP  fed larvae of genotypes  
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Figure S 6 : Effect of quinacrine  (QA) staining on larval wing discs with depletion of nucleotide synthesis enzymes  
in CIN cells. All wing discs w ere stained with QA (50uM) . The dotted line shows the  en >CD8GFP marked  
posterior compartment in which the  genes were depleted. The other half of each disc serves as a wild type internal  
control. (a, b, c,) high QA staining was observed, when nucleotide candidates ADSS, PRPS2 and TKL were  
depleted in CIN cells as compared to candidates knocked down in non - CIN  cells (a’, b’, c’). (d) Control disc of  
mCherry  mad2 RNAi.  (e) Quantification of QA stainings show the normalized grey value of staining, obtained by  
subtracting the mean grey value of the wild type from the affected region of each disc. The error bars repr esent  
the 95% CIs, n ≥10 in all cases. The p values were calculated by two - tailed t - tests with Welch’s correction.  (f, g,  
h ) control wing discs of nucleotide synthesis enzymes ADSS, PRPS2 and TKL depleted in CIN c ells show high  
AO phenotypes. (f’, g’, h ’) wing discs of same genotype treated with bafilomycin (75nM) treatment for 30 min  
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Figure S7 : Blocking v - ATPase activity causes some apoptosis in nucleotide depleted CIN cells. Dcp - 1 antibody  
staining was used to detect the level of apoptosis in bafilomycin treated wing discs of  candidates’  knockdowns in  
CIN cells. (a) Negative control  (b) positive control  PEPCK RNAi  mad2 RNAi . (c, d, e) wing discs of knockdowns of  
ADSS, PRPS2 and TKL in CIN cells without bafilomycin  treatment show no apoptosis. (c’, d’) Knockdown of  
ADSS and PRPS2 significantly increased the level of apoptosis in CIN cell s after treatment with bafilomycin. (e’)  
knockdown of TKL in CIN cells did not show significant apoptosis in these proliferating cells.  
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Figure S8 :   Nicotinamide rescues the AO phenotype in CIN cells. (a, b, c) represent the AO staining in control  
wing discs without NAM treatment of candidates  ADSS RNAi ,  PRPS2 RNAi   and  TKL RNAi   in non - CIN cells. (a ’, b’,  
c’,) feeding the larvae with NAM (1mM) significantly rescued the AO in wing disc of genotype  ADSS RNAi ,  
PRPS2 RNAi   and  TKL RNAi   in CIN cells. (d) Wing discs with high CIN induced by Rad21 depletion showed high AO  
staining. (d’) feeding NAM to the larva e with high C IN caused reduced AO staining.  ( g) increased in  anti - PAR  
antibody  staining in Parg with  high - CIN cells  (UAS - Rad21 R NAi , UAS - Dicer2 )  was observed  compared to the  













Chromosomal instability (CIN) is a hallmark of cancer cells in which they fail to maintain their 
stable chromosomal number and/or integrity. CIN is frequent in most human solid tumours and 
is linked to tumorigenesis, metastasis, worse prognosis, relapse and drug resistance (Bakhoum 
and Compton, 2012, Hanahan and Weinberg, 2011a). CIN is common in cancer cells but not 
in normal cells, thus, it has been hypothesized that targeting CIN provides an opportunity to 
specifically target cancer cells that exhibit CIN without affecting normal cells as well as 
limiting the ability of tumours to develop drug resistance in late stage cancers. In our lab we 
have used Drosophila melanogaster as a model organism to study CIN. We generated different 
levels of CIN by either weakening spindle assemble checkpoint function or depleting cohesin 
genes. mad2 is an essential spindle checkpoint gene and its knockdown in Drosophila causes 
lagging chromosomes and chromosome bridges during cell division in > 25% of brain cells 
without affecting overall viability (Shaukat et al., 2012). Rad21 is involved in chromatid 
cohesion during mitosis and its co-expressing with dicer2 (to enhance the level of RNAi 
knockdown) in proliferating wing discs cells led to aneuploidy in 46% of metaphase cells, 
indicating a higher rate of CIN with this approach (Liu et al., 2015) 
Our lab has carried out a genome-wide screen for kinases and phosphatases that when depleted, 
cause CIN-dependent apoptosis. This screen identified candidate genes that belonged to 
various pathways such as the JNK pathway, the DNA damage response pathway, centrosomal 
function, and metabolic pathways that are required to maintain the survival of CIN cells 
(Shaukat et al., 2012, Wong et al., 2014). Identification of clinically significant cancer targets 
such as Nek2 from our screen confirms that the screen has the potential to select promising 
therapeutic targets for cancer treatment (Kokuryo et al., 2007). 
 CIN and aneuploidy are known to cause proteotoxic and oxidative stress (Oromendia et al., 
2012b). CIN cells adapt to high stress conditions by increasing their glucose consumption, 
which could also lead to increased mitochondrial output. We have observed that CIN cells are 
sensitive to metabolic disruption. Depletion of metabolic candidates such as PEPCK (a key 
enzyme of gluconeogenesis) or G6PD gave increased mitochondrial output, oxidative stress, 
DNA damage and apoptosis in CIN cells without affecting normal cells. Having found 
metabolic targets that were able to induce CIN-specific cell death, we further tested the 
effect of these candidates on CIN tumours in order to understand their mechanism of action 
in the context of a growing CIN tumour.  We observed that knockdown of candidates such as 
G6PD and JNK gave elevated cell death and smaller primary tumours, however they were not 
able to prevent the growth of CIN tumours and their metastases. Interestingly, depletion of 
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PEPCK, however, was able to completely hamper the growth of these tumours. PEPCK 
depletion was consistent with PEPCK inhibitors and their ability to stop tumour growth 
(Chapter 3). These result were encouraging, thus, we focused our attention on explaining the 
mechanism by which PEPCK might be affecting CIN cells. 
PEPCK is involved in gluconeogenesis in the liver and the kidney (Burgess et al., 2007), but it 
is also known to be expressed in non-gluconeogenic tissues as well as in cancer cells, 
suggesting PEPCK may have other roles (Previs et al., 2009). Many cancers such as 
neuroendocrine prostate cancer and uterine carcinoma express elevated levels of PEPCK 
despite having high hexokinase activity for glycolysis. In addition, whether PEPCK is a rate-
limiting factor in gluconeogenesis is still unclear. Rognstad (1979) found that inhibiting 
PEPCK with mercaptopicolinic acid stops gluconeogenesis, but later studies found a limited 
effect of PEPCK inhibition on gluconeogenic rate (Rognstad, 1979, Argaud et al., 1991). Some 
recent studies found that PEPCK is involved in glucose metabolism in tumour growth and 
proliferation (Montal et al., 2015, Leithner et al., 2014, Leithner, 2015). These studies showed 
that PEPCK is involved in catabolism of glutamine in the absence of glucose. It was observed 
that PEPCK converts oxaloacetate to phosphoenolpyruvate which can support the TCA cycle 
and biosynthetic intermediates for tumour growth and survival in glucose limited conditions 
(Leithner, 2015, Vincent et al., 2015), and enhance glycolysis when glucose is available. Major 
metabolic intermediates like pyruvate, glutamate, citrate, fumarate, phosphoenolpyruvate, and 
malate were decreased with PEPCK deficiency (Vincent et al., 2015, Leithner, 2015, Montal 
et al., 2015). However, these studies did not address the glycerogenic role of PEPCK. PEPCK 
is one of the rate limiting steps in glyceroneogenesis (Hanson and Reshef, 2003, Bartok et al., 
2015). Glyceroneogenesis produces glycerol-3-phosphates from sources other than glucose, 
like pyruvate, amino acids, and metabolic intermediates such as OAA, to generate 
triacyglycerol (Hanson, 2005). When PEPCK was knocked down, Drosophila larvae had lower 
lipid levels (Shaukat et al., 2015). Bartok et al., (2015) also found PEPCK inhibition lowered 
glucose, glycerol and TAG levels in the animal suggesting an effect of PEPCK on lipid 
metabolism (Bartok et al., 2015). Our data suggest that the glyceroneogenic role of PEPCK is 
an important factor to restrict tumour growth by affecting ROS production and manipulating 




Figure 5.1 Proposed model for the role of PEPCK in CIN cancer cells. CIN cells are 
vulnerable to metabolic interventions that increase ROS. Depletion of PEPCK increases 
cytoplasmic NADH, which drives ROS via mitochondrial GPDH. High ROS and high NADH 
blocks glycolysis, so PEPCK depletion is effective in CIN cells. 
NADH is made from NAD+ during glycolysis in proliferating cells, and must be oxidized for 
glycolysis to continue. NADH can also be oxidized by converting pyruvate to lactate, but 
this option is limited in proliferating cells because pyruvate is needed for energy and lipid 
synthesis. Our data reveals that the glycerol-3-phosphate shuttle is the primary pool for NADH 
production: Glycerol phosphate dehydrogenase is utilised by this shuttle in order to oxidize 
cytoplasmic NADH through mitochondria. This process permits glycolysis to continue, 
however, by doing so it produces ROS in the mitochondria via glycerophosphate oxidase 
(GPO1) (Miwa et al., 2003, Orr et al., 2012). We know that CIN cells have elevated ROS levels 
and depend on antioxidants for survival (Shaukat et al., 2015). Consistent with this finding, we 
observed that feeding hosts inhibitors to the shuttle (hydrazine or iGP1) or RNAi mediated 
knockdown (GPDH-RNAi or PEPCK-RNAi) lowers ROS levels. Inhibition of GPO1 
reduced ROS levels as well as limiting the growth of brat tumours by preventing the 
oxidation of cytoplasmic NADH because in this case the shuttle was unavailable for NADH 
oxidation (Hussain et al., 2017). In contrast, we observed that lowering ROS by feeding the 
host antioxidants (propyl gallate) was able to rescue tumour growth: in this scenario the 
shuttle is available without the toxic consequences of high ROS. These findings suggest that 
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the mechanism of PEPCK depletion to block CIN tumour growth is through inhibition of the 
oxidation of cytoplasmic NADH by glyceroneogenesis, and that elevated NADH generates 
more redox stress than the CIN cells are able to cope with. Further, feeding nicotinamide (added 
NAD+) to the host animal, rescued the growth in PEPCK depleted brat tumours, suggesting 
that in these tumours, the glycerol phosphate shuttle has not been able to adequately oxidise 
NADH, regardless of the availability of glucose to fuel this pathway. Oxidizing cytoplasmic 
NADH by feeding with ferricyanide had the same effect. This suggests that growth was being 
limited by the accumulation of NADH. By using the appropriate level of PEPCK and GPO1 
inhibitors we could completely inhibit the growth of these aggressive CIN tumours. 
A plausible contributor to the effect of CIN on cells under oxidative stress is aneuploidy. 
Trisomy is known to give inappropriate gene expression levels and stress responses in diverse 
organisms, consistent with perturbation in the endoplasmic reticulum (ER) resulting in protein 
folding problems (Sheltzer et al., 2012, Oromendia et al., 2012a). We are also interested to 
understand the causal relationships between aneuploidy, oxidative stress and protein folding 
because chromosomal instability and its consequent aneuploidy are common, tumour-specific 
phenotypes that offer the prospect of similar tumour-specific therapies. We have observed 
increased chaperone levels (Hsc70, Hsp83) and ER stress markers (XBP1) in aneuploid cells 
and we hypothesize that aneuploidy causes oxidative stress due to altered metabolism and this 
oxidative stress enhances the proteotoxic effect of aneuploidy. Our data also confirms that 
aneuploid cells suffer protein folding stress such that chaperones are incapable of resolving 
additional stress (i.e. aggregation-prone poly-glutamine (polyQ) proteins).  
Published evidence demonstrated that in ER-stressed cells, Ca2+released from the ER is taken 
up by mitochondria and releases cytochrome c which then inhibits complex III of the ETC and 
increases ROS production. Moreover, increased Ca2+ in the mitochondria stimulates Krebs 
cycle dehydrogenases, thus increasing the oxygen consumption and ROS production. 
Mitochondrial Ca2+ also activates nitric oxide synthase, whose product disturbs the ETC and 
enhances ROS generation (Brand, 2010, St-Pierre et al., 2002). However it is not clear whether 
ER stress generates ROS or ROS generates stressed ER or both. We wished to address this 
question and observe whether the stressed ER generates ROS (by Ca2+ release) and whether 
ROS generates stressed ER (by damaging proteins).  We added  antioxidants to CIN cells and 
measured the level of ROS and ER stress expression (Chapter 4). We found that antioxidants 
rescued protein folding stress in CIN cells, demonstrating that ROS is responsible for protein 
folding stress in CIN cells, which could be rescued by antioxidants.  
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Nucleotide stress has been linked to CIN and cancer development. Nucleotide pool 
disequilibrium results in genetic abnormalities and oncogenic transformation. In order to 
identify the genes of nucleotides pathways that could be involved in regulating the fate of 
CIN cells, we tested a range of genes affecting purine biosynthesis (Adenylosuccinate 
synthetase (ADSS), phosphoribosyl-pyrophosphate synthetase2 (PRPS2), GMP Synthetase, 
IMP dehydrogenase, PRAT), pyrimidine biosynthesis (CTP Synthetase, Carbamoyl 
Phosphate Synthetase) and the PP pathway (Transketolase (TKL), Transaldolase, PP 
Epimerase). We selected the candidates on the basis of their acridine orange (AO) 
phenotype.  AO, a metachromatic dye, has long been known as a convenient non-specific tracer 
of acidic vesicles. This dye readily crosses plasma membranes as well as membranes of 
cytoplasmic vesicles and becomes trapped in vesicles with low internal pH (Pierzyńska‐Mach 
et al., 2014). Its mechanism of accumulation in acidic vesicles involves molecule protonation 
in the interior of an acidic vesicle. The positive charge impedes the its ability to cross the vesicle 
membrane. Hence, the protonated dye molecules are trapped inside the acidic vesicles and 
reach significantly higher local concentrations than in the cytoplasm. Such brightly stained 
vesicles can be readily detected and traced by fluorescence microscopy. The fluorescence 
spectra of AO make it a sensitive marker to measures the changes in the cells.  The change in 
AO staining was reliable indicator of cell injury or death (Plemel et al., 2017).  
The knockdown of ADSS, phosphoribosyl-pyrophosphate synthetase (PRPS2) and TKL gave 
significantly higher AO staining in CIN cells. The nucleotide candidates such as PRPS2 and 
ADSS play a central metabolic role in the synthesis of nucleotides. The PRPS enzyme adds a 
pyrophosphate group from ATP to ribose-5-phosphate generated from the PP pathway to 
produce a nucleotide precursor called 5-phosphoribosyl-1-pyrophosphate (PRPP). PRPP is a 
substrate for all nucleotide salvage pathway enzymes, as well as for the rate-limiting enzymes 
of purine and pyridine biosynthesis. Modulation of PRPS levels by either knockdown or 
overexpression respectively inhibited or potentiated nucleotide production, suggesting that 
levels of PRPP may be sufficient to govern the overall rate of purine metabolism. 
Notably, PRPS1 and PRPS2 are two isoforms of PRPP synthetase expressed in somatic tissues. 
Interestingly, the PRPS2 isoform is largely resistant to the allosteric feedback inhibition by the 
nucleotide biosynthetic pathway products ADP and GDP (Nosal et al., 1993). This enzymatic 
property of PRPS2 may facilitate the PRPS2-expressing cells to continue production of 
nucleotides when their intracellular concentrations are elevated. PRPS2 activity is more 
sensitive to fluctuations in ATP concentration, elevated in Myc-overexpressing B cells and less 
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sensitive to feedback inhibition by purine nucleotides biosynthesis products than PRS1 which 
explains why the levels of PRPS2, but not PRPS1, are increased in cancer cells (Nosal et al., 
1993). Genetic knockout of PRPS2 gave a normal physiology in mice. However, is essential 
for Myc-driven tumorigenesis (Cunningham et al., 2014). ADSS is downstream of the de novo 
pathway and it is a vital component of the de novo pathway as well as the salvage pathway. 
ADSS is a highly conserved enzyme among all living organisms, it converts inosine 
monophosphate (IMP) to adenosine monophosphate (AMP) as part of ATP biosynthesis.  
These high AO phenotypes in nucleotide candidate knockdowns in CIN cells suggest that 
CIN cells are sensitive to changes in nucleotide levels. In addition, the increased Lysotracker 
and DNA damage phenotype was also observed in nucleotide candidate knockdowns of ADSS, 
PRPS2 and TKL in a CIN background. However, the involvement of ROS and cell cycle arrest 
were not observed when these candidates were depleted in CIN cells. Cell death either by 
apoptosis or necrosis was also not observed when these candidates were depleted in CIN cells. 
Therefore, we suspected that the autophagy pathway could be activated in CIN cells. 
Autophagy is activated in response to various stresses including nutrient starvation (White, 
2015, Jiang and Mizushima, 2014). We found that CIN cells are dependent on the autophagy 
of mitochondria to tolerate their aneuploidy and avoid triggering innate immune signalling (Liu 
et al., 2016). For example, blocking the autophagy pathway in CIN cells led to an increased 
number of dysfunctional mitochondria, increased levels of oxidative stress, DNA damage and 
apoptosis, while enhancing autophagy could reduce the level of ROS and apoptosis (Chapter 
4). So we hypothesized that autophagy might be triggered in response to nucleotide depletion. 
Surprisingly, autophagy was not detected in ADSS and PRPS2 deficient CIN cells. However, 
elevated puncta of mCherry-tagged Atg8a were observed in TKL deficient CIN cells, 
suggesting that autophagy is activated in that case.  
TKL is a pivotal enzyme of the PP pathway. The PP pathway is connected with glycolysis and 
mainly involved in the production of ribose-5-phosphate and NADPH via the non-oxidative 
and oxidative arms, respectively (Figure 5.2). TKT is a reversible enzyme of the non-oxidative 
arm of the PP pathway which catalyses the common two-substrate reactions. First it transfers 
two-carbon groups from xylulose-5-phosphate to ribose-5-phosphate to generate 
sedoheptulose-7-phosphate to glyceraldehyde-3-phosphate. Second, TKL transfers two-carbon 
groups from xylulose-5-phosphate to erythrose-4-phosphate to generate glyceraldehyde-3-
phosphate and fructose-6-phosphate, which re-enter glycolysis. When cells are in need of 
nucleotides, the PP pathway produces ribose through the oxidative as well as the nonoxidative 
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arm from fructose-6-phosphate and glyceraldehyde-3-phosphate (Figure 5.2). Increased 
expression of TKL was reported in various cancers such as cervical, lung, gastric, colorectal, 
and endometrial cancers (Krockenberger et al., 2010, Schultz et al., 2008, Staiger et al., 2006). 
Induced expression of TKL1 in advanced colorectal and urothelial cancer is associated with 
malignancy, invasiveness, therapeutic resistance and poor prognosis (Schwaab et al., 2011). 
Published evidence suggested that TKL1 also enhances the PPP flux for biosynthetic reactions, 
as the PPP generates ribose-5-phosphate for nucleic acid synthesis and NADPH for fatty acid 
synthesis and maintaining redox homeostasis to protect cells against oxidative stress and 
apoptosis (Vaughn and Deshmukh, 2008, Diaz-Moralli et al., 2016).  
 
Other studies also showed that the non-oxidative arm of PPP to be the major provider of PRPP, 
with more than 70% of nucleic acid ribose in several human cancer cell lines derived through 
the TKL, transaldolase, and triose phosphate isomerase reactions and inhibition of TKL 
suppress the PP pathway and interrupt the synthesis of important coenzymes such as ATP, 
CoA, NAD(P)+, FAD, and genetic material, RNA and DNA in cancer cells (Cascante et al., 
2000, Comín‐Anduix et al., 2001, Saha et al., 2014). Though these findings suggest TKL may 
control purine synthesis and represent a potential target for cancer therapy.  
 
 
Figure 5.2: A model for triggering autophagy in CIN cells by TKL. CIN cells are sensitive to 
nucleotide stress. Transketolase (TKL, depletes the level of ATP which leads to disequilibrium 





Besides the importance of TKT in the nucleotide production, a recent study showed that TKL 
has been implicated in the regulation of autophagy via interacting with Atg1 kinase protein and 
changes in the endogenous TKT activity in Dictyostelium discoideum strains lacking or 
overexpressing Atg1, suggesting that additional metabolic pathways between autophagy and 
the pentose phosphate pathway influence the regulation of autophagy in D. discoideum 
(Mesquita et al., 2015). In this study, we found that depletion of TKL in CIN cells triggered 
autophagy, so we proposed that depletion of TKL decreased the level of ATP (Figure 5.2). Low 
ATP and high AMP levels activate AMPK and trigger autophagy which is needed for CIN cell 
survival (Chapter 4).  
We observed high lysotracker staining in ADSS and PRPS2 deficient CIN cells. Lysosomes 
play a crucial role in cancer progression by regulating complex processes involving protein 
secretion, endocytic receptor recycling, energy metabolism, and cell signalling (Appelqvist et 
al., 2013). Moreover, the autophagy–lysosome pathway is closely linked with the hallmarks of 
cancer including escaping cell death pathways, evading immune surveillance, and deregulating 
metabolism (Hanahan and Weinberg, 2011b). Advanced cancer cells are extremely reliant on 
effective lysosomal function. As a consequence, cancer progression and metastasis are related 
with unusual changes in lysosomal compartments, such as lysosome volume, composition, 
cellular distribution, and lysosomal enzyme activity, as compared with normal cells (Nishimura 
et al., 1998, Gocheva et al., 2006). Thus, targeting lysosomes in cancer has great therapeutic 
potential because it not only triggers apoptotic and lysosomal cell death pathways but also 
inhibits autophagy. Furthermore, lysosomes contribute to the development of drug resistance 
by sequestering cancer drugs in their acidic environment which reduces the effect of the drug 
(Gotink et al., 2011). Therefore, the lysosomes are thought of as an Achilles’ heel of cancer 
cells. Furthermore, consistent with the lysotracker staining, high quinacrine (a lysosomal ATP 
marker) was observed in knockdown of nucleotide synthesis enzyme in CIN cells, suggesting 
lysosomal induction in these cells (chapter 4). However, as expected, when we blocked 
lysosomes by inhibiting v-ATPase, the CIN cells died. These results suggest that in the 
absence of autophagy, lysosomes worked hard to compensate for the lack of autophagy and 
when we blocked lysosomes the CIN cells died. So, we concluded that CIN cells use lysosomes 
to compensate for AMP-blocked autophagy loss. However it remains unclear how loss of AMP 




Moreover, depletion of ADSS and PRPS2 decreased the level of AMP which further led to 
depletion of ATP in CIN cells (Figure 5.3). So, we examined whether feeding both rATP and 
dATP to ADSS and PRPS2 deficient CIN larvae would have an effect on the AO phenotype. 
First, we fed rATP to larvae with double knockdown of ADSS and PRPS2. We observed that 
in larvae knocked down for ADSS or PRPS2 feeding rATP significantly rescued the AO 
phenotype in CIN cells relative to their controls. Similarly, we fed dATP to larvae knocked 
down for ADSS or PRPS2. We observed a significant reduction in the AO phenotype in 
knockdown of ADSS and PRPS2 in CIN cells. These results suggest that CIN cells are sensitive 
to ATP changes. To further understand why ATP might be limited in CIN cells we tested for 
the Poly (ADP-ribose) Polymerase (PARP) and found that it is upregulated in CIN cells. 
In addition, our preliminary screen for candidates that are needed for death in response to high 
aneuploidy levels has identified several members of the dosage compensation complex (e.g. 
Unr, Msl1, Mof, roX1, CLAMP, JIL-1). Significantly, we have observed that loss of Unr, 
CLAMP and JIL-1 can lower ROS levels and rescue cell death in aneuploid cells (unpublished 
data). The chromatin modifiers such as CLAMP, JIL-1 are associated with aneuploidy sensing 
and regulation of redox response through PARP. CLAMP depletion in highly aneuploid cells 
rescues oxidative stress and lethality by reducing the level of PARP, suggesting CLAMP uses 
PARP to induce aneuploidy specific ROS and cell death. Similarly we also observed rescue of 
oxidative stress and cell death when we knockdown PARP in CIN cells. The PARP enzyme 
PARylates a variety of protein substrates and alters their interaction with DNA and other 
proteins. PARP is currently in clinical trials for DNA damage sensitive cancers because of its 
role in the DNA damage response (Weaver and Yang, 2013). PARP activation causes depletion 
of its substrate, which further leads to loss of ATP (Zong et al., 2004) . We found that adding 
ATP or nicotinamide (a precursor in the synthesis of NAD+) rescued the AO phenotype in CIN 
cells. These results suggest that ATP and NAD+ are consumed for PARP activation and CIN 





Figure 5.3: CIN cells are sensitive to nucleotide stress. PRPS2 and ADSS, deplete the 
nucleotide level and cause DNA damage as a result PARP is activated for repair. ADSS 
depletion in CIN cells decreases the AMP level which could not activates AMPK and trigger 
autophagy, so in absence of autophagy lysosomes work hard to compensate autophagy in CIN 
cell. 
 
We proposed that knockdown of ADSS and PRPS2 in CIN cells depletes the nucleotide level 
which results in DNA damage. DNA damage activates PARP and causes a reduction in both 
the NAD+ and the ATP pool. CIN cells already lack ATP due to activation of PARP and lower 
levels of ATP in CIN cells is normally paralleled by increasing AMP levels.  High AMP levels, 
sensed by AMPK, lead to activation of autophagy, which is required for CIN cell adaptation in 
a nutrient starved condition. However, blocking AMP synthesis by ADSS knockdown in CIN 
cells prevented activation of autophagy (Figure 5.3). An elevated lysosomal phenotype in 
ADSS deficient CIN cells suggests that in the absence of autophagy, lysosomes worked hard 
to compensate for the autophagy defect. When we blocked lysosomes by inhibitor, the CIN 
cells died, which suggest the importance of lysosomes in CIN progression (Figure 5.3). 
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Targeting lysosomes in cancer by exploring lysosomal biogenesis and its role could emerge as 
a new therapeutic strategy to overcome drug resistance in cancer. 
Future Directions 
Our studies demonstrate the importance of metabolism in CIN tumour therapy. Further 
exploration would provide a mechanistic understanding for these complex metabolic 
interactions in the cell to be able to target cancer.  However, it is ineffective to depend on any 
single therapeutic agent due to the emergence of drug resistance during tumorigenesis. Thus, 
targeting additional features that CIN cells have in common, along with our metabolic approach 
could develop a strategy that robustly clears the tumour. There are still some open questions 
that need to be addressed. 
• We have shown that CIN tumours depend on PEPCK to decrease cytoplasmic NADH 
but the level of NADH has not been measured. By measuring the effect of removing 
PEPCK on NADH metabolism in normal and induced-CIN tissue as well as in CIN 
tumours, this data could help to confirm our hypotheses about the inhibitory role of 
NADH in PEPCK deficient CIN cells or tumours. 
• Our study suggests that elevated NADH in CIN cells leads to increased ROS production 
from mitochondria, however this still needs to be validated. Identification of the most 
effective targets for perturbing NADH levels in a range of tissue types will show what 
effect this has on CIN cells 
• We know that tumours adapt to therapy, therefore it is important to identify ways to 
block the available stress response pathways that potentially mitigate metabolic 
therapy. We found that ER stress responses, mitophagy and innate immune signalling 
pathways are regulated in CIN cells to avoid CIN-specific cell death. However, we did 
not test their ability to block NADH-induced ROS and growth arrest in CIN cells and 
tumours to identify effective inhibitors.  
• In this project, we found that the CIN cells are sensitive to nucleotide changes but 
depletion of purine nucleotide synthesis enzymes did not trigger apoptosis in CIN cells. 
This strongly suggested that other pathways might be activated in CIN cells to 
compensate for the demand for nucleotides. The role of the salvage pathway in CIN 
cells is not clear. Therefore, manipulation of nucleotide recycling pathway candidates 




• Why is ATP limited in CIN cells? We suggest that is due to activation of PARP in CIN 
cells and showed that feeding ATP rescued the AO phenotype, but we did not measure 
the ATP level in CIN cells. ATP measurement in nucleotide depleted CIN cells and 
high CIN (Rad21 with Dicer2) will provide valuable confirmation of the effect of ATP 
in CIN cells.  
• In this study, induction of lysosomes was observed in response to nucleotide stress in 
CIN cells and when we blocked the lysosomes, CIN cells died. Consequently, this study 
shows the importance of lysosomes in CIN cell progression under nucleotide stress. 
Thus, further investigations to determine the interaction between the lysosomal 
pathway and nucleotide pathway in response to CIN will be significant. 
• The effect of ADDS, PRPS2 and TKL in tumours has not been tested. We still do not 
know whether these candidates that are directly involved in nucleotide synthesis can 
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The Role of JNK Signalling in Responses to Oxidative DNA Damage 
Zeeshan Shaukat, Dawei Liu, Rashid Hussain, Mahwish Khan and Stephen L. Gregory* 
School of Molecular and Biomedical Science, University of Adelaide, North Terrace, Adelaide S.A. 
5006, Australia 
Abstract: The production of reactive oxygen species is a normal part of cell physiology, but many in-
ternal and external stimuli are able to trigger the production of excess levels of oxidants that are poten-
tially damaging. The threat of oxidative damage is particularly significant to DNA, as damaged bases 
can interfere with replication to generate lasting mutations. Signalling through the JNK pathway is a 
key cellular response to oxidative damage. Depending on the intensity and duration of the damage sig-
nal, JNK signalling can lead to distinct alternative responses including DNA repair, anti-oxidant pro-
duction or cell death. These responses are highly relevant to cancer therapy, as tumours are often un-
der oxidative stress that produces elevated JNK levels and therapy often involves inducing DNA damage with the inten-
tion of driving cell death. In this review we examine the causes and consequences of JNK activation that relate to oxida-
tive DNA damage, with a focus on the potential therapeutic implications. 
Keywords: Aneuploidy, cell cycle, chromosomal instability, DNA damage, Drosophila, JNK, oxidative stress, ROS, therapeu-
tic target. 
INTRODUCTION 
The family of Jun N-terminal kinases (JNKs) was origi-
nally identified as UV responsive proteins that activate Jun 
to give transcription of a range of stress response target 
genes [1]. There is now a huge literature on JNK that docu-
ments its role in processes as diverse as cell migration, pro-
liferation, apoptosis, insulin signalling and neuronal survival 
[2]. In this review we will focus on how JNK signalling is 
triggered by oxidative damage to DNA, and the downstream 
responses that determine cell fates after oxidative damage. 
This topic is relevant to cancer treatment for several reasons. 
Firstly, tumours often have an altered metabolism that fa-
vours glycolysis but generates elevated levels of reactive 
oxygen species (ROS) from the mitochondrial electron 
transport chain [3]. Because high ROS levels can damage 
DNA, tumours can potentially generate heightened genetic 
diversity that promotes drug resistance and cancer progres-
sion [4]. The JNK pathway is frequently activated in tu-
mours, as part of the oxidative stress response [5], so inhibit-
ing JNK signalling may be an effective way to prevent can-
cers from being able to tolerate a high ROS metabolism. 
Oxidative damage to DNA can also be incurred by the can-
cer therapy, such as radiotherapy or metabolic interventions 
that rely on the production of ROS to kill tumours. However, 
the activation of JNK in response to DNA damage can have 
widely divergent outcomes including proliferation, cellular 
repair or apoptosis [6]. Consequently, an understanding of 
what drives cellular responses to JNK is essential to allow 
effective therapeutic intervention. 
*Address correspondence to this author at the School of Molecular and 
Biomedical Science, University of Adelaide, North Terrace, Adelaide S.A. 
5006, Australia; Tel: +61 8 83137536; Fax: +61 8 83137534;  
E-mail: stephen.gregory@adelaide.edu.au 
ACTIVATION OF JNK SIGNALLING BY OXIDA-
TIVE DAMAGE 
A wide range of cellular insults are known to result in ac-
tivation of JNK, primarily by causing phosphorylation of 
conserved residues in the JNK kinase domain [7]. These 
stresses include UV light, genotoxic damage, oxidative 
stress, hypoxia, wounding, nearby apoptosis, growth factor 
signalling, and immune cell activation. In each case, a sensor 
protein detects changes in the cellular environment, trigger-
ing the activation of a phosphorylation cascade that culmi-
nates in the phosphorylation of JNK. The process may be 
better described as a network response than a pathway, as 
numerous inputs can contribute to JNK activation and these 
signals are integrated with negative feedback from JNK tar-
gets to generate a dynamic response (Fig. 1) [8].  
There is evidence that the strength and duration of JNK 
activation can significantly alter the cellular response to JNK 
signalling. For example, sustained JNK activation is ob-
served following treatment with cisplatin [9]. Cisplatin may 
initially trigger JNK activation by oxidative stress, but cis-
platin also activates JNK later via the DNA damage sensing 
pathway to give the sustained response. Whereas ionising 
radiation can trigger JNK to drive rapid apoptosis of dam-
aged cells [10], sustained weak activation of JNK by low 
concentrations of cisplatin may improve cell survival by 
upregulating DNA damage repair [9]. However, a sustained 
high level of activation of JNK can lead to robust apoptosis, 
as seen in cells lacking feedback inhibition of JNK [11, 12]. 
Consequently, interpretation of JNK activation requires care-
ful consideration of dosage and timing as well as other po-
tential variables such as cell type [13], cell cycle stage [14] 
and metabolic status [15]. 
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Fig. (1). Cell stresses that generate oxidative damage activate JNK 
signalling via multiple redox sensors including JNK Phosphatase 
(JNK P-ase), Glutathione-S-Transferase pi (GST) and ASK1 (via 
Thioredoxin). Oxidative DNA damage also activates JNK via sev-
eral routes including the damage sensors ATM and ATR. The result 
of JNK activation generally includes either DNA repair, autophagy 
and antioxidant production to promote stress tolerance, or the in-
duction of apoptosis. 
Two features frequently seen in stressors that activate 
JNK signalling are that they cause elevated levels of reactive 
oxygen species (ROS) and that they lead to DNA damage. 
High ROS levels are thought to increase JNK activity pri-
marily through loss of JNK inhibition, as negative regulators 
of JNK, such as Glutathione-S-Transferase and JNK phos-
phatase, are ROS sensitive [16]. ROS can be generated by 
external stimuli including ionising radiation, pro-oxidant 
chemicals, hypoxia, toxins like alcohol that activate cyto-
chrome p450 enzymes, and drugs like cisplatin that affect 
mitochondria [17]. Internal sources of ROS include the mito-
chondrial electron transport chain, NADPH oxidase (Nox), 
and peroxisomes. The levels of ROS from these sources are 
normally balanced by appropriate levels of antioxidants such 
as reduced Glutathione or Thioredoxin and antioxidant en-
zymes including Superoxide Dismutase, Catalase and Perox-
iredoxins. JNK activity can thus be stimulated either by in-
creasing ROS generation or by depleting the cell of antioxi-
dants. It seems likely that a strong upregulation of JNK by 
elevated ROS levels contributes to the apoptosis generated 
by ROS-producing cancer therapies such as fenretinide and 
cisplatin [18, 19]. 
High levels of ROS lead to oxidative damage. In the case 
of lipids and proteins they may be repaired or replaced, but 
oxidative DNA damage can lead to lasting mutations. This is 
particularly significant for mitochondrial DNA, which is 
exposed to superoxide and peroxide from the electron trans-
port chain in an organelle that lacks catalase [20]. Ideally, 
oxidatively damaged nucleotides are removed before DNA 
replication to avoid fork stalling and the resulting double 
strand breaks that contribute to genomic instability [21]. Be-
cause mitochondrial superoxide has a short half-life [22], the 
nuclear DNA is usually less exposed to oxidative stress, and 
in some tissues is better able to replace damaged nucleotides 
[23]. An exception to this may be in mitosis, when the DNA 
is no longer shielded by the nuclear membrane and DNA 
repair is limited [24]. 
Whether generated by ROS or other means, DNA dam-
age can activate JNK signalling. In particular, double 
stranded breaks in DNA have been shown to lead to the acti-
vation of JNK [6, 25]. Possible mechanisms include the 
DNA damage sensors ATM and ATR triggering the JNK 
signalling pathway via Tak1 and c-Abl, or DNA damage 
effects on translation reducing the amount of the JNK phos-
phatase MKP-1. Replication stress can also lead to JNK acti-
vation, in this case via MKK4 and independent of 
ATM/ATR damage sensing [26]. This defective replication 
mechanism can explain how simply adding DNA that carries 
intra-strand crosslinks can activate JNK [9]. In this context it 
is interesting that inter-strand crosslinks do not produce the 
same effect on JNK [27], partly because the mismatch repair 
system does not detect inter-strand crosslinks. There are sig-
nificant clinical differences between drugs that predomi-
nantly generate one or other type of crosslink [28], so it is 
tempting to speculate that JNK activity contributes to these 
differences. 
There are a number of features of tumourigenesis that re-
late to oxidative induction of JNK signalling. Prior to tumour 
formation, chemicals that promote ROS, such as cigarette 
smoke and alcohol, are implicated in the accumulation of 
oncogenic mutations. JNK is typically activated by these 
kinds of cellular stresses, either to repair or, if necessary, to 
kill damaged cells [7]. It is intuitively obvious that oxidative 
DNA damage can generate deleterious mutations, but the 
opposite hypothesis, hormesis, should also be considered. 
Hormesis suggests that an ongoing low level of oxidative 
stress encourages the production of cellular antioxidants, 
repair and immune surveillance that results in a lower rate of 
surviving deleterious mutations [29]. The role of JNK in 
mediating hormesis is still poorly characterised, though there 
is evidence that hormetic radiation resistance may require 
JNK [30].  
Once a tumour has formed, it is common to observe high 
levels of ROS [31, 32] and JNK activation [7]. ROS produc-
tion is known to result from growth factor stimulation of 
Nox or from mitochondrial disruption that accompanies a 
metabolic shift to oxidative glycolysis [33]. In these cases, 
the demands of proliferation result in higher levels of ROS 
generation that must be counteracted for the tumour to avoid 
self-destruction. Another feature of tumours that induces 
oxidative stress is chromosomal instability (CIN). CIN is a 
common feature of tumours that gives ongoing variation in 
karyotype due to impaired mitotic fidelity [34]. This means 
that most tumours are aneuploid, and aneuploidy has been 
shown to cause oxidative stress [35], though the mechanisms 
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are still unclear. Nonetheless, we have found that the induc-
tion of CIN causes an increase in ROS and activation of JNK 
(our unpublished results). Because JNK signalling is a pri-
mary oxidative stress response, it is thought to be critical for 
tolerating high ROS production as it can enhance DNA re-
pair, autophagy and antioxidant levels (see below). It is in 
this context, to block the ability of tumours to tolerate high 
ROS levels, that JNK inhibitors are being considered for 
cancer therapy [7, 36].  
Finally, treatment of tumours also often results in further 
elevated levels of ROS, in this case with the objective of 
generating JNK-driven apoptosis [12]. For example, cisplatin 
is a front-line therapy that damages mitochondrial DNA 
leading to loss of mitochondrial gene products and hence a 
defective electron transport chain that produces ROS [37]. 
There is evidence that activation of JNK is necessary for 
cisplatin to be able to induce apoptosis [12] and to effec-
tively treat tumours in animal models [38]. Radiation therapy 
also induces high levels of ROS, and similarly relies on JNK 
induction to give effective apoptosis in tumours [39]. 
In each of these cases it can be seen that JNK activation 
can be beneficial or detrimental depending on the signalling 
outcomes. For example, JNK activation can lead to the in-
duction of DNA damage repair enzymes and the production 
of antioxidants [40]. This is a highly adaptive response for 
cells that have been exposed to low levels of an environ-
mental toxin, but is the opposite of the desired effect for cis-
platin chemotherapy. Conversely, JNK signalling can lead to 
apoptosis, which might suggest that upregulating JNK would 
be an effective cancer therapy, but JNK can also promote 
autophagy , which can be counterproductive for therapy [41]. 
Clearly, a more detailed understanding is needed of how 
stimulus and response are coupled in JNK signalling. 
JNK SIGNALLING OUTCOMES 
In any multicellular organism, the cellular response to 
genotoxic damage has to be delicately balanced. On one 
hand, a decision to keep damaged cells and attempt repair, 
risks the build-up of mutations and the threat of diseases 
such as cancer. On the other hand, a too robust apoptotic 
response to damage risks self-destruction or too much reli-
ance on compensatory proliferation from stem cells that may 
also have been damaged. Consequently, organisms have de-
veloped stress sensing mechanisms such as the JNK path-
way, which to some extent assess the threat level in order to 
produce the appropriate response: to maximise the chance 
that surviving cells are effectively repaired and to ensure that 
where cell death is needed, apoptotic cells are efficiently 
removed and replaced. These responses will be discussed in 
more detail in the following sections. 
Survival: DNA Damage Repair and Protection 
Cells are continually exposed to oxidative stresses from 
both internal sources such as active mitochondria, and exter-
nal threats such as radiation or UV light. Cells generate anti-
oxidants to counter these threats, but even so, a certain 
amount of ongoing oxidative DNA damage appears to be an 
inevitable feature of metazoan metabolism. It has been esti-
mated that mammalian cells suffer 20,000 DNA lesions per 
cell per day, mostly from reactive oxygen species [42]. 
These lesions are repaired, typically by the constitutively 
active base excision repair process in G1 or G2 [43]. This 
results in “silent” DNA repair that is completed before the 
lesion has any impact on the cell [44]. Oxidative damage 
during replication, however, is more problematic: damaged 
bases can cause C:G to A:T transversion mutations [42], or 
stall the replication fork [45], potentially generating double 
strand breaks. To avoid breaks, cells can employ alternative 
polymerases such as Pol ι that can tolerate abnormal DNA 
structures and carry out trans-lesional synthesis [21]. Consis-
tent with the role of JNK in oxidative stress responses, JNK 
signalling can upregulate Pol ι [46, 47], and this polymerase 
has recently been shown to be essential to avoid tumorigene-
sis in a mouse model [48]. JNK can also phosphorylate His-
tone 2AX to form part of the DNA double strand break re-
pair complex [49]. There is now evidence for the activation 
of a wide range of DNA damage recognition and repair en-
zymes in response to JNK signalling, mostly via the JNK 
activated transcription factors FOXO or AP1. 
The JNK-activated heterodimer AP1 is unusual in that its 
structure is directly redox sensitive: both Fos and Jun have 
ROS sensitive Cysteines that inactivate AP1 if oxidised [50]. 
Consequently, although lower levels of ROS can lead to AP1 
activation by JNK-dependent phosphorylation, strong oxida-
tive stress directly inhibits AP1 function. This threshold ef-
fect may contribute to generating dose dependent alternative 
outputs from JNK signalling. AP1 activity stimulated by 
DNA damage increases the transcription of a wide range of 
genes that are known to mediate DNA damage repair includ-
ing MSH2, MLH1, XPA, RAD21, RAD50, GADD45 and 
ERCC1 [51]. It is interesting to note that AP1 activity also 
inhibits p53 transcription [52], which seems counterintuitive 
given that p53 can activate many of the same DNA repair 
genes. On the other hand, JNK has also been seen to directly 
stabilize p53 by phosphorylation [53]. These varied effects 
on p53 may reflect the difference between the steady state 
role of AP1 in cell cycle progression versus differing stress-
activated levels of JNK signalling, in which the priority may 
be either to avoid or to ensure p53-dependent apoptosis de-
pending on the damage level. 
Activation of FOXO-dependant transcription is another 
JNK signalling output that has been connected with the 
stimulation of DNA repair. JNK pathway signalling leads to 
the nuclear localization of FOXO, preventing the retention 
and degradation of FOXO in the cytoplasm [54]. It is inter-
esting to note that although FOXO can be negatively regu-
lated by growth factors via the PI3K/Akt pathway, activation 
by stress through JNK appears to be a dominant effect, al-
lowing FOXO activation even in proliferating cells [55]. 
Active nuclear FOXO has two effects that are relevant to 
oxidative DNA damage. Firstly, like AP1, FOXO activates 
the transcription of GADD45α, which has been shown to 
mediate the repair of either UV [56] or nitric oxide damaged 
DNA [57].  
The second effect of FOXO activation is to drive the ex-
pression of a range of antioxidants. This is distinct from the 
role of AP1 which downregulates some antioxidants [58]. 
FOXO induces targets that include Superoxide Dismutase, 
Catalase and Peroxiredoxins [40, 54, 59] to remove superox-
ide and peroxide radicals, and Sestrin, which regenerates 
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Peroxiredoxins as well as increasing levels of autophagy and 
the antioxidant-regulating transcription factor Nrf2 [60]. As 
might be expected, loss of FOXO confers sensitivity to oxi-
dative stress in a range of organisms [47, 61, 62]. Given that 
FOXO contributes to the survival of oxidatively stressed 
cells by both repairing damaged DNA and by boosting anti-
oxidant defences, it might seem that depletion of FOXO 
would be a logical strategy for chemotherapy. Unfortunately, 
activation of FOXO is known to be needed for the effective-
ness of several frontline cancer therapies including cisplatin 
and microtubule poisons [63]. This underlines the need to 
understand the role of JNK targets in detail to allow separa-
tion of their pro- and anti-apoptotic roles. 
Cellular Repair: Autophagy  
As well as repairing damaged DNA, cells that have suf-
fered oxidative stress must react to the accumulation of oxi-
dised protein and lipids. Autophagy is a common process 
cells employ to degrade unnecessary protein aggregates and 
dysfunctional organelles via the lysosomes. Autophagy is 
initiated with the formation of double-membraned vesicles 
referred to as autophagosomes to isolate targeted cytoplas-
mic components, then the autophagosomes are delivered and 
fused with lysosomes for the degradation of the sequestered 
components [64]. The degradation of those cytoplasmic 
components allows cells to eliminate harmful organelles, 
recycle nutrients and maintain energy homeostasis. It is a 
self-protection process which can be activated in response to 
a variety of cellular stresses including nutrient starvation, 
oxidative stress, DNA damage and damaged organelles [65].  
JNK signalling in response to oxidative stress (Fig. 2) is 
known to increase the levels of sestrins [60], which can acti-
vate AMPK to increase autophagy by blocking the effect of 
mTOR [66]. Consistent with this model, JNK signalling has 
been seen to activate autophagy through up-regulating essen-
tial autophagy genes such as atg1, atg8a and atg18 in re-
sponse to chemical induced oxidative stress [67]. An impor-
tant result of this stress-induced autophagy is the removal of 
damaged mitochondria, which would otherwise produce 
ROS and increase the level of oxidative stress [60]. Consis-
tent with this, JNK signalling is required for the survival of 
cells with induced chromosomal instability (CIN), which 
causes oxidative stress and DNA damage [68]. The shut-
down of either JNK signalling or the autophagy pathway 
leads to an increased number of dysfunctional mitochondria, 
increased levels of ROS, and DNA damage as well as apop-
tosis in CIN cells, while inducing autophagy is able to sig-
nificantly rescue these cells (our unpublished data). Auto-
phagy has also been implicated in regulating the timing of 
mitosis in the presence of DNA damage [69], which may 
also contribute to the need for JNK signalling in CIN cells. 
Aberrant autophagy is associated with tumorigenesis; 
however, its actual role in cancer development is highly con-
troversial. The current view is that functional autophagy can 
suppress early stage tumorigenesis whereas it can facilitate 
advanced tumours to develop resistance against chemother-
apy [70]. Autophagy exerts its protective function and sup-
presses tumorigenesis in many ways: autophagy increases 
tolerance of metabolic stress and limits chromosomal insta- 
 
bility in cells, two hallmarks of cancer [64, 71]; autophagy 
could remove dysfunctional mitochondria which are the 
main source of endogenous ROS generation that contributes 
to tumorigenesis [72]; autophagy could also suppress tu-
morigenesis by eliminating the accumulation of certain onco-
proteins, such as p62 which can alter the NF-kB pathway and 
promote tumorigenesis [73]. Therefore, by activating auto-
phagy, ROS-mediated JNK activation could effectively pro-
tect cells from endogenous and external cellular stresses and 
prevent tumorigenesis. 
On the other hand, in tumours being treated with chemo-
therapy, autophagy has been reported to exert either a pro-
survival or pro-death role [74]. Pro-survival autophagy is 
seen in P53 deficient colorectal cancer cells that activate 
autophagy through JNK signalling to develop chemo-
resistance against the widely used chemotherapeutic 5-
fluorouracil (5-FU). Inhibition of either JNK signalling or 
autophagy can effectively kill the tumour cells after 5-FU 
treatment [41]. Similarly, treating human glioblastoma cells 
with evodiamine gave autophagy activation via JNK signal-
ling, and shutting down either autophagy or JNK signalling 
increased apoptosis and reduced tumour cell viability [75]. 
However, other research showed the pro-death function 
of autophagy: in chalcone-24 treated lung and bladder tu-
mour cells, the sequential activation of JNK signalling in-
duce autophagy-dependent necroptosis which effectively 
killed the cancer cells [76]. Similarly, human hepatoblastoma 
(HepG2) cells activate autophagy through the ROS-JNK 
signalling pathway to facilitate the efficacy of anticancer 
drug isoorientin (ISO), and inhibition of autophagy reduces 
the apoptosis after isoorientin treatment [77]. It appears that 
JNK-mediated autophagy can have both tumour suppressing 
and tumour promoting roles during the process of tumori-
genesis which is highly dependent on the cell type and anti-
cancer drug properties. Clearly we need to know more about 
the interactions between autophagy and chemotherapy to be 
able to avoid chemo-resistance and maximize drug efficacy. 
Arrest: Cell Cycle Effects 
Oxidative stress signals are sensed by FOXO, forkhead 
transcription factors that act as effectors of the subsequent 
cellular response i.e cell proliferation, apoptosis, or regula-
tion of oxidative stress and DNA damage. As a key integra-
tor of pro- and anti-proliferative signals, it is not surprising 
that aberrant regulation of FOXO leads to tumour develop-
ment and progression [78]. 
Oxidative stress and ROS signalling can affect FOXO 
not only through JNK, but also via activation of the 
PI3K/Akt pathway (Fig. 2) [79]. Akt phosphorylates FOXO 
and inhibits its activity by ensuring its cytoplasmic localiza-
tion and degradation [55, 80]. This allows progression 
through G1, which is otherwise inhibited by FOXO activity 
[81]. Activated FOXO has nuclear localization and acts as a 
transcription factor to block cell cycle entry via p27
kip1
. 
FOXO activity also decreases the transcription of genes such 
as CyclinB and Cdc2 that are needed for G2/M progression 
[82]. Overall, the activity of FOXO is anti-proliferative and 
acts at several stages to prevent cell cycle progression unless 
it is inhibited by growth factor signalling through Akt. 
158    Current Drug Targets, 2016, Vol. 17, No. 2 Shaukat et al. 
The oxidative stress-activated JNK pathway is known to 
activate FOXO. This can be by direct phosphoryla-
tion/activation of FOXO4 at Thr447 and Thr451 [83], and by 
blocking the inhibitory effect of PKB/Akt on FOXO [84]. 
Oxidative stress can also activate FOXO by directly activat-
ing MST1, which phosphorylates FOXO1 and FOXO3a 
[85], or by disrupting inhibitory 14-3-3 binding [86]. How-
ever, ROS can also activate PI3K/Akt signalling by inhibit-
ing the PI3K negative regulator (PTEN) phosphatase [87], so 
it has become clear that, like AP1, FOXO is either up- or 
down-regulated by ROS through multiple mechanisms to 
coordinate an appropriate response [88]. 
In a normal cell cycle, nuclear JNK is degraded by the 
APC/C in mitosis [14], resulting in low levels of JNK during 
mitosis and G1. However, activation of JNK in response to 
oxidative stress leads to inhibition of the APC/C which re-
sults in persistent cyclinB, Plk and cdc20, giving mitotic 
arrest [14]. Oxidative stress mediated activation of JNK also 
correlates with inhibitory phosphorylation of cdc25 at Ser-
168 [89], again resulting in G2/M arrest. It would seem plau-
sible that JNK might contribute to checkpoint function in G2 
to prevent mitotic progression in the presence of DNA dam-
age, however the evidence for this is limited. Although JNK 
can phosphorylate cdc25c [90], there is inconclusive evi-
dence that it does so in vivo, primarily because the JNK in-
hibitors used (SP600125 or TAT-JIP) efficiently inhibit 
other cell cycle regulators such as CDK1, MPS1 and CDK2 
[91, 92]. This lack of a specific inhibitor has meant that some 
cell cycle roles of JNK are still poorly characterised. 
We and others have directly tested whether JNK function 
is needed for the DNA damage checkpoint in G1 [93] or G2 
[68], and have found that cells lacking JNK can still effec-
tively arrest in response to irradiation. JNK is activated in 
response to DNA damage, but it seems that its role is not to 
induce arrest so much as to drive either repair or apoptosis. 
We found that JNK depletion increased both the level of 
DNA damage and apoptosis in stressed cells, but that in-
creasing the duration of G2 could rescue these defects [68], 
suggesting that if repair can be completed before mitotic 
entry, there is no lasting damage done. DNA damage persist-
ing into mitosis, on the other hand, is likely to be perpetuated 
by mitotic errors [94]. In addition, we and others have ob-
served activated JNK on centrosomes during early mitosis 
which is then lost during anaphase [68, 95]. This is consis-
tent with degradation of JNK by APC/C cdh1 [14]. Several 
DNA damage response genes and cell cycle regulators are 
 
Fig. (2). Oxidative stress typically activates FOXO by several mechanisms including direct phosphorylation, blocking 14-3-3 binding and 
blocking the PI3K/Akt pathway that otherwise inhibits FOXO during growth factor signalling. Activation of FOXO typically leads to cell 
cycle arrest in G1 or G2 as well as activation of autophagy via AMPK. JNK activity normally peaks during G2, and may ensure effective 
DNA repair before mitotic entry, when it is degraded by the APC/C. 
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also localized on centrosomes. Their functional interactions 
are still poorly understood, but consistent with vertebrate 
data showing evidence of JNK-regulated targets in mitosis 
[90, 96-98]. 
Although oxidative stress can activate JNK and FOXO to 
give cell cycle arrest or apoptosis, JNK is also implicated in 
triggering compensatory proliferation to replace dying cells 
[99, 100]. It is superficially paradoxical that a cellular re-
sponse to genotoxic damage should encourage proliferation, 
but this tension has been noted for decades [101], and several 
explanations exist, including the need for multicellular ani-
mals to maintain enough cells to support organ function, 
despite high levels of damage. Because chemotherapy can 
generate high levels of apoptosis, JNK-mediated compensa-
tory proliferation is of significant clinical interest. Apoptosis 
can trigger proliferation in the neighbouring cells by activat-
ing Wnt and JNK signalling pathways via Dronc/Caspase 9 
[99]. It is not yet clear how Caspase 9 activates JNK, nor 
why JNK stimulates proliferation in this setting, though it 
may relate to a known developmental requirement for JNK 
in EGF signalling [102]. JNK is also activated in the cells 
near to wounds, possibly by localized ROS production [103], 
and is required for the onset of regeneration in the absence of 
cell death [100], consistent with the known roles of JNK in 
migration and differentiation during development [104, 105].  
Death: Induction of Apoptosis 
Experiments using JNK mutants have clearly shown that 
JNK is needed for normal apoptotic responses [93, 106]. 
Lack of JNK prevented apoptosis in response to irradiation 
and DNA damage, and was accompanied by a failure to re-
lease cytochrome c and activate caspases. In vertebrates, a 
range of mechanisms seem to be involved downstream of 
active JNK, centring on the activation of Bax and the inacti-
vation of Bcl at the mitochondria [107, 108]. Bax activation 
can come from JNK triggering cleavage of Bid [109] or sta-
bilization of p53 [110]. Similarly, JNK can also stabilize 
p73, which is needed for the appropriate apoptotic response 
to the DNA damaging pro-oxidant cisplatin [111]. Elevated 
levels of JNK have been shown to sensitize cells to cisplatin 
induced apoptosis [38].  
Activated JNK is known to move to the mitochondria to 
facilitate the release of pro-apoptotic factors [112-114], as 
well as its nuclear role in transcriptional upregulation 
through AP1 and FOXO [63, 115]. The transcriptional role 
in apoptosis is thought to be particularly significant in organ-
isms such as Drosophila where JNK signalling gives in-
creased transcription of genes that lead to the degradation of 
DIAP and the release of apoptosis inhibition [116]. Interest-
ingly, this pathway can give p53 independent apoptosis in 
response to DNA damage [10], which may be helpful in the 
context of tumour treatment, which often involves DNA 
damage to p53 mutant cells. 
As described earlier, activation of JNK that leads to 
apoptosis is typically protracted and intense, and can come 
from either external or internal sources. For example, JNK1 
is activated by the pro-oxidant and pro-apoptotic factor TNF-
α. This occurs via the JNK activator ASK1 (Apoptosis signal 
regulating kinase 1), which responds to a broad spectrum of 
stimuli including TNF-α, ROS, lipopolysaccharide (LPS) 
and endoplasmic reticulum (ER) stress [107]. For activation 
by oxidative stress, an inhibitory interaction between ASK1 
and thioredoxin is removed when ROS oxidises thioredoxin 
[117]. This promotes ASK1 dimerization, allowing the re-
cruitment of TNF-receptor associated factors (TRAF2 and 
TRAF6) and the activation of JNK to drive apoptosis. JNK 
can be transiently activated by TNFα/ROS through other 
pathways (such as DNA damage), but ASK1 is needed for 
persistent activation that gives apoptosis [118]. ROS can 
activate JNK to activate AP1, which increases transcription 
of TNF-α to produce more ROS, so feedback amplification 
of cell death signals may occur, though as noted earlier, this 
may be limited by oxidative inactivation of AP1. Further-
more, TNF-α can be secreted, so in some cases the induction 
of cell death in one cell can lead to the JNK-dependent death 
of nearby cells [119]. What prevents this mechanism from 
spreading indefinitely is not known, but it may relate to evi-
dence that cell death can also generate protection from apop-
tosis in surrounding cells [120, 121]. The balance between 
these processes is currently poorly understood, but JNK sig-
nalling is likely to be a critical component. 
THE JNK PATHWAY AS A CANCER THERAPY 
TARGET 
Sequencing of human tumours has identified mutations 
that inactivate either JNK or its upstream regulators [122-
125], suggesting that mutations that disable the JNK pathway 
can promote cancer development. However, such mutations 
are relatively rare (<1% of COSMIC database samples have 
mutated JNK1) and studies on both rodent model systems 
and human cancers, have suggested that JNKs can have ei-
ther oncogenic [126] or tumour suppressive effects [127]. 
For example, in hepatocellular carcinomas (HCC), JNK1 can 
be oncogenic, as increased kinase activity is associated with 
tumour formation [128]. Similarly, JNK activity is needed 
for cellular transformation by common oncogenic mutations 
in RAS, Bcr-Abl [129], but conversely, JNK is also needed 
for the apoptotic effectiveness of several chemotherapies 
[19, 63]. Since JNK activity can either promote or prevent 
carcinogenesis, therapeutic intervention in the JNK pathway 
must consider the cellular environments that trigger each 
response. For example, oxidative stress plays a vital role in 
liver and colorectal cancers, at both the initiation and pro-
gression steps [130], so it is essential to understand the rela-
tionship between oxidative stress-triggered JNK signalling 
and cellular outcomes.  
Chemicals that produce high levels of ROS in the liver 
normally trigger a JNK-dependent stress response, and de-
fects in this response can, for example, lead to increased 
HCC tumorigenesis [131, 132]. In this case, lack of JNK-
dependent antioxidant production may speed up the accumu-
lation of mutations needed for transformation. Once a tu-
mour has formed, however, the same lack of antioxidants 
may restrict the growth of chemical induced HCC tumours 
[128]. Similarly, mice lacking JNK1 show a marked de-
crease in the growth of gastric tumours caused by the ROS 
generating drug N-methy-N-nitrosurea, as compared to wild-
type controls [5]. This case is interesting because the mutant 
mice apparently showed less DNA damage and less apopto-
sis than wild types, but still developed fewer tumours. In this 
case it may be that in wild type animals the chemical-
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induced high ROS levels gave JNK-mediated apoptosis trig-
gering undesirable compensatory proliferation that promoted 
tumorigenesis as well as being able to effectively increase 
antioxidant levels to promote tumour survival. The problem 
here is evident: if a genotoxin generates more tumours in 
JNK mutants we can explain it by saying that JNK is needed 
for cell death, but if we see fewer tumours in JNK mutants 
we can instead explain the result by saying that JNK is 
needed for compensatory proliferation or for anti-oxidant 
production in stressed tumour cells. Presumably both proc-
esses are at work, and the outcome may depend on the levels 
and timing of JNK activation, though this has not been ex-
amined in detail in animal cancer models. Because we lack a 
detailed time-course of tumour induction, it is not clear 
where in the process JNK has its effect - it could be during 
the accumulation of oncogenic mutations, in the stress-
response adaptation to those mutations, in the ability to 
apoptose in response to the mutations or in the ability to re-
place apoptosed cells, as well as the later processes of metas-
tasis and therapy resistance. 
Manipulating JNK signalling is of interest to drug com-
panies due to its involvement in so many disease processes. 
The knock-down of JNK genes alone or in combination has 
been an important step in understanding JNK function and 
was significant in detecting the specific JNK pathway genes 
that are relevant. However, alternative approaches including 
antisense or RNAi techniques, and chemical and peptide 
inhibitors have now been developed that can inhibit JNK 
function. Mounting evidence has shown that these inhibitors 
can be effective in vivo, indicating that the JNK pathway 
may be accessible for therapeutic manipulation [36]. Three 
different kinds of inhibitors have been thoroughly studied to 
date. The first are the ATP-competitive inhibitors of the JNK 
pathway such as CEP-1347 and SP600125. CEP-1347 can 
inhibit the activation of the JNK pathway to prevent β -
amyloid, NGF-withdrawal, oxidative-stress, and UV irradia-
tion-induced cell death in PC12 cells and rat sympathetic 
	

However, high cellular levels of ATP 
can reduce the efficacy of ATP-competitive inhibitors, and 
this has been observed for CEP-1347 [135]. SP600125 also 
has the significant drawback of being poorly specific for 
JNK over other significant kinases such as MPS1 [92, 136]. 
The second type of inhibitor targets the substrate-binding 
site. For example, JNK-interacting protein-1 (JIP1) functions 
as a scaffold with other JNK pathway proteins to build a 
functional signalling complex. Overexpression of JIP1-
derived peptides can effectively block JNK activity, though 
again there are concerns with specificity [91]. A third kind of 
inhibitor targets allosteric regulatory sites using peptides or 
chemicals to bind and block their phosphorylation. While all 
these types of inhibitor can effectively decrease JNK activ-
ity, their use in therapy remains problematic, perhaps due to 
the need for JNK in normal cell maintenance as well as for 
tumour cell apoptosis. Consequently, no JNK inhibitors are 
in clinical use, though several companies such as Celgene 
have been pursuing trials for some time (CC401, CC930). 
However, new inhibitors are being developed, and our un-
derstanding of the multiple roles of JNK is being refined 
[137], so there is reason to expect more specific and better 
targeted manipulation of the JNK pathway as a clinical ap-
proach in the near future. 
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